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Abstract  
 
The binding kinetics of several benzimidazole compounds were determined with 
recombinant tubulin monomers and heterodimers from benzimidazole-sensitive and         
-insensitive organisms. This study utilised the naturally occurring high efficacy of the 
benzimdazoles for the parasitic protozoa Giardia duodenalis and Encephalitozoon 
intestinalis. The benzimidazoles are not active against the protozoan Cryptosporidium 
parvum or mammalian hosts, including humans. The affinity of several benzimidazole 
derivatives for monomeric and heterodimeric β-tubulin was clearly demonstrated, thus 
supporting previous studies of drug-resistant nematode  and  fungal  populations.           
A homology model of protozoan αβ-tubulin, produced using the three-dimensional 
structure of mammalian αβ-tubulin, identified a strongly hydrophobic domain only on the 
β-tubulin protein of sensitive protozoa. This domain is proposed to be the 
benzimidazole-binding domain and the amino acid residues within it include three key 
residues which are substituted between benzimidazole-sensitive and -insensitive 
organisms. These residues are Ile-189, Val-199, and Phe-200 that all have non-polar, 
hydrophobic side groups and are proposed to bind with the R5 side chain of several 
benzimidazole derivatives. In addition to this, the benzimidazole derivatives were able 
to bind irreversibly with assembling microtubules from sensitive parasites. The 
incorporation of benzimidazole-bound αβ-heterodimers into assembling microtubules 
was shown to arrest polymerisation in vitro although the addition of benzimidazole 
compounds to assembled microtubules did not result in depolymerisation. Taken 
together, these results suggest that the mechanism of action of these compounds is 
through disruption of the dynamic equilibrium that balances the cycle of microtubule 
polymerisation and disintegration within these protozoa. Further, this effect is brought 
about by preferential binding of the benzimidazoles to a hydrophobic region on the β-
tubulin protein.  
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1.1.  The cytoskeletal microtubules  
 
The cytoskeleton is a dynamic framework which plays a central role in a wide variety of 
cellular processes including organelle transport, maintenance of cellular integrity, 
mitosis, motility, and cell division (reviewed by Desai and Mitchison, 1997). The main 
components of the cytoskeleton are the microtubules, formed from tubulin, 
microfilaments, composed of actin, and intermediate filaments composed of individual 
types  of  different  proteins.  The  main  focus  of  this  project  is  tubulin  which  form            
αβ-tubulin heterodimers that polymerise to form the major component of microtubules 
(Fig. 1.1). Microtubules are regulated at several levels within cells, including assembly 
and disassembly through dynamic instability and treadmilling, posttranslational 
modifications, and stabilisation by several different microtubule-associated proteins 
(MAPs).  
 
1.1.1.  Structure and assembly of microtubules  
 
Microtubules are cylindrical cytoskeletal polymers which perform a wide variety of 
functions in eukaryotic cells ranging from cell motility to cellular transport and mitosis 
(Desai and Mitchison, 1997). Some of these functions are achieved through interaction 
with specific motor proteins, such as dynein and kinesin, which are responsible for 
ciliar and flagellar motion (Bloom and Endow, 1995; Mandelkow and Johnson, 1998). 
The wide variety of functions performed by microtubules is partly explained by the 
existence of several α- and β-tubulin isoforms or isotypes, which are the main 
components of microtubules. The expression of the different isotypes is controlled 
transcriptionally and is directly related to the cell type or developmental stage of the 
organism (Lewis et al., 1985; Panda et al., 1994; Schwarz et al., 1998).  
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The first stage in microtubule formation is the dimerisation of α- and β-tubulin 
monomers by a noncovalent association (Fig. 1.1). The αβ-tubulin heterodimers then 
polymerise to form the microtubule which is stabilised by additional proteins such as 
MAPs and tau (mammalian cells). The incorporation of the αβ-subunits into 
microtubules requires guanosine 5’-triphosphate (GTP) hydrolysis in the presence of 
magnesium ions (Fontalba et al., 1993; Menéndez et al., 1998).  
 
The  αβ-tubulin dimers are arranged in a head-to-tail orientation which is believed to 
expose particular residues at the ends of the microtubule and this creates its polarity. 
The exposure of the β-tubulin carboxy-terminal creates a positive or fast-growing end 
(Mitchison, 1993) and the α-tubulin  amino-terminal  is  exposed  at  the  minus  or        
slow-growing end (Fan et al., 1996). Understanding microtubule polarity is particularly 
important as it is believed to form the basis of the interaction with motor proteins (Song 
and Endow, 1996). The two ends of the microtubule also attach to different cellular 
components depending on the function of the microtubules (Wolf et al., 1996).  
 
QuickTime™ and a
TIFF (Uncompressed) decompressor
are needed to see this picture.
 
Fig. 1.1.  Ribbon diagram of the 
porcine  αβ-tubulin heterodimer. 
The location of GDP and GTP 
are indicated (pink) along with 
the plus and minus ends of the 
microtubule (Downing and 
Nogales, 1998b).  
Microtubule minus end
Microtubule plus end 
β-Tubulin  
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1.1.2.  Dynamic behaviour of microtubules  
 
Microtubules are highly dynamic and can switch stochastically between growing and 
shortening phases both in vivo and in vitro (Margolis and Wilson, 1998). This 
nonequilibrium behaviour is termed dynamic instability (i.e. rapid switching between 
growth and rapid shortening) and treadmilling (i.e. net assembly at one end and 
disassembly at the opposite end). The mechanisms which underlie this switching or 
dynamic instability have been most widely studied using mammalian forms of the 
protein and are believed to be based on the binding and hydrolysis of GTP on the       
α- and β-tubulin subunits (Caplow and Fee, 2002; Caudron et al., 2000). Each 
monomer binds one GTP molecule at the nonexchangeable or N-site on α-tubulin    
(Bai et al., 1998) and the exchangeable or E-site on β-tubulin (Shivanna et al., 1993). 
After the αβ-tubulin dimers are incorporated into microtubules the E-site GTP is 
hydrolysed to GDP and becomes nonexchangeable (Carlier et al., 1987). There are 
two models which describe the dynamic instability of microtubules in vivo and in vitro: 
the GTP-cap model and the treadmilling hypothesis.  
 
1.1.2.i.  Dynamic instability: GTP-capping model  
 
The more favoured of the two dynamic instability models is the GTP-cap model which 
is based on the gain and loss of a stabilising GTP- or GDP-Pi-liganded tubulin 
(Dougherty et al., 1998) at the E-site of the β-subunit at the plus or growing end of a 
microtubule. The GTP-monomer stabilises the microtubule and when they are 
stochastically lost the microtubule rapidly depolymerises (Drechsel and Kirschner, 
1994; Tran et al., 1997). The most recent high-resolution models of the microtubule 
(Löwe et al., 2001; Nogales et al., 1999) place a β-tubulin subunit at the plus end of the 
microtubule which exposes its nucleotide to solution while the minus or shortening end 
contains an α-subunit exposing its catalytic end (Fig. 1.1). Therefore the nature of the Chapter 1.  General Introduction 
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subunit at either end of a microtubule is the critical factor in the GTP-cap model (Janosi 
et al., 2002).  
 
 
 
 
Fig. 1.2.  Diagram of the GTP-capping model of microtubule dynamic 
instability. The GTP-cap is represented by a stabilising single layer of   
GDP-Pi molecules (Panda et al., 2002).  
 
For the GTP-cap model to be correct when a dimer is added to the plus end of a 
microtubule its catalytic sites will come into contact with the E-site nucleotide (Fig. 1.2) 
of the polymerised subunits and the creation of this interface is what is believed to 
drive GTP hydrolysis (Mitchison, 1993). The GTP on the newly polymerised GTP-
tubulin dimer therefore will not be hydrolysed until another dimer is added (Margolis 
and Wilson, 1981). This process results in the microtubule plus end having a GTP-cap 
on the uppermost tubulin dimers. At the minus end, as dimers are removed the 
catalytic portions of microtubular dimers are exposed though without any GTP or GDP 
involvement (reviewed by Carlier, 1982). The rapid assembly and disassembly of 
cytoskeletal microtubules favoured with this model allows the cytoskeleton to respond 
rapidly to a wide variety of stimuli which results in its role in the wide variety of 
processes detailed above.  
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1.1.2.ii.  Dynamic instability: treadmilling model  
 
The second model, which may exist simultaneously or during particular stages of the 
cell cycle with the GTP-cap model (Caplow et al., 1985; Caplow and Shanks, 1996),   
is termed treadmillling. It has been demonstrated in vitro and in vivo (Margolis and 
Wilson, 1998) and is described as the constant flux or recycling of αβ-dimers such that 
the net gain from the plus end and the net loss from the minus end is constant and a 
constant microtubule length is therefore maintained (Margolis and Wilson, 1981). It is 
still unknown what determines or controls the length of a microtubule in this model, 
although it is possibly functional constraints as a result of specific cellular requirements 
(Desai and Mitchison, 1997).  
 
1.1.3.  Microtubule nucleation  
 
The nucleation of microtubules in cells at microtubule-organising centres (MTOCs) is 
also essential for their dynamic behaviour and functions (reviewed by Archer and 
Solomon, 1994; Bornens, 2002). MTOCs include the centrosome (animal cells), 
flagellar basal bodies (protozoa), and spindle pole bodies (fungi, yeast). Depending 
upon their function they are either stable, long-term assemblies involved in the 
formation of cilia and flagellar or unstable, transient assemblies required for 
cytoplasmic microtubules or mitotic spindle formation (Tucker et al., 1995).  
 
The centrosome of animal cells has been widely studied, particularly for the role its 
interaction with microtubules plays in their dynamic instability (Rodionov et al., 1999).  
A typical animal cell centrosome consists of two centrioles surrounded by an 
amorphous cloud of pericentriolar material. While the protein composition and 
molecular organisation of the pericentriolar material is still largely unknown (Archer and 
Solomon, 1994) it has been demonstrated that one essential component is γ-tubulin 
(Moritz and Agard, 2001; Wiese and Zheng, 1999). γ-Tubulin has high sequence Chapter 1.  General Introduction 
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homology with α- and β-tubulin and is the point of attachment between the microtubule 
minus end (α-tubulin) and the MTOC (Li and Joshi, 1995; Rodionov et al., 1999). More 
recently γ-tubulin has been shown to be part of a ring complex, termed γ-TuRC, which 
is thought to be the template for microtubule assembly on centrosomes (Job et al., 
2003; Moritz et al., 2000; Wiese and Zheng, 2000).  
 
A newer member of the tubulin family, ε-tubulin, has also been identified as being 
essential for the assembly and cellular positioning of centriolar and basal bodies 
microtubules (Dupuis-Williams et al., 2002). Further roles of ε-tubulin in these 
microtubules are being investigated and will help to identify the mechanisms underlying 
their development as will the roles of other recently identified tubulins such as δ-tubulin 
(Smrzka et al., 2000; Vaughan et al., 2000) and η-tubulin (Chang and Stearns, 2000; 
Dutcher, 2001; McKean et al., 2001).  
 
Several investigators have also demonstrated noncentrosomal nucleation of 
microtubules (Mogensen et al., 2000) particularly in a wide range of mammalian cell 
types such as neurons (Baas et al., 1991; Lunn et al., 1997), skeletal muscle cells 
(Tassin et al., 1985), kidney cells (Bré et al., 1987), and the cochlea (Tucker et al., 
1998). These points of nucleation are believed to perform a pivotal role in the 
specialised functions of these cells and may also create a noncentrosomal population 
of microtubules for rapid nucleation and release (Keating et al., 1997).  
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1.1.4.  Promotion of microtubule stability or instability  
 
The dynamic behaviour of microtubules is further regulated at the cellular level through 
interaction with factors which promote either stability or instability of microtubules.  
 
1.1.4.i.  Factors which promote microtubule stability  
 
Several MAPs have been identified and they may be divided into two groups as either 
structural or dynamic MAPs (reviewed by Desai and Mitchison, 1997). Structural MAPs 
have been demonstrated to stimulate tubulin assembly, enhance microtubule stability, 
and influence the spatial distribution of microtubules within cells (Gamblin et al., 1996; 
Mandelkow and Mandelkow, 1995). Proteins in this group include the structurally and 
biochemically related proteins MAP1-4 and tau, which interact with the carboxy-
terminus of the α- or β-tubulin portion of the heterodimer (Al-Bassam et al., 2002; Chau 
et al., 1998; Saoudi et al., 1995). Dynamic MAPs, including kinesin and dynein, are 
molecular motors which interact with microtubules to bring about adenosine 
triphosphate (ATP)-dependent uni- or bi-directional movement within cells such as 
chromosome segregation during mitosis and meiosis (Hunter and Wordeman, 2000; 
Mandelkow and Johnson, 1998; Vorobjev et al., 2001). The role of MAPs has not been 
studied in protozoan organisms but functionally similar mammalian equivalents can be 
used to gain valuable information regarding microtubule stability and dynamics.  
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1.1.4.ii.  Factors which destabilise microtubules  
 
There are two well characterised factors which are involved in the regulation of 
microtubule dynamics in vivo. One of these is the Oncoprotein18/stathmin (Op18) 
(Cassimeris, 2002) which is believed to promote GTP hydrolysis resulting in the loss of 
the stabilising GTP-cap from microtubules and subsequent depolymerisation (Amayed 
et al., 2000; Holmfeldt et al., 2001; Howell et al., 1999). Another group of microtubule 
depolymerisers is the kinesin-like proteins, XKCM1 and XKIF2, which are required in 
the formation and maintenance of the mitotic spindle (Kline-Smith and Walczak, 2002; 
Anderson and Wittmann, 2002). These are particularly interesting microtubule 
disruptors as they bind to both the plus and minus ends of the microtubule in a way 
which destabilises the microtubule lattice (Desai et al., 1999; Niederstrasser et al., 
2002; Walczak et al., 2002).  
 
1.1.5.  Post-translational modifications of tubulin  
 
In addition to the regulation of microtubules at the genetic and macromolecular level, 
microtubules also undergo tissue and cell-cycle specific post-translational 
modifications. These modifications have been identified in a wide range of organisms 
from the ancient protists, such as Giardia and Trypanosoma, through to mammalian 
cells.  Several types of post-translational modifications occurring in tubulin are unique 
to it (reviewed by MacRae, 1997). These modifications have been found to be 
enzymatically driven, reversible, and except for acetylation they all occur at the highly 
variable and acidic carboxy-terminus. Some of the modifications occur on both the           
α- and β-tubulin monomers and include polyglycylation and polyglutamylation.  
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Polyglycylation involves the addition of glycine residues onto carboxy-terminal 
glutamate residues and can involve the addition of up to thirty-four glycine residues 
(Bré et al., 1998; Weber et al., 1996). Polyglycylation may be functionally significant as 
it has been identified only in cells with either cilia or flagella (Bré et al., 1998; Million    
et al., 1999) including several species of protozoa such as Giardia duodenalis 
(Campanati et al., 1999, 2003; Weber et al., 1997).  
 
Further analysis of Paramecium cilia has determined that higher polyglycylation levels 
are associated with inactive or stable microtubules than with active or dynamic ones 
(Bré et al., 1998; Vinh et al., 1999). It has been proposed that polyglycylation results in 
a bulkier and more negatively charged carboxy-terminal domain. Mutational analysis 
has also demonstrated that the amount of polyglycylation is more important than 
whether it occurs on either the α- or β-tubulin monomer (Xia et al., 2000) although 
whether or not this is functionally significant is unknown.  
 
Polyglutamylation is the successive addition of glutamyl residues to carboxy-terminal 
glutamic acid residues on α- and β-tubulin (Eddé et al., 1990; Redeker et al., 1994). It is 
also commonly found in ciliated or flagellated cells (Gagnon et al., 1996) and neurons 
across a wide species range from protozoa, including G. duodenalis (Boggild et al., 
2002; Weber et al., 1997), Trichomonads (Schneider et al., 1998) and Trypanosoma 
(Schneider et al., 1997) to mammalian cells (Regnard et al., 1999). A greater amount 
of this modification has been observed in proliferating cells than resting or non-dividing 
ones. Combined with polyglutamylation’s association with mammalian centrioles and 
protozoan basal bodies it has been suggested it may perform a microtubule regulatory 
function (Bobinnec et al., 1998; Lechtreck and Geimer, 2000; Regnard et al., 1999).  
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Palmitoylation and tyrosination are unique to α-tubulin. Palmitoylation involves the 
addition of palmitate to cysteine residues with the main site for this being cysteine-376 
(Ozols and Caron, 1997). The functional significance of this modification has been 
investigated in platelets and palmitoylation has been found to decrease with platelet 
activation (Caron, 1997). The amount of palmitoylation in vitro has also been found to 
be decreased by antimicrotubule drugs, including the benzimidazole compound 
nocodazole and the Vinca alkaloid vinblastine, although whether this is related to their 
function is unknown (Caron, 1997). Palmitoylation may also contribute to the 
attachment of tubulin to particular cell membranes in a regulatory manner (Caron et al., 
2001; Zambito and Wolff, 1997).  
 
The  α-tubulin specific tyrosination/detyrosination cycle involves the removal of a 
genetically encoded tyrosine residue from the carboxy-terminus and re-addition of 
another tyrosine in a dual enzyme process (reviewed by Idriss, 2000). Stable 
microtubules are more frequently found to be detyrosinated although it is not essential 
for their stability or function in vivo (Webster et al., 1990) or in vitro (Skoufias and 
Wilson, 1998). It has also been observed that mammalian brain microtubules are more 
frequently found to have the carboxy-terminal tyrosine and glutamic acid residues 
removed, which produces a non-tyrosinatable form of tubulin which is very stable when 
incorporated into microtubules (Alonso et al., 1993; Lafanechère and Job, 2000; 
Paturle-Lafanechère  et al., 1994). This observation has also led to the connection 
between tissue specific modifications and the role they may perform in regulating 
microtubule assembly and stability in vivo (Banerjee, 2002; Multigner et al.,  1996).       
It has been demonstrated in diplomonads, such as G. duodenalis, that tubulin does not 
undergo the tyrosination/detyrosination cycle but instead retains its genetically 
encoded terminal tyrosine residue (Boggild et al., 2002; Weber et al., 1997).  
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1.1.6.  Folding of tubulin monomers  
 
Analysis of the tubulin folding pathway has revealed that the α- and β-tubulin 
polypeptides interact with a series of chaperone proteins in order to attain their native 
structure (reviewed by Lopez-Fanarraga et al., 2001). Chaperonins are ubiquitous 
multisubunit complexes that aid protein folding in an ATP-dependent manner. The first 
step in tubulin’s folding pathway involves interaction between the nascent α-  and         
β-tubulin amino acid chains with prefoldin (Geissler et al., 1998; Vainberg et al., 1998) 
which then transfers them to the cytosolic chaperonin CCT (i.e. chaperonin containing 
T-complex polypeptide-1; also termed TRiC, TCP-1, or c-cpn) (Fig. 1.3) (Llorca et al., 
2001; Melki et al., 1997; Roobol et al., 1999; Tian et al., 1995).  
 
Subsequent folding steps by CCT involve binding and full release (Farr et al., 1997) 
which consumes ATP (Melki et al., 1997; Tian et al., 1995). The resulting quasi-native 
tubulin intermediates then interact with a series of tubulin-specific chaperones termed 
cofactors A – E which bind sequentially to the α- and β-tubulin monomers. These 
cofactors are essential for the formation of normal αβ-tubulin heterodimers (Tian et al., 
1997, 1999).  
 
Briefly, the folding intermediates released from CCT are bound and stabilised by 
cofactors B and E for α-tubulin and cofactors A and D for β-tubulin (Fig. 1.3). The αE 
and βD complexes then interact with cofactor C to form a transient pentameric complex 
(Tian et al., 1997). Hydrolysis of GTP bound to the β-tubulin component of the complex 
is then believed to be the trigger for the release of the native tubulin dimers (Fontalba 
et al., 1993; Tian et al., 1999).  
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Fig. 1.3.  Schematic diagram of the α- and β-tubulin folding pathway. These 
chaperonins and cofactors are required for the formation of functional 
heterodimers and regulation of the monomer to dimer ratio in cells 
(Nogales, 2000).  
 
The folding cofactors are also important in regulating the ratio of α- and β-tubulin within 
cells and normal microtubule assembly is highly dependant upon this regulation. In 
yeast, even a small excess of β-tubulin is lethal (Abruzzi et al., 2002) and the cofactors 
A and B form αB and βA complexes which remove its lethality and provide a reservoir 
of tubulin folding intermediates (Tian et al., 1997). Whether these complexes can be 
directly converted from αB and βA to αE and βD, respectively, seems unlikely as an 
extensive study has demonstrated that αB and βA only convert with CCT which then 
form αE and βD, respectively (Tian et al., 1997).  
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The relative levels of α- and β-tubulin in yeast have been most extensively studied 
recently using native gel electrophoresis of protein mixtures. This has facilitated the 
identification of several additional regulatory or monomer-binding proteins. Thus, 
proteins such as Pac10p have been demonstrated to enhance binding of α- to β-tubulin 
which suppresses β-tubulin’s lethality (Alvarez et al., 1998) while others such as Rbl2p 
bind to β-tubulin in equilibrium with α-tubulin and in a manner similar to cofactor A 
(Abruzzi et al., 2002). Other yeast cofactors, termed Alp11 (Feierbach et al., 1999), 
Alp1 (Hirata et al., 1998), and Alp21 (Radcliffe et al., 1999), which are homologs of 
cofactors B, D, and E, respectively, have all been demonstrated to interact directly with 
microtubules which indicates a wider role for these cofactors in different organisms 
(Radcliffe et al., 2000).  
 
It has been demonstrated that tubulin undergoes a facilitated folding pathway via 
interaction with CCT and other cofactors, and that the mechanism of action of CCT 
parallels that of other chaperonins in that it generates folding intermediates that bind 
with several chaperonins in an ATP-dependent reaction in a process termed cycling 
(Tian  et al., 1995). A similar cycling of intermediates occurs in the prokaryotic 
GroEL/GroES chaperonin pathway and produces the filament temperature sensitivity 
proteins (i.e. FtsA, FtsZ), which are structural homologs of eukaryotic tubulin (Löwe 
and Amos, 1998). It should therefore be possible to produce assembly-competent 
tubulin monomers in Escherichia coli-based in vitro protein expression systems.  
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1.1.7.  Expression of α- and β-tubulin in vitro  
 
As the initial parasitic organism extensively studied for benzimidazole activity and 
resistance was Haemonchus contortus it is not surprising that the first attempts to 
produce recombinant β-tubulin in E. coli were with the genes from this species (Lubega 
et al., 1993). This and subsequent studies demonstrated that under particular 
conditions the α- and β-tubulin protein from several protozoa and amoebae, when 
expressed in E. coli, tended to form insoluble inclusion bodies (Hollomon et al., 1998; 
Oxberry et al., 2001a). However, when these conditions were varied, for example by 
altering the fusion protein partner, E. coli strain, or rate of recombinant protein 
synthesis, the α- and β-tubulin proteins were expressed in a soluble form (Hollomon    
et al., 1998; Linder et al., 1998; MacDonald et al., 2001, 2003a).  
 
When a recombinant protein is expressed in an insoluble form it requires refolding after 
being lysed from intracellular inclusion bodies. As it has been demonstrated that the 
microtubule assembly and drug-binding characteristics of refolded tubulin are 
significantly different to the native protein (Guha and Bhattacharyya, 1997; Sackett         
et al., 1994; Shah et al., 2001) it is preferable to produce soluble, correctly folded 
tubulin if it is to be used for characterisation studies.  
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1.1.8.  Determination of the three-dimensional structure of 
microtubules  
 
The resolution of the atomic structure of the αβ-tubulin dimer has gone through several 
stages of improvement which have progressively allowed the construction of maps with 
successively higher resolution and detail.  
 
In order to understand the key discoveries which have led to the determination of the 
three-dimensional (3-D) structure of the αβ-tubulin dimer some terminology must 
initially be clarified. The two techniques which have been combined to describe the 
structure of tubulin are two-dimensional (2-D) projection maps and 3-D reconstructions. 
The projection maps of tubulin take electron microscopy to the limit of its resolution of 
approximately 15Å (Wolf et al., 1993). The most valuable information obtained from the 
optical diffraction patterns generated in this way has related to the organisation and 
polarity of α- and β-tubulin monomers in zinc-induced crystalline sheets and 
macrotubes. 3-D reconstructions became possible after improvements in resolution 
resulting from the application of electron crystallography, as it is better suited to 
identifying α-helices and β-sheets as well as some of the loops connecting them.  
 
The first high-resolution model of the structure of tubulin was produced by Downing 
and Jontes (1992) using 2-D zinc-induced crystalline sheets (Larsson et al., 1976) 
which were analysed using electron crystallography. The resulting electron diffraction 
patterns began to provide valuable information, albeit with limited resolution, using the 
2-D crystalline sheets. This model was improved the following year by Wolf et al., 
(1993) who continued to work at a 4Å resolution with electron crystallography. They 
were able to produce three polymerised forms of bovine tubulin dependent upon the 
pH of the crystallisation solution. These forms were zinc-sheets, microtubules, and 
macrotubes and the model describing them was able to assign the alternating polarity Chapter 1.  General Introduction 
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of adjacent protofilaments. This work also provided a 2-D projection map at 15Å 
resolution of the zinc-sheet and macrotube crystal forms. One of the main limitations of 
these early projection maps is that they were not able to assign which monomer was  
α- and which was β-tubulin.  
 
This problem was addressed by the Nogales group (1995a) which produced a 6.5Å 
resolution 3-D reconstruction of bovine tubulin using electron crystallography of the 
same 2-D crystalline sheets (Fig. 1.4). They utilised the preferential binding of the 
antimitotic drug paclitaxel (Taxol
™) to β-tubulin (Rao et al., 1992, 1995) as a marker to 
distinguish between the monomers. Using this method they were able to identify that 
the paclitaxel binding site was located near the interprotofilament contacts which 
agreed with observations that it bound preferentially to polymerised tubulin (Manfredi  
et al., 1982; Parness and Horwitz, 1981). Nogales study also supported the hypothesis 
that paclitaxel acts by stabilising or strengthening the lateral interactions between 
protofilaments (Díaz et al., 1993; Howard and Timasheff, 1988). The resolution of 
many regions of secondary structure was made possible with the 6.5Å level of detail 
and in particular a long α-helix between the lateral and longitudinal contacts between 
the subunits (helix-A) was identified. The location of several internal β-sheets in both 
subunits was also achieved and confirmed their previously predicted perpendicular 
orientation to the central axis of the protofilaments (Downing and Jontes, 1992).  
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QuickTime™ and a TIFF (Uncompressed) decompressor are needed to see this picture.
 
 
 
At this level of resolution it was not possible to identify the GTP-binding site of either 
monomer, that was to come later in 1998 (Nogales et al.) when the resolution was 
significantly improved to 3.7Å. (Fig. 1.4). Subsequent work with this model was able to 
relate the 3-D structure to some microtubule functions (Downing and Nogales, 1998a) 
such as longitudinal stability and interaction with accessory proteins.  
 
 
 
Fig. 1.4.  The αβ-tubulin dimer 
of porcine brain microtubules. 
This model was produced using 
a 6.5Å resolution and with Taxol 
in situ to distinguish between 
the α- and β-tubulin monomers. 
The model also indicates the 
location of the α-helices (blue), 
β-sheets (green), GDP and GTP 
(pink), and Taxol (yellow) 
(Nogales et al., 1995a).  Chapter 1.  General Introduction 
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Fig. 1.5.  Ribbon diagram of the three-dimensional reconstruction of 
porcine β-tubulin at 3.7Å. The location of the α-helices (H) and β-sheets (S) 
are indicated (Nogales et al., 1998).  
 
The most recent and thorough explanation of the current atomic level information 
available on the αβ-tubulin dimer is provided by Löwe et al., (2001). This paper, written 
in collaboration with Nogales, extended the electron crystallography model to a 
resolution of 3.5Å. This allowed previously unresolved secondary structures to be 
identified as well as other postulated binding regions to be defined (e.g. magnesium 
and zinc ions). The most significant improvement to previous models was in defining 
the side-chains of the amino acids involved in the formation of the intra- and inter-dimer 
interfaces and the binding sites of the guanine nucleotides (i.e. GTP and GDP) and 
taxol. The 3.5Å model is a significant milestone in the determination of the structure of 
αβ-tubulin and also provides important information towards understanding the dynamic 
instability of microtubules (Downing and Nogales, 1998b; Meurer-Grob et al., 2001).  
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Table 1.1.  Summary of the atomic resolution of the αβ-tubulin dimer in 
chronological order. Structures were determined using two-dimensional 
zinc-induced crystalline sheets (Larsson et al., 1976) with the exception of 
the study by Amos and Klug (1974).  
 
Investigators   Year  Resolution  Technique   Result  
Amos and Klug   1974  Low (>20Å) Optical 
diffraction 
studies  
Identified arrangement of 
heterodimers in 
microtubules  
Mandelkow et al.   1977  Low (>20Å) X-ray  fibre 
diffraction  
First structure using zinc-
induced crystalline sheets 
Amos and Baker   1979  20Å  20Å 3-D projection map 
Ceska and 
Edelstein  
1984 20Å  
Electron 
microscopy   First structure of MAP-
free microtubules  
Beese et al.   1987  18Å  X-ray  diffraction 
with electron 
microscopy  
Improved resolution of 
microtubule internal 
structure  
Andreu et al.   1992  30Å  X-ray  scattering 
with cryo-
electron 
microscopy  
First model using taxol-
stabilised microtubules  
Downing and 
Jontes  
1992 4Å  4 Å 3-D projection map  
Nogales et al.   1995  Resolved secondary 
structures and visualised 
taxol binding site  
Wolf et al.   1996 
6.5Å  
Improved the 6.5Å 3-D 
model  
Nogales et al.   1997  4Å  Resolved  most  secondary 
structures  
Nogales et al.   1998  3.7Å 3-D reconstruction  
Nogales et al.   1999  Docked 3.7Å tubulin 
model onto 20Å 
microtubule map  
Meurer-Grob et al.   2001 
3.7Å  
Docked 3.7Å tubulin 
model onto 14Å 
microtubule map  
Löwe et al. 2001  3.5Å  
Cryo-electron 
crystallography  
3.5Å 3-D reconstruction  Chapter 1.  General Introduction 
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1.2.  Antimitotic compounds  
 
There are several classes of compounds which bind to tubulin (reviewed by Downing, 
2000) to inhibit polymerisation (colchicine: Chakrabarti et al., 1996), prevent 
depolymerisation by stabilising the microtubule (taxanes: Snyder et al., 2001), or 
prevent dimerisation (benzimidazoles: Lacey, 1988). The molecular basis of the 
mechanism of action of these compounds has been extensively studied and has 
generally focussed on sensitivity versus resistance as a basis for understanding their 
mechanism of action. The techniques which have been used to understand their 
mechanism of action have resulted in progressive improvements to the drug-binding 
model for each class of drugs.  
 
1.2.1.  Compounds that prevent microtubule dimerisation:  
Benzimidazoles  
 
The hypothesis that tubulin is the target of the benzimidazoles is based on the 
ultrastructural studies of cells. These observations included the degenerative changes 
caused by benzimidazoles which coincided with the disappearance of cytoplasmic 
microtubules (Borgers et al., 1975). The broad range of activity of the benzimidazoles 
has been demonstrated against a wide variety of organisms including nematodes 
(Enos and Coles, 1990; Roos et al., 1990), fungi (Cruz et al., 1994; Del Poeta et al., 
1998), and parasitic protozoa (Katiyar and Edlind, 1997; Morgan et al., 1993).  
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1.2.2.  Benzimidazoles as anthelmintics  
 
Since the introduction of the benzimidazoles in the 1960s as anthelmintics there has 
been increasing incidence and reporting of resistance amongst a range of agriculturally 
significant nematodes or strongylids, including H. contortus. The original studies of the 
mechanism of action of benzimidazoles in parasitic nematodes demonstrated some 
relatively generalised biochemical observations such as an inhibitory effect on glucose 
uptake and glycogen storage (Borgers et al., 1975). When ultrastructural studies 
revealed that mebendazole caused disintegration of the microtubule network in 
nematodes (Borgers et al., 1975) a link between benzimidazoles and tubulin was made 
which also provided an explanation for the biochemical observations. Subsequent 
studies have primarily focussed on determining the molecular basis of resistance to 
benzimidazole compounds. The development of benzimidazole-resistant strains in 
previously susceptible nematode populations assisted these studies and it was hoped 
that through understanding the mechanism of resistance the mode of action of the 
benzimidazoles would become clearer.  
 
The mode of action of the benzimidazoles in helminths is believed to involve direct 
binding to the β-tubulin monomer and thus inhibition of dimerisation and polymerisation 
into microtubules (Gill and Lacey, 1992; Lubega and Prichard, 1990, 1991a). The 
mechanism of benzimidazole resistance has been studied in detail for the nematodes 
H. contortus (Kwa et al., 1995; Roos et al., 1990) and Caenorhabditis elegans (Driscoll 
et al., 1989; Enos and Coles, 1990). In both organisms the expression of high affinity 
benzimidazole-binding sites has been linked to susceptibility (Lubega and Prichard, 
1991a, 1991b) whereas the expression of predominantly low-affinity benzimidazole-
binding sites has been linked with resistance (Beech et al., 1994). The switching 
between the expression of predominantly high- or low-affinity binding sites has been 
suggested to be the result of gene deletions (Driscoll et al., 1989; Roos et al., 1990) or 
point mutations in the β-tubulin genes (Kwa et al., 1995).  Chapter 1.  General Introduction 
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There is a substantial amount of evidence to suggest that the benzimidazoles generally 
bind to tubulin and that the amount of binding is lower for tubulin extracted from 
benzimidazole-resistant than -susceptible H. contortus while the rate of association 
(kon) is unaltered (Lacey and Prichard, 1986). This indicated that the benzimidazoles 
were affecting the amount of microtubules being formed but not their rate of formation. 
This hypothesis was reinforced by the observation that resistance relates to the 
amount of benzimidazole-tubulin complex formed and that this is partially dependent 
on the nature of the benzimidazole compound.  
 
Further studies by Lubega and Prichard (1990) using competitive ligand displacement 
studies with tritiated-benzimidazoles demonstrated that the reduction in the amount of 
drug bound by susceptible and resistant tubulin pools was due to a loss of high-affinity 
benzimidazole receptors or binding sites. They cited a limitation in the previous studies 
whereby there was no differentiation between high-affinity and low-affinity binding but 
instead only the total amount of binding was noted. They distinguished high-affinity 
binding as a specific type of binding that is inhibited by an excess amount of ligand as 
it is comparatively irreversible. Low-affinity binding is then easily inhibited, as it is more 
reversible and also more difficult to saturate. For this reason it is difficult to distinguish 
low-affinity binding from non-specific binding.  
 
The methods which had been employed using tubulin extracted from H. contortus have 
one significant flaw and that is that they failed to take into account the heterogeneity of 
the extracted tubulin pools. The heterogeneity resulted from tubulin biotypes from 
different worm sections, which perform different functions, being extracted and purified 
simultaneously. This is potentially significant in drug binding studies as it is believed 
that at least some of the functional diversity of microtubules is due to functionally 
specific post translational modifications of the tubulin monomers or dimers, as 
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benzimidazole binding. The early studies also failed to differentiate between either α- or 
β-tubulin as being involved in benzimidazole binding but treated binding as a 
heterodimeric interaction with these drugs.  
 
Therefore, significant improvements were made to the quality of the benzimidazole 
binding site information once DNA-based techniques were applied. A preliminary study 
by Roos et al., (1990) was able to identify the existence of mutant β-tubulin, and not    
α-tubulin, genes in benzimidazole-resistant H. contortus and these were later found in 
other benzimidazole-resistant helminths (Beech et al., 1994; Kwa et al., 1995; Lubega 
and Prichard, 1991c).  
 
1.2.3.  Benzimidazoles as fungicides  
 
The genetic basis of resistance to the benzimidazoles has also been widely studied in 
several fungi including Aspergillus nidulans and Neurospora crassa. The fungicidal 
activity of the benzimidazole compound thiabendazole has been most widely studied 
and its mode of action was initially described as an ability to inhibit mitosis but not DNA 
or RNA synthesis (Davidse and Flach, 1978). As with H. contortus it was with the 
development of resistance that the opportunity to study the genetic mechanisms 
underlying their mode of action presented itself. The benzimidazoles mode of action 
had already been proposed to be the same as for several other species and to involve 
preferential binding by the benzimidazoles to the β-tubulin monomer (Jung et al., 1992; 
Jung and Oakley, 1990). Several studies have identified mutant β-tubulin genes in 
benzimidazole-resistant fungi (Table 1.2).  
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Table 1.2.  Summary of the mutations which have been detected in 
benzimidazole-resistant biotypes of several fungi.  
 
Organism   Type of BZ-
resistance 
Amino 
acid 
position 
Type of 
substitution  
Investigator 
Thiabendazole   165   Ala → Val   Jung & Oakley, 
1990 
Aspergillus 
nidulans 
Thiabendazole  
Nocodazole  
Carbendazim  
Benomyl  
6  
198  
200  
His → Tyr  
Glu → Lys/Gln  
Phe → Tyr  
Jung et al., 
1992 
Carbendazim –  
Mildly resistant  
167  
198  
241  
Phe → Tyr  
None detected  
None detected  
Fujimura et al., 
1992a  
Neurospora 
crassa 
Carbendazim –  
Highly resistant  
167  
198  
241  
None detected  
Glu → Gly  
None detected  
Fujimura et al., 
1992b  
Cryptococcus 
neoformans 
Albendazole   6   His → Gln   Cruz & Edlind, 
1997  
 
From these studies, an inconsistent model of the key amino acids involved in 
benzimidazole resistance has emerged. Resistance appears to relate to the nature of 
the organism and the structure of the benzimidazole studied. As with the resistance 
studies of H. contortus it should again be noted that many assumptions were made 
regarding the target of the benzimidazoles in fungi and studies were restricted to this 
target. These studies also focussed on deducing amino acid sequences from complete 
or partial β-tubulin DNA sequences to identify mutated amino acids without a clear 
understanding of the background or basal mutation rate in the β-tubulin gene in 
cultured fungi.  
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1.2.4.  Benzimidazoles as antiprotozoan compounds  
 
Due largely to the selectivity of benzimidazole action in mammalian hosts these 
compounds have been examined for antiprotozoan activity against a wide range of 
parasites. Two protozoa which cause significant pathological sequelae and which have 
been demonstrated to be sensitive to a number of benzimidazoles are G. duodenalis 
and Encephalitozoon intestinalis.  
 
1.2.4.i.  Significance of Giardia duodenalis  
 
G. duodenalis is a flagellated parasitic protozoan that inhabits the upper small intestine 
of several hosts causing giardiasis. It is the most common cause of diarrhoeal illness 
worldwide (reviewed by Thompson et al., 1993) and is a major cause of waterborne 
enteric disease (Furness et al., 2000) and failure-to-thrive syndrome in children 
(Farthing, 1996). Giardia is thought to belong to the earliest lineage to diverge from the 
major eukaryotic line (Hashimoto et al., 1994; Sogin et al., 1989) and it lacks several 
common higher eukaryotic organelles such as mitochondria, endoplasmic reticulum, 
Golgi apparatus, and peroxisomes (reviewed by Adam, 2001; Gillin et al., 1996). One 
of the most striking features of Giardia is its unique cytoskeleton especially the flagellar 
and adhesive or ventral disc. The infective G. duodenalis trophozoite stage is believed 
to attach to the intestinal cells using the ventral disc although the mechanism for 
attachment has yet to be clearly defined. It is also difficult to verify the attachment 
mechanism experimentally due to the lack of a suitable in vitro model. Recently, 
attachment to human intestinal cells has been studied in vitro and was demonstrated to 
be reduced by temperature, colchicine, mebendazole, and glucose (Céu Sousa et al., 
2001) which suggests that a combination of mechanical and hydrodynamic forces are 
involved in attachment. These authors also described how surface lectins may mediate 
adherence involving specific recognition by host cells, such as intestinal cells.  
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1.2.4.ii.  Benzimidazoles in the treatment of giardiasis  
 
The increasing emergence of resistance to existing treatments of giardiasis, whether it 
is a result of low compliance with therapy regimes, reinfestation, or resistance to widely 
used treatments such as metronidazole, has resulted in increased application of the 
benzimidazole, albendazole. This is a highly effective anti-giardial compound in vitro 
(Katiyar et al., 1994; Meloni et al., 1990) and in vivo (Reynoldson et al., 1998) although 
treatment failures (Brasseur and Favennec, 1995) and resistance to it have been 
demonstrated (Abboud et al., 2001). While there is a low reportage of treatment 
failures due to resistance, in vitro resistance has been propagated (Lindquist, 1996; 
Upcroft  et al., 1996). The successful treatment of giardiasis with benzimidazoles 
(reviewed by Gardner and Hill, 2001; Upcroft and Upcroft, 2001a) has been 
demonstrated with albendazole (Hall and Nahar, 1993; Lemée et al., 2000; Reynoldson 
et al., 1998) and mebendazole (Al-Waili et al., 1988; Al-Waili and Hasan, 1992).  
 
Initial ultrastructural observations of the morphological changes to G. duodenalis 
following treatment with albendazole and mebendazole noted a loss in their ability to 
adhere to solid supports and diminished viability. Fragmentation of the ventral disc was 
also observed (Chavez et al., 1992) and supported the hypothesis that the 
benzimidazoles were disrupting normal cytoskeletal microtubule functions, although 
whether they are interferring with microtubules in particular  cellular  locations            
(i.e. flagellar, ventral disc) has not been clearly identified by ultrastructural studies 
(Chavez et al., 1992; Oxberry et al., 1994).  
 
In vitro assessment of the activity of the benzimidazoles against G. duodenalis has 
also demonstrated their therapeutic value. However, due to the lack of standardised 
methods to assess efficacy the variability in efficacy imparted by drug exposure time 
and drug effect has meant that results of separate drug efficacy studies are not 
concordant.  To  determine  which  benzimidazoles  are  most  efficacious  against             Chapter 1.  General Introduction 
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G. duodenalis several in vitro trials have been conducted utilising a variety of 
techniques to evaluate drug efficacy. These have included the measurement of an 
inhibitory concentration (Edlind et al., 1990; Katiyar et al., 1994; Morgan et al., 1993), 
inhibitory dose (Lemée et al., 2000), minimum lethal concentration (Cedillo-Rivera and 
Munoz, 1992), and minimum inhibitory concentration (Upcroft and Upcroft, 2001b). 
Unfortunately, this makes comparison of benzimidazole efficacy difficult and also 
complicates the process of relating the structure of different benzimidazoles to their 
efficacy.  
 
1.2.4.iii.  Significance of the Encephalitozoon species  
 
‘Microsporidia’ is a nontaxonomic term used to describe protozoan parasites belonging 
to the phylum Microspora (reviewed by Franzen and Müller, 1999). Several species of 
microsporidia have been identified as the cause of disease in humans, especially 
immunocompromised (Fournier et al., 2000; Leder et al., 1998) and 
immunosuppressed (Gumbo et al., 1999) individuals but also in immunocompetent 
people (Raynaud et al., 1998). The two microsporidia species most commonly detected 
in human immunodeficiency virus (HIV)-positive patients are Enterocytozoon bienusi 
and Encephalitozoon intestinalis (Sobottka et al., 1998), formerly Septata intestinalis 
(Hartskeerl et al., 1995). E. intestinalis is the most prevalent of the three significant 
Encephalitozoons which also include E. hellum and  E. cuniculi.  
 
The Encephalitozoon species are characterised as spore forming, obligate intracellular 
eukaryotes which parasitise other eukaryotic cells. Like Giardia, this group is 
considered to be an ancient eukaryote that multiplies by binary fission, has a 
membrane-bound nucleus, and lacks mitochondria and Golgi membranes (Franzen 
and Müller, 1999). The Encephalitozoons are also an emerging water-borne 
microsporidian species (Dowd et al., 1998) which is capable of zoonotic transfer 
(Deplazes et al., 1996; Didier et al., 1996; Snowden et al., 1999). In immunocompetent Chapter 1.  General Introduction 
- 51 - 
individuals E. intestinalis causes chronic diarrhoea (Raynaud et al., 1998; van Gool    
et al., 1997) which combines with enteritis and systemic infections in HIV-infected 
individuals (Asmuth et al., 1994; Coyle et al., 1996; Franzen et al., 1996).  
 
In host cells Encephalitozoon replicates in a unique parasitophorous vacuole and 
releases vegetative and spore stages into the host cell, resulting in the production of 
infective spores. These spores have a unique coiled polar tubule (Fig. 1.6) and it is 
through this tubule that they transfer their infective sporoplasm into host cells.                   
The mechanism by which the polar tube interacts with the host cell membrane is not 
clearly understood, although it may involve host cell proteins such as actin (Foucault 
and Drancourt, 2000). The polar tubule has been investigated as a target for 
chemotherapy, especially as the extrusion of the polar tubule is accompanied by an 
influx of calcium into the spore (He et al., 1996) and calcium channel blockers (e.g. 
metronidazole) have been shown to inhibit extrusion and therefore infection of host 
cells in vitro.  
 
 
Fig. 1.6.  Diagram of a microsporidian spore. The spore consists of a dense 
outer membrane (exospore, endospore, and plasma membrane), a single 
nucleus, posterior vacuole, coiled polar filament, and anterior anchoring 
disc (Franzen and Müller, 1999).  
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1.2.4.iv.  Activity of the benzimidazoles against 
Encephalitozoon species  
 
The efficacy, but not the mechanism of action, of the benzimidazoles has been 
demonstrated mainly with the most prevalent Encephalitozoon species, E. intestinalis 
and  E. hellum. In studies which have considered the benzimidazole mechanism of 
action it has been assumed to be the same as their action in helminths and fungi. 
Therefore, benzimidazoles are considered to be microtubule disruptors through 
selective binding to the β-tubulin monomer which inhibits polymerisation. From a 
therapeutic point of view the most widely used treatment is albendazole which has 
been demonstrated to be rapid and highly effective in the treatment of E. intestinalis 
(Leder et al., 1998; Molina et al., 1998). Albendazole has been reported to completely 
eradicate this microsporidian (Dore et al., 1995; Joste et al., 1996) although infections 
with E. intestinalis are reported to recur following ceasation of albendazole therapy 
(Molina et al., 1995, 1998).  
 
The investigation of therapeutic agents to treat microsporidiosis has been hampered by 
the time taken both to realise the identity of the infective agent and to culture it in 
sufficient amounts for in vitro drug trials, due in part to its unique host cell location. It is 
also due to the fact that the infection levels of Encephalitozoon species have only 
increased relatively recently as a result of the increasing number of HIV-positive 
individuals, particularly since the early 1980s (Coyle et al., 1996; Del Aguila et al., 
1998). In recent years though, several in vitro methods have been developed 
specifically for drug assays, including utilising kidney cells (Franssen et al., 1995), 
fibroblasts (Beauvais et al., 1994), and a fluorescent probe to detect drug-induced 
morphological changes (Leitch et al., 1997).  
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With the development of reliable in vitro models for assessing drug efficacy several 
studies have evaluated fumagillin (Beauvais et al., 1994; Leitch et al., 1997), 
metronidazole (Franssen et al.,  1995),  and  nifedipine  (calcium-channel  blocker)       
(He et al., 1996). When these studies have compared the efficacy of these compounds 
against E. intestinalis in vitro with different benzimidazoles the superior efficacy of the 
benzimidazoles to any of the other compounds tested has been clearly demonstrated 
(Beauvais et al., 1994; Didier et al., 1997; Leitch et al., 1997) and it is therefore the 
benzimidazole class of drugs which has been most widely studied.  
 
Several in vitro trials have investigated the activity of various benzimidazoles against 
Encephalitozoon species. These studies represent a relatively thorough examination of 
some benzimidazole compounds for anti-Encephalitozoon activity, particularly 
albendazole and its sulphoxide and sulphone metabolites (Didier et al., 1998; Katiyar 
and Edlind, 1997; Ridoux and Drancourt, 1998). There is a large amount of variability 
in the inhibitory concentrations reported and this is attributable to the method by which 
the  in vitro activity was assessed. Several attempts have been made recently to 
develop standard methods for the assessment of anti-microsporidial activity of drugs 
and this would greatly facilitate the comparison and screening of a large number of 
compounds.  
 
As a class of drugs the benzimidazoles have been demonstrated both in vivo  and       
in vitro to be the most promising. In addition, neither in vivo nor in vitro resistance has 
been observed, although they have been used therapeutically for less than ten years 
(De Groote et al., 1995; Lecuit et al., 1994; Molina et al., 1995). It is therefore 
worthwhile exploring the molecular basis of action of the highly effective 
benzimidazoles against E. intestinalis as these studies may lead to the identification of 
a binding site, possibly on a stably expressed protein in one or more E. intestinalis life 
stage.  Chapter 1.  General Introduction 
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1.2.5.  Molecular basis of benzimidazole activity  
 
Based largely on the studies which have been carried out with benzimidazole-sensitive 
and -resistant nematodes and fungi, the in vitro trials examining the molecular basis of 
benzimidazole activity in protozoa have focussed on the β-tubulin nucleotide and amino 
acid sequence. Several in vitro studies have taken a comparative approach using the 
β-tubulin gene from benzimidazole-sensitive and -insensitive organisms. These studies 
have identified phenylalanine-200 and glutamic acid-198 as being key determinants of 
susceptibility in G. duodenalis and E. intestinalis to benzimidazoles (Edlind et al., 1994; 
Katiyar et al., 1994). In addition to this, studies of the molecular basis of benzimidazole 
resistance in the A. nidulans fungi proposed that the benzimidazoles bind to amino acid 
residue 165 (Jung and Oakley, 1990). These studies of fungal resistance identified an 
alanine to valine mutation between sensitive and resistant A. nidulans populations. 
Subsequent work by Jung et al., (1992) identified several additional β-tubulin amino 
acid alterations in benzimidazole-resistant A. nidulans. From their analysis they 
proposed that amino acid residues 6, 165, 198, 199, and 200 were involved in 
benzimidazole binding and the subsequent development of resistance.  
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1.3.  Rationale of this project  
 
There is a significant lack of information and understanding of the mechanism of action 
of the benzimidazoles. This is partly due to the lack of direct drug binding data and is 
particularly true of the parasitic protozoa including G. duodenalis and E. intestinalis. 
Additionally, the parasitic protozoan Cryptosporidium parvum is insensitive to several 
benzimidazole compounds. Although several studies have investigated the molecular 
basis of benzimidazole resistance, a similar amount of information is not available to 
understand the basis of sensitivity or insensitivity to these compounds. This is partly 
due to a lack of techniques to either purify tubulin from protozoa or to express it in host 
cells lacking endogenous tubulin. To identify valid drug-binding sites it is also 
necessary that the tubulin protein is correctly folded and biochemically active in both a 
monomeric and heterodimeric form. These problems are compounded by the 
requirement for large amounts of α- and β-tubulin capable of assembling into 
heterodimers and microtubules for drug-binding studies.  
 
To address this problem, this project aims to combine benzimidazole-β-tubulin binding 
kinetics with homology models of β-tubulin from sensitive and insensitive organisms. 
This approach is based upon the rationale that if β-tubulin is the target protein of the 
benzimidazoles in sensitive protozoa then by studying the β-tubulin protein from 
sensitive and insensitive protozoa the benzimidazole-binding region should be 
identifiable. Further to this, the identification of the benzimidazole-binding region should 
be possible using recombinant α-,  β-, and αβ-tubulin proteins from benzimidazole-
sensitive organisms.  
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1.4.  Aims of this project  
 
The aims of this study were: 
 
1.  To produce recombinant α- and β-tubulin from G. duodenalis, E. intestinalis, 
and C. parvum using bacterial expression systems  
 
2.  To produce three-dimensional crystals of protozoan αβ-tubulin with 
albendazole  in situ utilising standard crystallisation conditions and a 
hanging-drop vapour diffusion method  
 
3.  To examine the validity of the proposed benzimidazole binding site on             
β-tubulin by homology modelling of β-tubulin from benzimidazole-sensitive 
and -insensitive organisms  
 
4.  To determine the binding rates and kinetics of several benzimidazoles 
previously demonstrated to have a range of efficacies in vitro  against        
G. duodenalis and E. intestinalis  
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Expression of recombinant protozoan tubulin in 
Escherichia coli  
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2.1.  Introduction  
 
One of the barriers to high-level expression of recombinant proteins in E. coli is their 
tendency to aggregate or accumulate in inclusion bodies. This can potentially lead to 
problems refolding the recombinant protein in vitro with the increased possibility of   
mis-folding or incomplete folding intermediates being produced (Georgiou and Valax, 
1996). Since the mid-1990s several protein expression fusion partners have been 
developed which favour the production of soluble recombinant proteins particularly for 
use in E. coli (Davis et al., 1999; LaVallie and McCoy, 1995; Nilsson et al., 1997). 
These include fusions with the maltose-binding protein, MBP (di Guan et al., 1988; 
Hennig and Schäfer, 1998; Sachdev and Chirgwin, 1998b), glutathione S-transferase, 
GST (Smith and Johnson, 1988), and thioredoxin, TRX (LaVallie et al., 1993; 
Yasukawa et al., 1995).  
 
There are several factors that may affect the solubility or rate of accumulation of a 
recombinant protein including the intrinsic characteristics of the fusion partner and the 
recombinant protein, and the rate of protein synthesis. Further, whether inclusion body 
formation is the result of the accumulation of incompletely synthesised or incorrectly 
folded proteins (Dobson and Ellis, 1998) or whether it is simply due to the abnormally 
high concentration of non-native polypeptides within E. coli (Lilie et al., 1998) is 
unclear. It has also been observed that hydrophobic proteins are commonly expressed 
in inclusion bodies and that by fusing these proteins to a hydrophilic partner their 
solubility can be greatly enhanced (Lilie et al., 1998). In addition to this, the solubility of 
a fusion protein may be based upon whether the first portion of the protein which 
emerges from the ribosome is soluble or insoluble and this will determine the solubility 
of the remaining portion of the fusion protein (Sachdev and Chirgwin, 1998a).  
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In order to provide further understanding of the factors which contribute to the 
sequestering of a recombinant protein in either a soluble or insoluble state the present 
study of the solubility properties of recombinant α- and β-tubulin monomers from 
several protozoa was undertaken. The parasites selected for this analysis are clinically 
significant and so are also important for drug targeting studies. More importantly, the 
extraction of sufficient amounts of native tubulin from these parasites for drug binding 
studies has never been successfully achieved. The parasites are G. duodenalis,         
E. intestinalis, and C. parvum which are all enteric pathogens that cause different 
severities of gastrointestinal symptoms. The course of infection is normally self-limiting 
but can become life-threatening in immunocompromised individuals (Furness et al., 
2000). Further, and of interest within the context of the overall project, the three 
species exhibit a range of sensitivity to the benzimidazoles.  
 
The protozoan α- and β-tubulin proteins are primarily cytoskeletal proteins of 
approximately 50kDa in size which naturally dimerise to form αβ-tubulin heterodimers 
that polymerise to form microtubules. They are acidic proteins with theoretical 
isoelectric points (pI) ranging from 4.83 to 4.98, compared with 5.17 to 6.20 for the 
ubiquitous mammalian forms. This overall protein charge difference is due to the high 
number of acidic amino acids, especially glutamic acid, in the carboxy-terminal region 
of all the protozoan forms of the monomers. When eukaryotic tubulin monomers have 
been expressed in E. coli previously they have been found to accumulate in inclusion 
bodies (Hollomon et al., 1998; Oxberry et al., 2001a) and also in soluble form 
(Hollomon et al., 1998; Linder et al., 1998) though without any clear reasons why a 
particular state is favoured (i.e. fusion partner, E. coli strain, intrinsic nature of tubulin).  
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The G. duodenalis β-tubulin was initially expressed as a soluble protein in E. coli using 
a poly-histidine (poly-His) fusion partner (MacDonald et al., 2001) and it was noted that 
with the same expression method recombinant tubulin from other protozoa exhibited 
aggregation or inclusion body formation. Hence, a fuller analysis of the solublity 
characteristics of protozoan tubulin was undertaken  using  the  tubulin  genes  from        
G. duodenalis, E. intestinalis, and C. parvum. Particular attention was paid to the effect 
of the fusion partner, effects of the E. coli BL21 strains used for protein expression, and 
the rate of protein synthesis as determined by the temperature at which protein 
expression was performed (MacDonald et al., 2003a).  
 
 
 
 
The aims of this study were:  
 
1.  To produce sufficient amounts of soluble α- and β-tubulin from several 
protozoa for further characterisation studies  
 
2.  To purify these proteins with minimal loses and without affecting the activity 
or three-dimensional structure of the recombinant tubulin  
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2.2.  Materials and Methods  
 
2.2.1.  DNA extraction and PCR amplification of protozoan 
tubulin genes  
 
The genomic DNA from G. duodenalis Portland strain (P1c10) and E. intestinalis (strain 
CDC:V297) was extracted using a modified cetyl trimethyl ammonium bromide (CTAB) 
method (Hopkins et al., 1997). The G. duodenalis α-tubulin gene (GDα-1) was amplified 
using the polymerase chain reaction (PCR) using primers designed to the GenBank 
accession number AF331826 (Elmendorf et al., 2001) and the β-tubulin gene (GDβ-1) 
to accession number XO6748 (Kirk-Mason et al., 1988) (Table 2.1).  
 
The  E. intestinalis  α-tubulin gene (EIα-1) sequence was PCR amplified using 
degenerate primers designed to the conserved 5’ amino acid motif MRE(I/L)VH(I/V) 
and the 3’ motif DYEEVG(V/A)(D/E). The E. intestinalis β-tubulin gene (EIβ-1) was PCR 
amplified using primers based on GenBank AF297876 (Table 2.1).  
 
The PCR mixture (50µl) contained 5µl Tth Plus 10X reaction buffer (containing 670mM 
Tris-hydrochloride (pH 8.8), 166mM ammonium sulphate, 4.5% Triton X-100, and 
2mg/ml gelatin), 1U Tth Plus DNA polymerase, 200µM each dNTP, 1.5mM magnesium 
chloride (all from Biotech International, Bentley, Western Australia), 1U Taq Extender 
DNA polymerase, (Stratagene, La Jolla, U.S.A.), 2% dimethyl sulphoxide (DMSO) 
(Merck, Kilsyth, Victoria), 25pmol  of  each  primer  (Gibco  BRL,  Rockville,  U.S.A.),      
5ng genomic DNA, and sterile distilled water (to 50µl). Amplifications were performed in 
a Perkin-Elmer PE 2400 thermal cycler (Foster City, U.S.A.) under the following 
conditions: 95°C for 5 min; 28 cycles of 95°C for 1 min, 55°C for 1 min, 74°C for 1 min; 
and a final 74°C elongation step for 8 min.  
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C. parvum oocysts (bovine assemblage) were initially suspended in 300µl lysis buffer 
(10mM Tris-hydrochloride (pH 6.8), 50mM ethylene diamine tetraacetic acid (EDTA), 
250mM sucrose, 8% Triton-X 100) and freeze-thawed four times to lyse the oocysts. 
They were then incubated at 56°C for 3 h with 50µl proteinase K (10mg/ml) as initially 
described by Morgan et al., (1995). Total RNA was extracted using the SV Total RNA 
Isolation system (Promega, U.S.A.) and reverse transcriptase (RT)-PCR was 
performed as described in the Omniscript RT-PCR kit (QIAGEN, Hilden, Germany). 
The C. parvum α-tubulin (CPα-1) and β-tubulin (CPβ-1) genes were RT-PCR amplified 
using primers designed to GenBank AFO82877 (Bonafonte et al., 1999) and Y12615 
(Cacciò et al., 1997), respectively, (Table 2.1).  
 
 
Gene and primer 
 
Primer sequence 
GDα-1  Forward primer
Reverse primer
5’ - GCGGAAGAATTCTCACGTGAGTGCATCTCG-3’  
5’ - GAACAAGCTTGCTTAGTAGGCGTCGTCCTC-3’  
GDβ-1  Forward primer
Reverse primer
5’ - ATCAGAATTCCGTCGTGAGATTGTCCACAT-3’  
5’- CAAGCTTTGCTACTCGTCGCCGAAGTCCTC-3’  
EIα-1   Forward primer
Reverse primer
5’ - GCGGAAGAATTCTCACGTGAGGTCATCTCG-3’  
5’ - GAACAAGCTTGCTTAGTAGGCGTCGTCCTC-3’  
EIβ-1   Forward primer
Reverse primer
5’ - ATCGAATTCGCAAGAGAAATCATACACTTG-3’  
5’ - GACGTTCTGCAGCAGTTAATTAACTAGAAA-3’  
CPα-1  Forward primer
Reverse primer
5’ - ATATTCCTGCAGGACAGAGAAGTTATTTCA-3’  
5’ - TTCAACCTGCAGGGATAACTAGAAATCGCC-3’  
CPβ-1   Forward primer
Reverse primer
5’ - AAGAACCTGCAGGACAGGGAAATTGTTCAT-3’  
5’ - TTCAACCTGCAGGGATAGTTAAGCCTCAAT-3’  
 
Table 2.1.  Primer sequences used to amplify protozoan tubulin genes.   
The likelihood of a PCR product being generated with these primers was 
assessed using the PCR Amplify programme version 1.2 (Bill Engels, 
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All the tubulin genes were amplified with unique 5' and 3' restriction sites for 
unidirectional cloning into pRSET-B (Invitrogen, Carlsbad, U.S.A.), pMAL-c2X (New 
England Biolabs, Beverly, U.S.A.), and pGEX-2T (Amersham Pharmacia Biotech, 
Buckinghamshire, England) and were maintained in E. coli strain TOP 10F' 
(Invitrogen). All the plasmid-tubulin constructs used for protein expression were 
sequenced using the ABI PRISM dye terminator cycle sequencing kit (PerkinElmer) 
according to the manufacturer’s recommended method. Sequencing primers were 
designed to the vector sequence 50 basepairs upstream (forward primer) and 
downstream (reverse primer) of the cloning site where the tubulin genes were inserted 
(Table 2.2). The forward and reverse sequences were analysed using the SeqEd 
version 1.0.3 (PerkinElmer) programme and aligned using the Clustal W (version 1.81) 
sequence alignment programme (Metrowerks).  
 
 
Vector and primer 
 
Primer sequence 
 
pRSET-B  
 
Forward primer 
Reverse primer 
 
5’- TAATACGACTCACTATAGGG-3’  
5’- TAGTTATTGCTCAGCGGTGG-3’  
 
pMAL-c2X  
 
Forward primer 
Reverse primer 
 
5’- CGATGAAGCCCTGAAAGACGCGCA-3’  
5’- GTAACGCCAGGGTTTTCCCAGTCA-3’  
 
pGEX-2T  
 
Forward primer 
Reverse primer 
 
5’- GGGCTGGCAAGCCACGTTTGGTGG-3’ 
5’- TTACAGACAAGCTGTGACCGTCTC-3’  
 
Table 2.2.  Primer sequences used to sequence protozoan tubulin genes.  
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2.2.2.  Expression of protozoan tubulin in E. coli  
 
The plasmid-tubulin constructs were transformed into the E. coli strains BL21(DE3), 
BL21(DE3)pLysS (Invitrogen), and BL21(DE3)RIL (Stratagene, Cedar Creek, U.S.A.) 
and single colonies were grown for 15 h at 37°C in 3ml Luria-Bertani (LB) broth 
containing 50µg/ml ampicillin and 35µg/ml chloramphenicol. The mid-log phase for 
each strain was determined using optical density (OD) measurements (wavelength 
600nm). The E. coli culture volumes were increased to 50ml and grown at 15°C, 25°C, 
30°C, or 37°C. Protein expression was induced with 1mM isopropyl-β-D-thiogalacto-
pyranoside (IPTG) when the OD600 was between 0.4 and 0.6. Soluble and insoluble 
protein expression levels were monitored by the removal of 1ml samples at 30 min 
intervals for a 6 h period. Uninduced bacterial cultures were also included to identify 
the basal bacterial protein expression levels. Negative controls for tubulin expression 
were the unligated plasmids pRSET-B, pMAL-c2X, and pGEX-2T which were also 
transformed into the E. coli strains and treated as described above.  
 
2.2.3.  Separation and analysis of recombinant tubulin 
solubility  
 
The  50ml  cultures  were  pelleted  by  centrifugation  at  4°C  then  resuspended  in         
0.1M MES (pH 6.5), 0.2M sodium chloride, 0.05% sodium azide, with protease 
inhibitors 1mM phenylmethylsulphonyl fluoride (PMSF), 0.7mg/ml leupeptin, and 
0.5mg/ml pepstatin A. The 1ml samples collected during expression were pelleted at 
4°C then resuspended in 100µl sample buffer, lysed by freeze-thawing, then 
centrifuged at 2,500 x g to separate the soluble (supernatant) and insoluble (pellet) 
expression fractions.  
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All the samples were analysed by gel electrophoresis and immunoblotting using Bio-
Rad Mini-Protean apparatus (Hercules, U.S.A.). The protein expression samples were 
analysed in a native form by agarose gel electrophoresis (AGE) and in a denatured 
form by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE: 
Laemmli, 1970). The native AGE sample buffer contained 62.5mM Tris-hydrochloride 
(pH 6.8), 7.5% Ficoll 400, and 0.01% bromophenol blue. The denaturing SDS-PAGE 
sample buffer contained 25% glycerol, 2.5% SDS, 62.5mM Tris-hydrochloride (pH 6.8), 
0.01% bromophenol blue, and 12.5% deionised water. The 4% agarose gels were 
prepared in buffer containing 90mM Tris-hydrochloride (pH 8.5), 90mM boric acid and 
electrophoresis was performed at 80V (constant voltage) for 60 min at 4°C. The           
12% Tris-glycine polyacrylamide pre-cast gels (Gradipore, Frenchs Forest, Australia) 
were electrophoresed at 80V (constant voltage) for 60 min in electrophoresis buffer 
containing 3.75% Tris-hydrochloride (pH 6.8), 1.25% SDS, and 18% glycine in distilled 
water. The AGE and SDS-PAGE gels were then stained for 12 h in Coomassie staining 
solution  containing  0.1%  Coomassie  Brilliant  Blue  R-250,  50%  distilled  water,          
40% methanol, and 10% acetic acid. The gels were de-stained in 50% distilled water, 
40% methanol, and 10% acetic acid for 24 h.  
 
Immunoblotting (i.e. Western and dot: Towbin et al., 1979) was performed using 
polyvinylidene difluoride (PVDF) transfer membranes (MSI, Westboro, U.S.A.) with 
polyclonal anti-poly-His (Invitrogen), anti-MBP (New England Biolabs), anti-GST 
(Amersham Pharmacia Biotech), or monoclonal anti-α-tubulin, and anti-β-tubulin 
primary antibodies (ICN Biomedicals, Aurora, U.S.A.). An alkaline phosphatase-
conjugated immunoglobulin G (IgG, whole molecule) secondary antibody (Sigma 
Chemical Company, St Louis, U.S.A.) was used for colorimetric detection using an 
alkaline phosphatase assay (Bio-Rad) performed according to the manufacturer’s 
recommended method.  
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2.2.4.  Purification of recombinant tubulin by affinity and 
ion-exchange chromatography  
 
Affinity chromatography of the tubulin fusion proteins was performed by binding the 
MBP-tubulin fusions to an amylose resin (New England Biolabs), GST-tubulin fusions 
to glutathione-agarose beads (Amersham Pharmacia Biotech), and poly-His-tubulin 
fusions to a nickel-nitriloacetic acid (Ni-NTA) resin (Invitrogen) at 4°C. The recombinant 
tubulin monomers were cleaved from the MBP partner using Factor Xa, from the GST 
partner using thrombin, and from the poly-His partner using an enterokinase enzyme. 
The tubulin was eluted in 0.1M MES (pH 6.5), 0.2M sodium chloride, and 0.05% sodium 
azide and was then separated from any MBP, GST, or poly-His contamination using 
anion-exchange chromatography with Uno-Q anion-exchange columns (Bio-Rad) at 
4°C. The eluants were analysed by AGE and SDS-PAGE and immunoblots as 
described above and quantified using a  Bio-Rad protein assay (Bradford, 1976).  
 
2.2.5.  Dimerisation of recombinant tubulin monomers  
 
The purified recombinant α- and β-tubulin monomers (5mg/ml) were dimerised in buffer 
containing 0.1M MES (pH 6.5), 1mM magnesium chloride, 1mM ethylene glycol-bis-   
(β-aminoethyl ether)-N, N, N’, N’-tetraacetic acid (EGTA), and 0.5mM GTP at 4°C for 30 
min. The progress of dimer formation was monitored by AGE and the inclusion of both 
the α- and β-tubulin components in the dimers was analysed by Western blotting as 
described above.  
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2.3.  Results  
 
The results of the expression of protozoan tubulin genes in E. coli demonstrated that 
they can be expressed at relatively high concentrations, of up to 50mg/l of purified 
protein, under a variety of conditions (Table 2.3). The choice of fusion partner and the 
temperature used for protein expression produced the most significant changes in 
soluble fusion protein concentrations. The results also demonstrated there was no 
detectable difference between the expression levels for the α- and β-tubulin genes from 
each protozoan while there were minor differences in α- and β-tubulin expression levels 
between the different protozoa.  
 
The effect of amino-terminal fusion partners on expression levels in the E. coli strain 
BL21(DE3)pLysS was tested. It was demonstrated that the two previously identified 
high-solubility partners, MBP and GST, produced a five-fold increase in soluble protein 
yields compared with the lower solubility poly-His partner (Table 2.3). This is likely to 
be due to an increased ability of the high-solubility proteins to compensate for and 
overcome the lower cytoplasmic solubility of tubulin and so maintain it in a soluble 
form, thus circumventing inclusion body formation. The highest expression levels prior 
to purification for the MBP fusion proteins of approximately 40% of the total cell protein 
agrees with the expected expression levels for a non-toxic MBP fusion protein in the   
E. coli cytoplasm (Hennig and Schäfer, 1998; Sachdev and Chirgwin, 1998b).  
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The effect of E. coli culturing temperature on the amount of soluble tubulin expressed 
was initially identified using a poly-His fusion partner (Fig. 2.1; MacDonald et al., 2001). 
As other protein expression systems (discussed below) have given optimal yields of 
soluble recombinant proteins at lower temperatures this was more fully examined using 
a high-solubility MBP fusion partner. Of the three parameters tested, expression 
temperature had the greatest effect on protein yield. At 37°C, expression of all three 
protozoan α- and β-tubulin genes was maximal and decreased by only 20% when the 
temperature was decreased to 30°C. Temperatures of 25°C and below resulted in a 
50% reduction in average yield of soluble tubulins.  
 
 
 
 
Fig. 2.1.  Expression of G. duodenalis β-tubulin at 37°C, 30°C, and 25°C. 
The variation in expression levels of soluble G. duodenalis MBP-β-tubulin at 
37°C (lane 1), 30°C (lane 2), and 25°C (lane 3) is illustrated in this SDS-
PAGE gel.  
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Parameter tested  
 
G. duodenalis
 
C. parvum 
 
E. intestinalis 
 
MBP  
 
40 – 50  
 
40 – 45  
 
35 – 40  
GST   35 – 40   40 – 45   35 – 40  
 
Fusion partner 
1 
poly-His   10 – 15   5 – 15   5 – 10  
 
BL21(DE3)  
 
10 – 20  
 
15 – 20  
 
10 – 20  
BL21(DE3)pLysS 30 – 40   30 – 40   30 – 40  
 
E. coli strain 
2  
BL21(DE3)RIL  25 – 35   25 – 35   20 – 30  
 
15°C  
 
<10  
 
<10  
 
<10  
25°C   15 – 20   15 – 20   15 – 25  
30°C   25 – 30   25 – 30   25 – 35  
 
Temperature 
3 
37°C   30 – 40   35 – 40   35 – 40  
 
Table 2.3.  Comparative expression of recombinant protozoan tubulin. 
Average yield (mg/l) of purified soluble recombinant α- and β-tubulin from  
G. duodenalis,  C. parvum, and E. intestinalis in several E. coli strains, 
expression temperatures, and fusion partners. The yields represent an 
average of quadruplicate samples.  
 
 
 
 
 
                                                 
1  Expression in E. coli strain BL21(DE3)pLysS at 37°C  
2  Expression as MBP-tubulin fusion proteins at 37°C  
3  Expression of MBP-tubulin fusion protein in E. coli strain BL21(DE3)pLysS  Chapter 2.  Expression of protozoan tubulin 
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The recombinant α- and β-tubulin monomers were demonstrated to form αβ-tubulin 
heterodimers under standard conditions in the presence of GTP and magnesium when 
analysed by Western (Fig. 2.2) and dot-blotting (Fig. 2.3). These results indicated that 
the band corresponding to the dimeric tubulin reacted with both the anti-α-  and        
anti-β-tubulin antibodies. They were therefore, found to not form αα- or ββ-homodimers 
which has been previously reported with recombinant nematode tubulin (Oxberry et al., 
2001a). The recombinant monomers also retained their antigenicity with monoclonal 
antibodies and Western (Fig. 2.2) and dot-blotting (Fig. 2.3). These results are a strong 
indication that the structural integrity of the tubulin monomers has been preserved 
throughout the expression and purification processes.  
 
 
 
Fig. 2.2.  Western-blot of monomerised αβ-tubulin from G. duodenalis,      
E. intestinalis, and C. parvum. G. duodenalis, E. intestinalis, and C. parvum 
αβ-tubulin heterodimers were dissociated and separated by SDS-PAGE. 
This Western-blot with anti-α-tubulin (lanes 1-3) or anti-β-tubulin (lanes 4-6) 
antibodies indicates that each heterodimer was composed of an α-  and      
β-tubulin monomer. The G. duodenalis (lane 1), E. intestinalis (lane 2), and 
C. parvum (lane 3) α-tubulin monomers had a molecular weight of 
approximately 50kDa. The G. duodenalis (lane 4), E. intestinalis (lane 5), 
and  C. parvum (lane 6) β-tubulin monomers had a molecular weight of 
approximately 48kDa.  
 
α-tubulin  
β-tubulin  
1   2  3  4  5 
75kDa  
 
50kDa  
 
 
37kDa  
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Fig. 2.3.  Dot-blot of monomeric recombinant α- and β-tubulin. The α- and  
β-tubulin from G. duodenalis (column 1), E. intestinalis  (column  2),  and     
C. parvum (column 3) were detected with monoclonal anti-α-tubulin (row 1) 
or anti-β-tubulin (row 2) antibodies.  
 
The protozoan α- and β-tubulin genes used for protein expression were sequenced in 
the expression vectors (i.e. pMAL-c2X, pRSET-B, pGEX-2T) using a standard dye-
terminator sequencing method. The sequencing primers were designed to match the 
vector sequences 50-basepairs upstream (forward primer) and downstream (reverse 
primer) from the tubulin gene insertion site. The sequences of all the tubulin-vector 
constructs indicated the correct codon reading frame had been maintained throughout 
the PCR, restriction enzyme digest, and ligation processes (Appendices I and II). The 
α- and β-tubulin sequences were analysed using the SeqEd programme and aligned 
using Clustal W with a ubiquitous Homo sapiens tubulin sequence for comparison.       
The sequences were deposited in the GenBank DNA database and have the following 
accession numbers: E. intestinalis  α-tubulin AY161322; E. intestinalis  β-tubulin 
AY161323;  C. parvum  α-tubulin AY161324; C. parvum  β-tubulin  AY161325;                
G. duodenalis  α-tubulin AY161326; and G. duodenalis  β-tubulin AY161327 and 
AF162281.  
 
Anti-α-tubulin antibody  
Anti-β-tubulin antibody  
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2.4.  Discussion  
 
An analysis of tubulin expression conditions as a means of maximising the amount of 
soluble recombinant protein through preventing or minimising inclusion body formation 
are presented. One of the strengths of this study was that the same protein was 
produced using several methods so that a comparison of the factors affecting its 
expression levels could be made, that is, the intrinsic effects due to tubulin were 
minimised. The cumulative effects of E. coli strain, fusion partner, and expression 
temperature have been previously demonstrated to have a significant effect on the 
level of expression of soluble proteins (Hollomon et al., 1998; Sheffield et al., 1999). 
However, it has also been suggested that there is no correlation between the 
propensity to inclusion body formation by a particular protein and its intrinsic properties 
such as molecular weight, hydrophobicity, and folding pathways (Lilie et al., 1998).  
 
To clearly identify the influence of the fusion partner on protein solubility a comparison 
was made between a relatively low solubility poly-His system (Kroll et al., 1993) and 
two higher solubility partners, MBP (Kapust and Waugh, 1999; Pryor and Leiting, 1997) 
and GST (Frangioni and Neel, 1993). These fusion partners were also chosen as they 
have the additional advantage of being purified using affinity chromatography and also 
have a fusion partner cleavage site within a few amino acids of the start of the protein 
of interest. These three fusion systems also use the T7 RNA promoter as indicated by 
the DE3 designation in the strain names signifying they contain the λDE3 lysogen 
which carries the gene for T7 RNA polymerase under the control of the lacUV5 
promoter. Therefore all the fusion systems used chemical induction with IPTG to initiate 
expression (Studier et al., 1990). Using the same promoter for all the expression 
systems tested removes any variability in soluble protein levels resulting from weaker 
or stronger promoters of protein expression.  
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It has previously been observed that recombinant protein expression levels can be 
reduced because of a limit in the amount of rare codons in E. coli which are present in 
lower amounts when compared with other organisms, particularly eukaryotes (Kleber-
Janke and Becker, 2000; McNulty et al., 2003), including protozoa. This has also been 
termed a codon bias amongst amino acid usage in E. coli compared with eukaryotic 
genes and it can reduce both the quality and quantity of recombinant proteins (Kane, 
1995) as a result of premature termination of translation, bypassing of codons, and 
misincorporation of amino acids (Calderone et al., 1996; Forman et al., 1998; McNulty 
et al., 2003).  
 
The effects of the codon bias are believed to be particularly significant when there are 
multiple consecutive rare codons near the amino-terminus of the coding sequence 
(Kurland and Gallant, 1996). It was therefore important to understand whether codon 
bias also resulted in low expression levels of protozoan tubulin genes, especially as 
they share high amino acid sequence and structural homology (80%) with the E. coli 
FtsZ cell-division protein (Erickson, 1998; Löwe and Amos, 1998; van den Ent et al., 
2001). To determine the amount of codon bias between E. coli and protozoan genes 
the Kazusa database was used (Nakamura et al., 2000). This contains the codon 
usage frequencies for the complete protein coding sequences compiled in the 
GenBank DNA database. The E. coli strains chosen for this study were BL21(DE3), 
BL21(DE3)pLysS, and BL21(DE3)RIL. The BL21(DE3)pLysS strain contains the pLysS 
plasmid which encodes the T7 lysozyme that inhibits the basal expression of the T7 
RNA polymerase and consequently the recombinant protein (Studier et al., 1990).  
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The BL21(DE3)RIL strain contains extra copies of the arginine (argU), isoleucine (ileY), 
and leucine (leuW) transfer RNA (tRNA) genes in order to produce high expression 
levels of proteins affected by this type of codon bias (Carstens and Waesche, 2001). 
These tRNAs recognise the AGA/AGG, AUA, and CUA codons, respectively, with 
different comparative codon usage between E. coli and particular protozoa (Table 2.4). 
Despite some codon bias differences the use of a strain providing extra rare tRNA 
genes, BL21(DE3)RIL, did not provide any additional benefit for the synthesis of 
protozoan  tubulin  when  compared  with  the  strain  containing  the  pLysS  vector           
(i.e. BL21(DE3)pLysS). There was however, an approximately two-fold increase 
between the strains containing the extra tRNAs and the basic BL21(DE3) strain     
(Table 2.3).  
 
 
Organism  
 
Codon 
 
tRNA product 
 
E. coli 
 
G. duodenalis
 
C. parvum  
 
E. intestinalis
 
AGA  
 
argU  
 
3.5  
 
6.1  
 
24.9  
 
17.7  
AGG   argU   2.0   9.6   6.3   10.5  
AUA   ileY   6.6   11.9   19.6   14.4  
CUA   leuW   4.2   7.1   7.8   13.4  
 
Table 2.4.  Comparative codon usage for particular codons by E. coli 
(strain BL21(DE3)), G. duodenalis, C. parvum, and E. intestinalis. Codon 
usage is indicated as frequency per thousand codons for codons thought to 
be in particularly low supply in E. coli (Nakamura et al., 2000).  
 
It has been demonstrated that the rate of protein synthesis can also have an effect on 
whether a recombinant protein is expressed in a soluble or insoluble state (Vasina and 
Baneyx, 1997). This has mainly been demonstrated by reducing the tendency of Chapter 2.  Expression of protozoan tubulin 
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certain proteins to aggregate when expressed at 37°C by lowering the rate of protein 
synthesis through decreasing the temperature, in turn increasing the amount of soluble 
protein expressed (Schein and Noteborn, 1988). The present study also demonstrated 
the effect of temperature upon soluble tubulin expression levels over a 37°C to 15°C 
range. Soluble protein expression levels were found to be significantly reduced below 
25°C when compared with 30°C and 37°C, although total protein expression levels of 
soluble and insoluble tubulin were relatively similar (data not shown). These results 
indicate there is an optimal temperature for expression of proteins with different fusion 
partners and these should be empirically investigated when optimising a protein 
expression system (MacDonald et al., 2003a).  
 
Taken together with previous studies on the expression of tubulin in a variety of host 
cells (Hollomon et al., 1998; Linder et al., 1997, 1998; Lubega et al., 1993; Oxberry     
et al., 2001a), the present results would indicate that the interplay between the intrinsic 
nature of tubulin, strength of the expression promoter, and choice of E. coli strain may 
have a greater effect on expression levels than other parameters, such as expression 
temperature or rate of protein synthesis. The pursuit of soluble protein expression is 
not a trivial one and until a more detailed structural analysis has been made of a 
protein in its native form, in a recombinant soluble form, and recombinant protein             
re-folded from inclusion bodies (Chaudhuri et al., 1999) it will not be known if incorrect 
conclusions are being made between in vivo and in vitro biological characteristics. 
These characteristics include protein-protein interactions (e.g. dimerisation) and 
antigenicity (e.g. monoclonal antibody reactivity). In addition to this, it has also been 
demonstrated that tubulin heterodimers lose some of their biological activities in a 
stepwise process during unfolding, activities which are not regained with refolding 
(Guha et al., 1997; Sackett et al., 1994). Significantly, drug-binding activities and the 
ability to form microtubules are functions which are lost in this manner.  Chapter 3.  Tubulin crystallisation studies 
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3.1.  Introduction  
 
The most recently solved atomic models of tubulin, with resolutions of 3.5Å           
(Löwe  et al., 2001) and 3.7Å (Nogales et al., 1998), were obtained by electron 
crystallography of 2-D zinc-induced crystalline sheets. While both these models 
represent significant milestones in tubulin’s structural determination the pursuit of an  
X-ray derived structural model is still essential. This is because several important 
regions, particularly of inter-dimeric interactions and nucleotide binding, cannot be 
clearly resolved with 2-D crystalline sheets (Löwe et al., 2001; Nogales et al., 1998). 
Recently, two groups have utilised similar crystallisation techniques to produce tubulin 
crystals stabilised with an anti-mitotic drug, podophyllotoxin (Schönbrunn et al., 1999), 
and a neuron-specific protein, SGC10 (Fleury et al., 2000). Unfortunately, the 
resolution of both these X-ray diffraction models was relatively poor, at 12Å and 6.1Å, 
respectively, compared with the most recent 3.5Å  electron  diffraction  model  (Löwe      
et al., 2001).  
 
There have been several unsuccessful attempts to produce X-ray quality 3-D crystals 
of tubulin (Amos et al., 1984; Lobert and Correia, 1991; Voter and Erickson, 1979). 
From these studies it has been proposed that the failure of tubulin to form 3-D crystals 
is primarily due to microheterogeneity in the tubulin sample as a result of it being 
extracted from brain tissue and therefore consisting of several different biotypes with a 
range of post-translational modifications. Other possible reasons for the failure of 
tubulin to form 3-D crystals include a high degree of thermal instability (Nogales et al., 
1995b) and a tendency to polymerise into pleomorphic structures, such as rings, 
plates, tubes, and sheets, even in the presence of microtubule stabilising compounds, 
such as paclitaxel (Nogales et al., 1995c; Schönbrunn et al., 1999; Wolf et al., 1993).  
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Significantly, the structurally unstable carboxy-terminal of tubulin is proposed to result 
in it having a large amount of conformational flexibility in solution (Jimenez et al., 
1999). To reduce this flexibility attempts have been made to crystallise subtilisin-
treated tubulin (i.e. tubulin-S) which removes the carboxy-terminus of the β-tubulin 
component of the heterodimer (Lobert and Correia, 1991; Redeker et al., 1992). The 
carboxy-terminus of the α-tubulin portion of the heterodimer is located within the inter-
monomeric region and is believed to be inaccessible to solvents (Nogales et al., 
1995a). Earlier crystallisation attempts also predicted that at a neutral pH this highly 
acidic carboxy-terminus would form a stable though unstructured conformation (Reed 
et al., 1992) which has since been confirmed by electron microscopy (Wolf et al., 
1996). In addition to this, the unstable carboxy-terminus has also been identified as a 
key site of proteolysis of tubulin which may also contribute to its thermal instability 
(Nogales et al., 1995b).  
 
This study of tubulin’s crystallisation properties was therefore designed to remove as 
many of the historical crystallisation problems as possible. The source of the tubulin 
was protozoan, rather than mammalian, and it was recombinant rather than extracted 
from the organisms. The recombinant protozoan tubulin was purified to greater than 
98% purity using affinity and anion-exchange chromatography and was maintained at 
4°C or -70°C prior to crystallisation trials. Monomeric and heterodimeric tubulin was 
utilised along with subtilisin-treated αβs-tubulin.  
 
The aims of this study were:  
 
1.  To investigate standard protein crystallisation techniques suitable for 
producing three-dimensional crystals of protozoan tubulin  
 
2.  To produce three-dimensional crystals of protozoan αβ-tubulin suitable for 
X-ray diffraction studies  Chapter 3.  Tubulin crystallisation studies 
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3.2.  Materials and Methods  
 
3.2.1.  Preparation and purification of recombinant tubulin  
 
Recombinant tubulin from G. duodenalis, E. intestinalis, and C. parvum were prepared 
as previously described (Chapter 2; MacDonald et al., 2003a). Briefly, the entire α- and 
β-tubulin genes were cloned into the pMAL-c2X vector (New England Biolabs) and 
MBP fusion proteins were expressed in the E. coli BL21(DE3)pLysS strain (Invitrogen). 
The tubulin fusion proteins were purified by affinity chromatography followed by 
cleavage of the MBP fusion partner with Factor Xa (New England Biolabs). The 
resulting tubulin monomers were further purified by anion-exchange chromatography 
using Uno-Q ion-exchange columns (Bio-Rad). The recombinant tubulin was 
concentrated using Centricon P30 ultrafiltration membranes (Millipore, Bedford, U.S.A.) 
at 4°C to final concentrations of 10, 20, or 30mg/ml. The recombinant α- and β-tubulin 
monomers,  αβ-tubulin heterodimers, and MBP-α- and MBP-β-tubulin fusion proteins 
were maintained in MBS buffer containing 0.1M MES (pH 6.5) and 0.2M sodium 
chloride (i.e. no protease inhibitors or preservatives were included) at -70°C.  
 
Subtilisin-treated  G. duodenalis  αβ-tubulin dimers (GDαβs-tub) were prepared by 
incubating G. duodenalis αβ-tubulin heterodimers in MBS buffer with 1% subtilisin (w/w) 
at 25°C for 45 min (Knipling et al., 1999; Redeker et al., 1992; Wolf et al., 1996). The 
reaction was stopped with 1% PMSF (w/v) in 100% DMSO. The progress of carboxy-
termini digestion was monitored by AGE (native) and SDS-PAGE (denatured) as 
described in Chapter 2.  
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3.2.2.  Vapour-diffusion method for screening 
crystallisation conditions  
 
The recombinant α- and β-tubulin monomers, αβ-tubulin heterodimers, and MBP-α- and 
MBP-β-tubulin fusion proteins were stored in MBS buffer at 4°C. The pH of the MBS 
buffer was tested from 5.4 to 6.5 at 0.1 pH unit intervals. The Hampton Research 
Crystal Screen reagents (Laguna Niguel, U.S.A.) were utilised to evaluate 104 unique 
combinations of pH, buffers, precipitants, and salt additives for their ability to promote 
crystal formation and growth. The details of the Crystal Screen I and 2 formulations are 
provided in Appendices III and IV, respectively.  
 
The hanging-drop vapour-diffusion method was used with 200µl Crystal Screen reagent 
in the reservoir and 2µl tubulin solution mixed with 2µl reagent in the hanging drop on a 
siliconised circular coverslip. Crystallisation plates were incubated at 4°C or 25°C 
(room temperature) and the progress of crystal development was monitored at 24 h,  
48 h, weekly for several months, and at bi-monthly intervals over a 2y period using 
stereo microscopy (10 – 100 x magnification).  
 
3.2.3.  Crystallisation trials with albendazole  
 
The effect of albendazole on the crystallisation of recombinant G. duodenalis α-, β-, and 
αβ-tubulin was assessed by adding 5% 0.1M albendazole in 100% DMSO to the tubulin 
solutions and applying them to the vapour-diffusion method described above.  
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3.3.  Results and Discussion  
 
Recombinant tubulin from G. duodenalis,  E. intestinalis, and C. parvum were 
expressed in E. coli to produce MAP- and post-translational modification-free tubulin 
monomers and dimers which were purified to greater than 98% purity as indicated by 
AGE and SDS-PAGE results (Chapter 2; MacDonald et al., 2003a). This highly 
homogenous form of monomeric and dimeric tubulin was investigated for its ability to 
form 3-D crystals suitable for X-ray crystallography.  
 
The combinatorial screening method tested 104 conditions for crystal formation and 
included a wide range of buffers, pHs, additives, and precipitants to promote crystal 
formation (Appendices III and IV). Initially, G. duodenalis  α-,  β-, and αβ-tubulin were 
tested with this screening method at 10, 20, or 30mg/ml concentrations in MBS buffer. 
Using this method, two sets of conditions were found to produce small (i.e. <1.0mm)   
3-D crystals. These conditions comprised: (1) 30% PEG-5000, 0.1M MES pH 6.5, and 
0.01M zinc sulphate or (2) 20% PEG-2000, 0.1M Tris, and 0.01M nickel chloride. The 
tubulin was heterodimeric and the crystals formed at 25°C after one week.  
 
The formation of 2-D microtubule crystals has been achieved previously using buffer 
containing MES, Pipes, sodium chloride, magnesium sulphate, and zinc sulphate (Wolf 
et al., 1996) to form zinc-induced crystalline sheets, as first described by Larsson et al., 
(1976). It is therefore interesting that conditions containing MES, sodium chloride, and 
zinc sulphate were also suitable for producing small 3-D crystals of recombinant 
tubulin. Further investigations of these conditions included testing the pH of the 
solution in which the tubulin was maintained in from pH 5.4 to 6.5 (0.1 pH unit 
increments), addition of the β-tubulin binding-drug, albendazole, de-carboxylation of the 
β-tubulin dimer portion with subtilisin (Wolf et al., 1996), and incubating the Chapter 3.  Tubulin crystallisation studies 
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crystallisation plates for over two years. These steps, however, did not improve the 
size or number of 3-D crystals of tubulin or produce 2-D microtubule crystals.  
 
The addition of microtubule stabilising drugs, such as paclitaxel (Nogales et al., 1995c) 
and podophyllotoxin (Schönbrunn et al., 1999), have been previously shown to 
promote the formation of 2-D and 3-D tubulin crystal forms, respectively. As 
albendazole has been demonstrated to bind with a high affinity to recombinant                     
G. duodenalis and E. intestinalis β-tubulin (discussed in Chapter 5) its tubulin stabilising 
properties were investigated. The albendazole, unfortunately, did not promote 
crystallisation with αβ- or β-tubulin from either parasite under the conditions tested in 
this study.  
 
As it has been proposed that a significant amount of tubulin’s structural heterogeneity 
is due to its highly acidic and unstructured carboxy-terminus (Löwe et al., 2001) it was 
predicted that removal of this region by subtilisin digest would produce a more stable 
protein structure (Lobert and Correia, 1991; Wolf et al., 1996). The subtilisin digest also 
reduced the overall charge of the protein (Table 3.1), an effect predicted to assist in the 
formation of stable crystalline structures at neutral pH values (Wolf et al., 1996). 
Subtilisin digestion of αβ-tubulin removed a small (approximate molecular weight 2kDa) 
fragment of approximately twenty amino acids from the  carboxy-terminal  of  the            
β-tubulin subunit (Fig. 3.1). The resulting αβs-tubulin had a greatly reduced negative 
charge as demonstrated by native AGE which separates the components of a mixed 
protein sample on the basis of their charge (Knipling et al., 1999; Redeker et al., 1992; 
Sackett et al., 1985).  
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Organism  
 
αβ-tubulin  
 
αβs-tubulin  
 
G. duodenalis  
 
4.90  
 
5.15  
E. intestinalis   4.94   5.11  
C. parvum   5.02   5.30  
H. sapiens   5.17   5.47  
 
Table 3.1.  Theoretical pI values of protozoan tubulin dimers. The decrease 
in  acidity  following  removal  of  the  carboxy-terminus  of  heterodimeric        
αβ-tubulin (αβs-tubulin) is compared with the native form (αβ-tubulin). 
Theoretical pI values were calculated using the ExPASy internet-based 
tools (http://au.expasy.org/tools/pi_tool.html) utilising the nucleotide 
sequences of the αβ-tubulin genes determined in Chapter 2 (Appendices I 
and II). These were used to produce the recombinant tubulin used in this 
study, with the exception of the Homo sapiens sequences which were 
determined using GenBank accession numbers CAA25855 (α-tubulin) and 
ABO88100 (β-tubulin) for the ubiquitous forms of tubulin.  
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Fig. 3.1.  Native gel of subtilisin digested G. duodenalis α- and β-tubulin. 
The carboxy-terminus of β-tubulin  was  removed  and  dimerised  with           
α-tubulin to form αβs-tubulin. When these are separated by non-denaturing 
AGE on the basis of charge the difference in charge between tubulin and 
subtilisin-treated tubulin is clearly illustrated.  
 
Interestingly, some investigators have examined the improvement in crystallisation 
properties of proteins which are difficult to crystallise brought about by the inclusion of 
carrier proteins such as the high-solubility fusion partners MBP (Center et al., 1998) 
and GST (Lally et al., 1998; Zhan et al., 2001). The main requirements for carrier 
protein-driven crystallisation are that the carrier protein must be highly soluble and form 
well-ordered crystals suitable for high-resolution diffraction studies (Rhodes, 2000).     
As MBP satisfies these criteria, this approach was also investigated in this study using 
the G. duodenalis MBP-α- and MBP-β-tubulin fusion proteins. While the MBP-tubulin 
fusion proteins did not form 3-D crystals this approach could be modified and 
potentially be successful. In this study, the MBP fusion proteins placed the MBP on the 
amino-terminal of the tubulin proteins. If the MBP protein expression vectors were 
modified to place the MBP on the carboxy-terminal of the tubulin proteins it may 
remove some of the tubulin’s structural heterogeneity as well as attaching a highly 
soluble and well characterised carrier protein to them. This may also improve the 
crystallisation of the tubulin monomers or heterodimers.  
 
α-tubulin 
βs-tubulin  
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3.4.  Conclusions  
 
In the determination of the 3-D structure of heterodimeric tubulin one of the primary 
limitations of the techniques employed to date has been that only 2-D crystals have 
been produced and as a result of this it has not been possible to use high-resolution  
X-ray crystallography. This limitation has meant that only electron crystallography has 
been used and this has limited resolution, providing less detail of secondary structures 
when compared with X-ray crystallography.  
 
In order to address this problem a 3-D crystal of αβ-tubulin suitable for X-ray diffraction 
studies is required. The present study was undertaken to investigate techniques 
available for the crystallisation of highly purified and highly homogeneous recombinant 
protozoan tubulin. As the production of recombinant tubulin results in a protein which 
contains only one α- or β-tubulin isotype, and which is also free of post-translational 
modifications and MAPs, it is potentially suitable for the production of 3-D crystals. This 
approach would also address the reasons which have been proposed for extracted 
brain tubulin failing to form 3-D crystals, despite numerous trials and technical 
improvisations (Jan Löwe and Eva Nogales, personal communication). Recombinant 
heterodimeric tubulin however, is still conformationally unstable due primarily to the 
presence of a highly acidic and unstructured carboxy-terminus, and very high thermal 
instability. As the crystallisation trials of monomeric or dimeric tubulin, MBP-tubulin 
fusion proteins, and αβs-tubulin produced only small 3-D crystals it is possible that other 
intrinsic characteristics of tubulin prevented it from successfully forming 3-D crystals.  
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4.1.  Introduction  
 
As the production of an X-ray crystallography structure of protozoan αβ-tubulin was not 
successful (Chapter 3) an alternative approach that can be utilised to determine the 
structural differences between two proteins is based on comparative or homology 
modelling. Homology models are commonly utilised to compare the structure of 
different protein biotypes when a high-resolution model of one biotype is available.  
 
To date, there is no comparative modelling data available for the benzimidazoles, 
either for understanding the basis of drug action or resistance. Therefore, this type of 
comparative modelling can provide a significant amount of structural information that 
cannot be produced by other techniques. This is particularly true as the formation of   
3-D αβ-tubulin crystals (with or without benzimidazole compounds) which are suitable 
for X-ray crystallography has not been achieved. However, comparative modelling can 
be utilised to develop a model of the benzimidazole-binding site as the 3-D structure of 
two benzimidazole-insensitive organisms has been determined. These are the 3.7Å 
model of porcine αβ-tubulin (Nogales et al., 1999) and the 3.5Å  model  of  bovine         
αβ-tubulin (Löwe et al., 2001). The detailed electron-density map which has been 
produced in this way is suitable for comparative molecular modelling. Essentially, this 
type of homology modelling technique is crucial to understanding the molecular basis 
of benzimidazole binding as it will assist in identifying which amino acids are potentially 
involved in the formation of the benzimidazole binding site of β-tubulin.  
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This study was undertaken to provide additional structural information regarding the 
location of the benzimidazole-binding site on protozoan αβ-tubulin through utilisation of 
the crystal structure of bovine αβ-tubulin as a model to predict the structure of the 
protozoan form of the protein. The rationale behind this approach is that the 3-D map 
of the electron density, hydrophobicity, and solvent accessibility of β-tubulin will 
illustrate significant areas of difference on β-tubulin from either benzimidazole-
insensitive or -sensitive organisms. In turn, by combining the location of these 
differences with the amino acid residues which have been proposed to be involved in 
the formation of the benzimidazole-binding site, that a 3-D map of the binding site on 
protozoan αβ-tubulin will be produced.  
 
By using this approach it was possible to develop a model of the benzimidazole-
binding domain on G. duodenalis and E. intestinalis β-tubulin and identify an area of 
increased hydrophobicity, which is absent from the β-tubulin of insensitive organisms 
such as Bos taurus,  C. parvum, and H. sapiens. The homology model-derived 
benzimidazole-binding site involves a distinctive hydrophobic binding domain from 
residues Ala-186 to Phe-213 on the β-tubulin monomer of sensitive protozoa. The 
interactions which are likely to occur between several benzimidazoles and the 
comparative side groups of the amino acids in this binding domain are described with 
respect to benzimidazole-sensitive and -insensitive organisms.  
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4.2.  Materials and Methods  
 
4.2.1.  Homology modelling of protozoan tubulin  
 
The structural co-ordinates for the 3.7Å model of porcine αβ-tubulin (1TUB.pdb: 
Nogales et al., 1999) and the 3.5Å model of bovine αβ-tubulin (1JFF.pdb: Löwe et al., 
2001) were retrieved from the Research Collaboratory for Structural Bioinformatics 
(RCSB) Protein Data Bank (PDB; http://www.rcsb.org/pdb/: Berman et al., 2000; 
Westbrook  et al., 2003). Homology models comparing the 3-D structure of the 
mammalian and protozoan tubulin monomers were created using the Swiss-MODEL 
server (http://www.expasy.ch/swissmod/). Homology models were received via e-mail 
and visualised using the Swiss-PDB Viewer (http://www.expasy.org/spdbv/mainpage: 
Schwede  et al., 2003) and RasMol (http://www.openrasmol.org/) programmes. The 
deduced amino acid sequences of the G. duodenalis, E. intestinalis, and C. parvum    
α- and β-tubulin genes, which were expressed in E. coli (Chapter 2; MacDonald et al., 
2001, 2003a) and were used for benzimidazole binding kinetic studies (Chapter 5; 
MacDonald et al., 2003b), were used to produce the homology model with the bovine 
α-tubulin (1JFFA.pdb) and β-tubulin (1JFFB.pdb) structural co-ordinates.  
 
4.2.2.  Modelling of benzimidazole compounds  
 
The structure of each benzimidazole used for β-tubulin binding kinetic studies     
(Chapter 5; MacDonald et al., 2003b) was produced using ISIS Draw version 2.3. 
Additionally, the structural co-ordinates for the central benzimidine ring structure were 
obtained from the PDB entry for 1L5F.pdb (Cheong et al.,  2002).  The  structural         
co-ordinates for albendazole and mebendazole were obtained from the HIC-Up 
database (http://xray.bmc.uu.se/hicup/: Kleywegt and Jones, 1998). These 3-D 
structures were utilised to obtain the size of each benzimidazole using the RasMol or 
Swiss-PDB Viewer programme.  Chapter 4.  Molecular modelling of benzimidazoles 
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4.3.  Results  
 
4.3.1.  Amino acid sequence comparison  
 
4.3.1.i. Comparison of β-tubulin sequences from 
mammalian and protozoan organisms  
 
The β-tubulin deduced amino acid sequences from several benzimidazole-insensitive 
and -sensitive organisms were aligned (Appendix II) to facilitate the identification of 
amino acids potentially involved in the formation of the benzimidazole-binding site. The 
β-tubulin alignment also illustrates the differences between mammalian and protozoan 
forms of tubulin and the selectivity of the benzimidazoles efficacy may be reflected in 
these differences. The alignment of the β-tubulin deduced amino acid sequences of    
B. taurus,  H. sapiens,  C. parvum,  G. duodenalis, and E. intestinalis (Appendix II) 
represents a comparison of mammalian and protozoan tubulin. There are 23 amino 
acid substitutions in the 439 amino acid sequence (Table 4.1) which represents a         
5% difference between mammalian and protozoan β-tubulin at the amino acid level. 
While this type of sequence alignment has been used previously to identify potential 
benzimidazole-binding sites (Edlind et al., 1994; Jung et al., 1992; Kwa et al., 1995) it 
does not indicate the differences between benzimidazole-sensitive and -insensitive 
organisms. It should be noted that at the positions where two possible amino acid 
substitutions were observed (i.e. 35, 44, 56, 153, 165, 196, 200, 231, 232, 238, 268, 
349, 351) the differences were always between C. parvum and both G. duodenalis, 
and E. intestinalis. These divergent substitutions represent 13 of the 23 substitutions 
(56%). This means that most of the amino acid substitutions observed by performing 
this type of primary sequence-based alignment are unlikely to play a central role in 
benzimidazole binding although they may be involved in the formation of the 
benzimidazole-binding site. This idea is further supported by the fact that these 
substitutions are present in the benzimidazole-insensitive C. parvum sequence.  Chapter 4.  Molecular modelling of benzimidazoles 
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4.3.1.ii.  Comparison of β-tubulin sequences from 
benzimidazole-sensitive or -insensitive 
organisms  
 
When comparison is made between the β-tubulin deduced amino acid sequences of 
benzimidazole-sensitive and -insensitive organisms there are 14 amino acid 
differences which represents 2.5% of the total amino acid sequence (Table 4.1). The 
notable substitutions change five amino acids from polar uncharged residues 
(benzimidazole-insensitive organisms) to nonpolar hydrophobic residues 
(benzimidazole-sensitive organisms). These polar to hydrophobic substitutions occur at 
amino acid residues at positions 145, 196, 200, 232, and 280 in the β-tubulin protein. In 
addition to this, two substitutions between benzimidazole-insensitive and -sensitive 
organisms alter the side-chain polarity of the amino acids involved. This occurs at 
positions 296 and 373 in the β-tubulin protein where the nonpolar hydrophobic alanine 
residue (benzimidazole-insensitive organisms) is substituted with either asparagine, 
serine, or cysteine (benzimidazole-sensitive organisms), which all have polar 
uncharged amino acid side-groups.  
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Position 
 
Benzimidazole-
insensitive  
 
Amino 
acid 
charge 
 
Benzimidazole-
sensitive  
 
Amino 
acid 
charge 
 
Effect of 
substitution  
 
30  
 
Isoleucine  
 
NH  
 
Valine  
 
NH  
 
None  
 
33  
 
Threonine  
 
PU  
 
Serine  
 
PU  
 
None  
 
37  
 
Histidine  
 
Positive 
 
Arginine  
 
Positive  
 
None  
 
145  
 
Serine  
 
PU  
 
Alanine  
 
NH  
 
Increased 
hydrophobicity 
 
163  
 
Isoleucine  
 
NH  
 
Methionine  
 
NH  
 
None  
 
165  
 
Asparagine / 
Glutamine  
 
PU  
 
Cysteine  
 
PU  
 
None  
 
196  
 
Threonine / 
Serine  
 
PU  
 
Alanine  
 
NH  
 
Increased 
hydrophobicity 
 
200  
 
Tyrosine / 
Glutamine  
 
PU  
 
Phenylalanine  
 
NH  
 
Increased 
hydrophobicity 
 
231  
 
Alanine / Valine 
 
NH  
 
Leucine  
 
NH  
 
None  
 
232  
 
Threonine  
 
PU  
 
Valine  
 
NH  
 
Increased 
hydrophobicity 
 
258  
 
Valine  
 
NH  
 
Isoleucine  
 
NH  
 
None  
 
280  
 
Glutamine  
 
PU  
 
Isoleucine or 
Lysine  
 
NH  
 
Increased 
hydrophobicity 
 
296  
 
Alanine  
 
NH  
 
Asparagine or 
Serine  
 
PU  
 
Increased 
polarity  
 
373  
 
Alanine  
 
NH  
 
Cysteine or 
Serine  
 
PU  
 
Increased 
polarity  
 
Table 4.1.  Comparison of β-tubulin amino acid differences between 
benzimidazole-sensitive and -insensitive organisms. The charge of the 
amino acids shown in this table is described as nonpolar hydrophobic (NH), 
polar uncharged (PU), or positive.  Chapter 4.  Molecular modelling of benzimidazoles 
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4.3.2.  Tubulin homology model validation  
 
The quality of the homology models created using the Swiss-MODEL server was 
assessed by modelling the two published αβ-tubulin 3-D models against each other.    
In this way the α- or β-tubulin  amino  acid  sequences  used  to  obtain  the  porcine          
αβ-tubulin model were modelled against the bovine α- or β-tubulin models (1JFFA.pdb 
and 1JFFB.pdb, respectively) (Fig. 4.1 and 4.2). Conversely, the bovine α- or β-tubulin 
amino acid sequences were also modelled with the porcine α- or β-tubulin structures 
(1TUBA.pdb and 1TUBB.pdb, respectively). It should be noted that the porcine and 
bovine  αβ-tubulin models had different resolutions; the porcine structure had a 3.7Å 
resolution (Nogales et al., 1998) while the bovine model had a resolution of 3.5Å (Löwe 
et al., 2001). The difference in the resolution in these two models resulted in the bovine 
3.5Å  model having fewer amino acids whose side-chain location within the 3-D 
structure of the protein could not be unambiguously resolved (Löwe et al., 2001). Using 
this approach it was possible to determine that this method of creating a homology 
model based on a protein amino acid sequence and the Swiss-MODEL programme 
was a valid means of obtaining a robust 3-D model.  
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Fig. 4.1.  Homology model of porcine and bovine α-tubulin. This homology 
model shows the amino acid sequence of porcine α-tubulin (green) which 
was threaded onto the bovine α-tubulin (blue) 3-D structure. GDP is shown 
in white and the monomer is viewed from the inter-monomeric region of the 
α-tubulin monomer.  
 Chapter 4.  Molecular modelling of benzimidazoles 
- 73 - 
 
 
Fig. 4.2.  Homology model of porcine and bovine β-tubulin. This homology 
model shows the amino acid sequence of porcine β-tubulin (green) which 
was threaded onto the bovine β-tubulin (blue) 3-D structure. GTP is shown 
in white and the monomer is viewed from the plus- or assembling-end of 
the microtubule.  
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4.3.3.  Homology modelling of protozoan αβ-tubulin  
 
The deduced amino acid sequences of G. duodenalis, E. intestinalis, and C. parvum   
β-tubulin which were expressed in E. coli (Chapter 2; MacDonald et al., 2003a) and 
used for benzimidazole binding kinetic studies (Chapter 5; MacDonald et al., 2003b) 
were utilised in creating the homology models. The  structural  models  of  protozoan      
β-tubulin were created using the structural co-ordinates of the 3.5Å bovine β-tubulin 
model (1JFFB.pdb) and Swiss-MODEL. The homology models were visualised using 
Swiss-PDB Viewer and RasMol. As the α-tubulin monomer has not been proposed to 
be involved in benzimidazole binding it was not included in the homology modelling 
procedure. It should also be noted that as the carboxy-terminus of bovine β-tubulin is 
not present in the 3.5Å model, and so would not be included in the homology model, it 
was deleted from the protozoan β-tubulin amino acid sequence prior to construction of 
the bovine-protozoan homology models.  
 
The carboxy-terminus of the β-tubulin monomers include amino acids from Arg-280 to 
Gln- or Asn-439 and has been proposed to form an unstructured and highly disordered 
region of the protein (Nogales et al., 1998; Wolf et al., 1996). In addition, for the 
purposes of modelling potential benzimidazole-binding sites, the β-tubulin carboxy-
terminus is not located within 10Å of the postulated key benzimidazole-binding residue, 
Phe-200 (Fig. 4.6). From this it was assumed that the carboxy-terminus region of               
β-tubulin is not involved in the formation of the benzimidazole-binding site.  
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The overall structure of the β-tubulin monomer was found to be highly conserved 
between the protozoan and mammalian forms of the protein. This high degree of 
homology was also predicted from the primary amino acid sequences that are 85-90% 
homologous. However, the location of residues that are substituted between 
benzimidazole-sensitive and -insensitive organisms can be visualised on this model 
(Fig. 4.3). From the mammalian-protozoan β-tubulin homology model it was observed 
that the substituted residues are located throughout the 3-D structure of β-tubulin.  
 
 
QuickTime™ and a TIFF (Uncompressed) decompressor are needed to see this picture.
 
 
Fig. 4.3.  The location of substituted amino acids between mammalian and 
protozoan  β-tubulin. The amino acid residues that are altered between a 
benzimidazole-insensitive (left, red) and -sensitive (right, green) organism 
are shown on this β-tubulin homology model.  
 
 
 Chapter 4.  Molecular modelling of benzimidazoles 
- 76 - 
As several amino acid substitutions were identified between the benzimidazole-
sensitive and -insensitive organisms that alter the hydrophobicity of the amino acids 
involved (Table 4.1) it was considered whether or not these substitutions would affect 
the overall hydrophobicity of particular regions of the β-tubulin protein. This is also an 
important consideration regarding benzimidazole-binding as it has been proposed to be 
dependent on covalent interactions (Lacey, 1988; Prichard, 2001). When the electron-
density of a comparative model of β-tubulin from the benzimidazole-insensitive bovine 
and -sensitive G. duodenalis or E intestinalis was visualised a substantial difference in 
hydrophobicity was observed (Fig. 4.4). This model was orientated so that the plus-end 
or assembling portion of the β-tubulin monomer was visible to mirror the manner in 
which the microtubule would be exposed during heterodimer polymerisation or 
assembly  in vivo. Interestingly, the large hydrophobic region of G. duodenalis  and      
E. intestinalis was located in this region of the β-tubulin protein.  
 
QuickTime™ and a TIFF (Uncompressed) decompressor are needed to see this picture.
 
 
Fig. 4.4.  Electron density map (red) of bovine and E. intestinalis β-tubulin. 
The homology model of B. taurus (left) and E. intestinalis (right) β-tubulin is 
viewed from the plus or assembling end. The yellow bars indicate the 
location of the M-loop on the β-tubulin monomers.  Chapter 4.  Molecular modelling of benzimidazoles 
- 77 - 
When the β-tubulin homology models were visualised from the plus-end of the 
microtubule the location of the structurally important M-loop was observable (Fig. 4.4). 
The M-loop region is composed of amino acid residues from position 279 to 287 in the 
β-tubulin protein (Nogales et al., 1998; Nogales, 2000). The M-loop was incorporated 
into the large hydrophobic region of β-tubulin from benzimidazole-sensitive organisms 
(i.e. G. duodenalis or E. intestinalis) but was absent from the model of β-tubulin from 
benzimidazole-insensitive organisms (i.e. mammalian or C. parvum). This is significant 
as the β-tubulin M-loop is structurally important in the formation of stable inter-dimer 
contacts between adjacent assembling microtubule heterodimers (Nogales et al., 
1999). In particular, this region of the β-tubulin component of the microtubule-bound  
αβ-tubulin  heterodimer  forms  lateral  contacts  with  the  H1  and  H3  regions  of  the           
α-tubulin component of αβ-heterodimers as they are incorporated into the microtubule 
(Nogales et al., 1999). This is a significant region of α-tubulin as it is also believed to be 
the site of GTP binding and subsequent hydrolysis when the αβ-heterodimer is 
polymerised to form a stable component of the microtubule (Nogales, 2000).  
 
This model provides two key pieces of evidence that the benzimidazole-binding site is 
located in this region of the β-tubulin protein. Firstly, it is a highly hydrophobic region of 
the protein found only in this region of the β-tubulin monomer. Secondly, this region of 
the β-tubulin monomer is exposed to the cellular environment, or ligands therein, during 
microtubule assembly. Benzimidazoles have been proposed to arrest microtubule 
assembly (Gill and Lacey, 1992; Lubega and Prichard, 1991a) and this location of the 
drug-binding site within this region would support this drug-binding model.  
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4.3.4.  The β-tubulin–benzimidazole hydrophobic binding 
region  
 
The electron density map of hydrophobicity of β-tubulin from benzimidazole-sensitive 
and -insensitive organisms has identified a structurally important region of increased 
hydrophobicity in the sensitive organisms that is highly accessible during microtubule 
assembly (Fig. 4.4). Within this region are several residues that are substituted 
between benzimidazole-sensitive and -insensitive organisms. These residues include 
amino acids Cys-165, Ala-196, Phe-200, Leu-231, and Val-232. These residues are 
also  located  within  three  structurally  important  loop  regions  named  T5  (Ala-196),        
T6 (Phe-200), and T7 (Leu-231 and Val-232). In particular, the T6-loop region 
encompasses amino acids Ala-186 to Asp-205 (Fig. 4.5) and has been identified as 
being structurally important as it is located adjacent to the M-loop in the 3.5Å model of 
β-tubulin (Löwe et al., 2001; Nogales et al., 1999). The T6-loop region also includes 
several amino acids that have been proposed to result in the benzimidazole-resistant 
phenotype in the parasitic nematode, H. contortus (Beech et al., 1994; Kwa et al., 
1995; Nare et al., 1996). More particularly, the amino acids located at position 198, 
199, and 200 in the β-tubulin protein have been proposed to confer benzimidazole-
resistance in H. contortus by utilising comparative nucleotide sequence data.  
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Fig. 4.5.  The T6-loop region of protozoan β-tubulin. The amino acid 
residues spanning the region Ala-186 to Phe-213 are indicated with GTP at 
the top of the loop region. The T6-loop is viewed in cross-section through 
the β-tubulin monomer with the microtubule interior on the left and exterior 
on the right.  
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The T6-loop region creates a 3-D structure with a cone-like shape with a depth of 
17.20Å and an upper distance between residues Ala-187 and Asp-205 of 13.30Å    
(Fig. 4.6). The benzimidazoles utilised in the drug-binding kinetics component of this 
study (Chapter 5) were all R5-carbamate derivatives with the exception of 
thiabendazole (Fig. 5.1; Table 5.1). The benzimidazoles used in this modelling study 
were albendazole, albendazole-sulphoxide, fenbendazole, mebendazole, 
oxibendazole, parbendazole, and thiabendazole. The central benzimidine ring structure 
of these benzimidazoles had an average size of 4.55Å (Fig. 4.7). The benzimidazole R5 
analogues, including the R2-carbamate side-chain, have a minimal length of 9.25Å 
which increased depending upon the length of the R5 side-chain.  
 
The models of each benzimidazole within the proposed hydrophobic binding domain 
(Fig. 4.5) provides some information in relation to the interaction of the different 
benzimidazole derivatives with the amino acids of this binding region (Fig. 4.8 to 4.21). 
The benzimidazole interaction plots were determined for benzimidazole-sensitive and   
-insensitive organisms. Within this region, the key amino acid interactions are proposed 
to involve Ile-189, Val-199, and Phe-200 which are all located at the base of the 
proposed binding region (Fig. 4.5). These three residues in benzimidazole-sensitive 
organisms also increased the hydrophobicity of this region of the β-tubulin monomer 
(Fig. 4.4).  
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Fig. 4.6.  Distances between amino acids of the hydrophobic 
benzimidazole-binding domain of protozoan β-tubulin. The secondary 
structure of this region is also indicated with α-helix (red), β-sheet (yellow), 
and loop region (grey). The amino acid residues  spanning  the  region     
Asn-186 to Ala-208 are indicated. The T6-loop is viewed in cross-section 
through the β-tubulin monomer with the microtubule interior on the left and 
exterior on the right.  
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Fig. 4.7.  Distances within the R5-carbamate benzimidazole derivatives. 
The length of the central benzimidine ring structure was determined to be 
4.55Å. The length of the central benzimidine rings with the R2-carbamate 
group was found to be 9.25Å.  
 
 
The proposed benzimidazole-binding site places the R5 side-chain in close proximity to 
the side-chains of residues Ile-189, Leu-192, Val-199,  Phe-200,  and  Cys-201  of          
β-tubulin from sensitive organisms. For each benzimidazole utilised in this study the 
chemical identity of the R5 side-chain was shown to determine the nature of the 
interaction particularly with the Ile-189 to Cys-201 region of the binding domain.  
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4.3.5.  Interaction models of benzimidazole compounds 
with β-tubulin  
 
4.3.5.i.  Interaction models of albendazole and 
albendazole-sulphoxide with β-tubulin  
 
In considering the structure of the benzimidazole compounds utilised in this study, 
albendazole and albendazole-sulphoxide differ only by the presence of an oxide group 
between the R5 sulphide moiety and the propyl side-chain shared by both albendazole 
and albendazole-sulphoxide. The location of this oxide group is significant as this 
model identifies a potential interaction between this group and the aliphatic side-group 
of Ile-189 (Fig. 4.9). As the β-tubulin amino acid at position 189 is altered from Ile-189 
to Val-189 in benzimidazole-insensitive organisms this side-group is likely to be 
involved in the formation of significant benzimidazole-binding interactions (Fig. 4.8).  
 
The sulphoxide group of albendazole-sulphoxide extends the distance that the propyl 
side-chain extends into the hydrophobic binding region. Specifically, instead of creating 
one potential interaction between the R5  side-chain  of  albendazole  with  Phe-200     
(Fig. 4.8) the propyl carbon chain of albendazole-sulphoxide places both the first and 
third carbon groups of the propyl side-chain in contact with the aromatic side-group of 
Phe-200 and the aliphatic side-group of Val-199 (Fig. 4.9). This is in contrast to the 
comparable region of the β-tubulin model of albendazole-insensitive organisms where a 
relatively chemically inert oxide group (Tyr-200) and hydroxyl side-group (Thr-199) are 
found (Fig. 4.8).  
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Fig. 4.8.  Structure of albendazole in proposed binding domain of 
benzimidazole-insensitive organisms.  
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Fig. 4.9.  Structure of albendazole in proposed binding domain of 
benzimidazole-sensitive organisms.  Chapter 4.  Molecular modelling of benzimidazoles 
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Fig. 4.10.  Structure of albendazole-sulphoxide in proposed binding domain 
of benzimidazole-insensitive organisms.  
 
N
O
S
N
O
N
O O
N
O O
N
O
N O
Cys201 Ile202
Asp203
Val199
Ala185
Thr186
Ser188
Ile189
Leu
192
N
O
N
O
Phe200
N
O
N
O
O
O
Albendazole sulphoxide
S C4
N
1
C7
C
2
C5
C6
N3
N
O
O
O
 
 
Fig. 4.11.  Structure of albendazole-sulphoxide in proposed binding domain 
of benzimidazole-sensitive organisms.  Chapter 4.  Molecular modelling of benzimidazoles 
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4.3.5.ii.  Interaction models of fenbendazole and 
mebendazole with β-tubulin  
 
Fenbendazole and mebendazole are structurally distinct from the other benzimidazoles 
used in this study due to the presence of a phenyl ring linked to the R5 position of the 
central benzimidine ring structure by either a sulphyl (fenbendazole) or carbonyl 
(mebendazole) group. The proposed binding model places the phenyl-ring structure in 
close proximity to the aliphatic side-group of Ile-189 (sensitive) (Fig. 4.13 and 4.15) 
which has a stronger electron-withdrawing capacity than Val-189 (insensitive) for both 
fenbendazole and mebendazole (Fig. 4.12 and 4.14). The sulphyl (fenbendazole) or 
carbonyl (mebendazole) group of both these drugs is proposed to form an electrophilic 
interaction with the oxide component of the sulphydryl side-group of Cys-201 (Fig. 4.13 
and 4.15). The presence of a carbonyl group in the mebendazole R5 side-chain 
introduces an additional interaction to those seen for fenbendazole (Fig. 4.14). This 
involves the hydrophobic phenyl ring of Phe-200 which is absent from the uncharged 
side-group of Tyr-200 of insensitive organisms (Fig. 4.14). In addition to this, the higher 
hydrophobicity of Val-199 (Fig. 4.15) compared with the uncharged Thr-199 of 
insensitive organisms (Fig. 4.14) is likely to further stabilise the carbonyl-phenyl-based 
interaction of mebendazole with residue Phe-200.  
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Fig. 4.12.  Structure of fenbendazole in proposed binding domain of 
benzimidazole-insensitive organisms.  
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Fig. 4.13.  Structure of fenbendazole in proposed binding domain of 
benzimidazole-sensitive organisms.  Chapter 4.  Molecular modelling of benzimidazoles 
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Fig. 4.14.  Structure of mebendazole in proposed binding domain of 
benzimidazole-insensitive organisms.  
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Fig. 4.15.  Structure of mebendazole in proposed binding domain of 
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4.3.5.iii.  Interaction models of oxibendazole and 
parbendazole with β-tubulin  
 
Oxibendazole and parbendazole differ from albendazole and albendazole-sulphoxide 
only in the loss of the R5-sulphyl group which is proposed to interact with the oxide 
component of the sulphydryl side-group of Cys-201 forming a relatively stable 
electrophilic interaction (Fig. 4.9 and 4.11). The main difference between oxibendazole 
and parbendazole is the extent to which the R5 carbon side-chain extends into the 
binding domain (Fig. 4.16 and 4.19). When the spatial location of the side-chain is 
considered, the butyl side-chain of parbendazole interacts with two substituted amino 
acid side-groups, the aromatic phenyl group of Phe-200 and the hydrophobic aliphatic 
group of Val-199 (Fig. 4.19). This could suggest the formation of a more stable 
complex between parbendazole and β-tubulin compared with the stability proportioned 
by the shorter propyl-group of oxibendazole. With respect to the propyl side-chain of 
oxibendazole, the proposed benzimidazole-binding site amino acid which may interact 
with the propyl side-chain is Phe-200 as this carbon chain is too short to bind with   
Val-199 (Fig. 4.17). The basis of the interaction with Phe-200 may involve hydrophilic 
binding between the oxibendazole R5 carbon chain with the aromatic phenyl side-group 
of Phe-200.  
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Fig. 4.16.  Structure of oxibendazole in proposed binding domain of 
benzimidazole-insensitive organisms.  
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Fig. 4.17.  Structure of oxibendazole in proposed binding domain of 
benzimidazole-sensitive organisms.  
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Fig. 4.18.  Structure of parbendazole in proposed binding domain of 
benzimidazole-insensitive organisms.  
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Fig. 4.19.  Structure of parbendazole in proposed binding domain of 
benzimidazole-sensitive organisms.  
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4.3.5.iv.  Interaction model of thiabendazole with       
β-tubulin  
 
To contrast with the other benzimidazoles, thiabendazole was selected as it lacks an 
R5 side-chain, instead having an R2-thiazole group. In terms of how this compound 
would interact with key amino acids in the proposed hydrophobic binding domain it is 
unlikely that there would be any significant interactions. Thiabendazole is also unlikely 
to form any significant interactions with the residues in the upper region of the binding 
domain including residues Ala-185, Thr-186, Ser-188, Ile-202, and Asp-203 (Fig. 4.20 
and 4.21). These amino acids are also conserved between benzimidazole-sensitive 
(Fig. 4.21) and -insensitive (Fig. 4.20) organisms and so would be unlikely to form the 
basis of the selective binding between the benzimidazoles and protozoan β-tubulin. 
Additionally, it is likely that the R2-thiazole group may prevent this compound from 
binding or interacting with any of the residues near the base of the hydrophobic binding 
domain including residues Ile-189, Leu-192, Val-199, and Phe-200 (Fig. 4.21). From 
this model it is predicted that thiabendazole may have a low affinity for the proposed 
binding domain. This is because thiabendazole lacks the necessary R5 side-chain 
which would interact with amino acid residues unique to the benzimidazole-sensitive 
protozoan form of the β-tubulin monomer.  
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Fig. 4.20.  Structure of thiabendazole in proposed binding domain of 
benzimidazole-insensitive organisms.  
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Fig. 4.21.  Structure of thiabendazole in proposed binding domain of 
benzimidazole-sensitive organisms.  Chapter 4.  Molecular modelling of benzimidazoles 
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4.4.  Discussion  
 
In this study, comparative molecular modelling of β-tubulin from benzimidazole-
sensitive and -insensitive organisms was utilised to visualise potential benzimidazole 
binding sites based on the location of substituted amino acids in the 3-D structure of   
β-tubulin. Initial analysis of the deduced amino acid sequence of β-tubulin from 
benzimidazole-sensitive and -insensitive organisms identified several amino acid 
substitutions. However, most of the amino acid substitutions identified by this method 
were between C. parvum and G. duodenalis or E. intestinalis. That is, they were not 
amino acid differences between benzimidazole-sensitive protozoa and -insensitive 
mammalian or protozoan (i.e.  C. parvum) sequences. It is therefore unlikely these 
residues would form a unique benzimidazole-binding site in G. duodenalis  or              
E. intestinalis as the residues comprising this site are expected to be divergent 
between sensitive and insensitive organisms and also conserved between all 
benzimidazole-insensitive organisms (mammalian and protozoan).  
 
Using the homology models of β-tubulin from benzimidazole-sensitive and -insensitive 
organisms a highly hydrophobic binding domain, which was unique to benzimidazole-
sensitive protozoa, was identified. The amino acids within this domain include the 
residues from Ala-186 to Phe-213 on the β-tubulin monomer of sensitive protozoa. The 
involvement of residues 198, 199, and 200 in the formation of this benzimidazole-
binding domain also corroborates previously identified results from investigations of the 
molecular basis of benzimidazole resistance in nematodes (Kwa et al., 1995; Nare et 
al., 1996) and fungi (Jung and Oakley, 1990; Jung et al., 1992). The interactions which 
are likely to occur between several benzimidazoles and the various side-groups of the 
amino acids in this binding domain were described with respect to benzimidazole-
sensitive and -insensitive organisms. The principal interactions are proposed to occur Chapter 4.  Molecular modelling of benzimidazoles 
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between the R5 side-chain of the benzimidazole compounds and Ile-189, Val-199, and 
Phe-200 which all have nonpolar, hydrophobic side-groups.  
 
In addition to this, the protozoan model places the potential benzimidazole-binding site 
closer to the GTP-binding site on the β-tubulin monomer or heterodimer than has been 
previously suggested. The proposed benzimidazole-binding domain places the drug 
binding site on the outer surface of the β-tubulin protein whether it is in a monomeric or 
heterodimeric state. Through the use of a homology model it was possible to identify 
that the proposed benzimidazole-binding domain is directly adjacent to the site of 
hydrolysis of β-tubulin-bound-GTP.  As  this  GTP  hydrolysis  occurs  when  a  new           
αβ-tubulin heterodimer binds with a microtubule bound αβ-heterodimer it is proposed 
that any changes in this region of the heterodimer may affect this process. This 
presents an interesting model whereby the presence of a benzimidazole compound at 
this location may prevent or inhibit the rate of the conformational change that is 
believed to accompany the hydrolysis of GTP to GDP (Muller-Reichert et al., 1998; 
Vulevic et al., 1997) and which is essential for microtubule assembly (Fontalba et al., 
1993; Menéndez et al., 1998). The consequences of this may be that microtubules can 
no longer polymerise and grow or alternatively it may decrease the internal stability of 
the microtubule lattice thereby promoting depolymerisation. If microtubule 
depolymerisation occurred at a higher rate than polymerisation there would be a net 
loss of microtubules from the cell. This would also support microscopic observations of 
the apparent effect of benzimidazole compounds on several sensitive organisms 
(Borgers et al., 1975; Chavez et al., 1992; Oxberry et al., 1994).  
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By using this approach it was possible to develop a model of the benzimidazole-
binding domain on G. duodenalis and E. intestinalis β-tubulin which is absent from the 
β-tubulin of insensitive organisms such as B. taurus,  C. parvum, and H. sapiens.          
A similar approach has been utilised with the anti-tumour compound, paclitaxel (Gupta   
et al., 2003) to identify the amino acids involved in the formation of the drug-binding 
site. The validity of this benzimidazole-binding site on the β-tubulin protein, however, 
requires further evidence that it is a key determinant of benzimidazole binding. This 
requires the analysis of direct-binding kinetics between the benzimidazole compounds 
utilised in the formation of this model and α-,  β-, and αβ-tubulin heterodimers and 
microtubules from sensitive and insensitive organisms.  
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5.1.  Introduction  
 
The  in vivo and in vitro  efficacy  of  several  benzimidazole  compounds  against              
G. duodenalis (Morgan et al., 1993; Reynoldson et al., 1998) and E. intestinalis        
(De Groote et al.,  1995;  Ridoux  and  Drancourt,  1998;  Katiyar  and  Edlind,  1997)        
has previously been demonstrated. In addition to this, several benzimidazoles have 
also been demonstrated to be inactive against other  parasitic  protozoa  such  as           
C. parvum (Fayer and Fetterer, 1995). This chapter presents an analysis of the binding 
kinetics involved when different benzimidazoles bind with tubulin from benzimidazole-
sensitive and -insensitive organisms. The benzimidazole-sensitive organisms used in 
this analysis were G. duodenalis and E. intestinalis while the benzimidazole-insensitive 
organism was C. parvum.  
 
The kinetic analysis involved determining the association (Ka) and dissociation (Kd) 
equilibrium constants for a number of benzimidazoles with recombinant α-,  β-,  and     
αβ-tubulin to investigate whether their differential efficacy in vitro relates to binding to 
monomeric or dimeric tubulin. This analysis was performed by comparing two 
techniques: the first technique was based on using optical biosensors and the second 
technique utilised fluorescence quenching, in order to identify the optimal analytical 
method. The first method, a biosensor chip-based technique, measured changes in 
resonance brought about by altering the refractive index of materials bound to the 
biosensor chip. The second method utilised the quenching of fluorescence from 
particular amino acid residues when a ligand binds to them. These two methods were 
utilised to determine the apparent association rate (kon) and dissociation rate (koff) from 
which the equilibrium constants were calculated.  
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The benzimidazoles used in this study were all R2-carbamate analogues with the same 
basic structure of 1,2-diaminobenzene (Fig. 5.1). These compounds were albendazole, 
albendazole-sulphoxide, fenbendazole, mebendazole, oxibendazole, and 
parbendazole. Thiabendazole was also studied as a non-R2-carbamate analogue 
(Table 5.1). All these benzimidazoles have previously been demonstrated to have a 
wide range of activity against G. duodenalis and E. intestinalis and are therefore 
expected to display selectivity of benzimidazole binding.  
 
C4
C7
C2
C5
C6
R5
R2
N1
N3
H
 
Fig. 5.1.  General structure of a benzimidazole compound.  
 
Side-chain composition   Benzimidazole 
derivative   R2 R 5 
Albendazole   -NHCOOCH3 -SCH2CH2CH3 
Albendazole-sulphoxide   -NHCOOCH3 -SOCH2CH2CH3 
Fenbendazole   -NHCOOCH3 -S-phenyl   
Mebendazole   -NHCOOCH3 -CO-phenyl   
Oxibendazole   -NHCOOCH3 -OCH2CH2CH3 
Parbendazole   -NHCOOCH3 -CH2CH2CH2CH3 
Thiabendazole   -4-Thiazole   -H  
 
Table 5.1.  Structure of benzimidazole derivatives tested for binding affinity 
with protozoan tubulin from sensitive and insensitive organisms.  
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The aims of this study were:  
 
1.  To determine the binding affinities and kinetics of several benzimidazole 
derivatives with recombinant protozoan tubulin  
 
2.  To identify whether the benzimidazoles have a differential affinity for 
recombinant tubulin from benzimidazole-sensitive or -insensitive 
organisms  
 
3.  To determine if the benzimidazoles have a differential affinity for α-  or        
β-tubulin monomers, or αβ-tubulin dimers  
 
4.  To relate the in vitro binding kinetics of the benzimidazoles tested to their  
in vivo and in vitro efficacy against G. duodenalis,  E. intestinalis,  and      
C. parvum  
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5.2.1.  Introduction  
 
The technique of measuring surface plasmon resonance (SPR) using an optical 
biosensor (reviewed by Nice and Catimel, 1999; Schuck, 1997) has been developed by 
BIAcore (Fägerstam et al., 1992; Jönsson et al., 1991) and relies upon measuring 
changes in resonance between a solid support and a liquid medium (Fig. 5.2). SPR is 
an optical phenomenon caused by the oscillation of electrons in a thin metallic film, 
usually gold, off which polarised light is reflected. The amount of resonance measured 
is therefore directly proportional to any changes in the refractive index brought about by 
an increase in the mass of molecules (e.g. proteins) attached to the surface (Stenberg 
et al., 1991).  
 
The sensor chip developed by BIAcore illustrates the application of this phenomenon 
(Fig.  5.2)  (Malmqvist  and  Karlsson,  1997).  In  this  system,  the  target  ligand               
(e.g. protein) is immobilised onto the sensor chip and the analyte (e.g. drug, DNA) 
flows over it using continuous flow conditions. The SPR signal, expressed as 
resonance units (RU), is measured continuously to detect changes in the refractive 
index caused by mass changes on the surface of the chip. These changes are brought 
about by binding of the mobile analyte to the immobilised ligand (Jönsson et al., 1991; 
Malmqvist, 1993) and are therefore proportional to the amount of binding that occurs. 
The continuous monitoring of the SPR signal allows the kinetics of binding to be 
followed in real time as they are displayed graphically as a sensorgram (i.e. RU versus 
time) (Fig. 5.3). From these sensorgrams the affinity and kinetic aspects of the 
interaction can be determined, particularly the association (kon) and dissociation (koff) 
rates, from which the equilibrium association (Ka) and dissociation (Kd) constants are 
calculated (Ben Khalifa et al., 2001; Quinn and O’Kennedy, 2001).  
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Fig. 5.2.  Surface plasmon resonance detection system within BIAcore 
instruments. The polarised light is focussed onto the sensor chip surface 
where the binding reaction occurs and is reflected to an optical detection 
unit. The angle of the reflected light varies with the refractive index of the 
sensor chip surface such that an increase in mass with binding to the 
surface results in a change in the refractive index (i.e. from I to II). The 
changes in reflectance with time are presented in a sensorgram.  
 
For these interactions to be accurately described kinetically, several potential sources 
of error must be eliminated or minimised. These include instrument artefacts such as 
instrument and baseline drift, non-specific binding, and refractive index changes that 
are not the result of macromolecular interactions (Myszka, 1997). These problems are 
all eliminated through careful experimental design (i.e. randomised, duplicate samples) 
and particularly by using a reference binding surface. The reference surface does not 
contain any ligand but is treated identically to the sample surfaces within a four channel 
sensor chip. The changes in resonance occurring on the reference surface due to 
artefacts are contained within its sensorgram which is then subtracted from all the 
binding reaction or test surface sensorgrams to eliminate them as a source of error 
(Roden and Myszka, 1996; Karlsson and Fält, 1997).  Chapter 5.  Benzimidazole binding kinetics 
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Fig. 5.3.  Typical phases of association and dissociation described by a 
sensorgram. Following injection of an analyte onto a stable binding surface 
association binding data is collected. After sample injection, the complex 
dissociates in running buffer followed by regeneration of the binding surface 
using a low pH solution. Kinetic rate constants are derived from the 
association and dissociation phases of the sensorgram.  
 
Another significant error may occur when an unstable or decaying binding surface is 
created (Joss et al., 1998). BIAcore has developed several different ligand 
immobilisation techniques to avoid this problem. These may be based on random 
immobilisations via amine-, thiol-, aldehyde, or streptavidin-biotin coupling (Fig. 5.4) 
(Johnsson et al., 1995; O’Shannessy et al., 1992) although these approaches create a 
degree of heterogeneity in the binding surface. There are also more specific methods 
which orientate the ligand via specific antibodies (Karlsson and Fält, 1997; Myszka         
et al., 1997) or antibodies to commonly used protein expression fusion partners 
(Nilsson et al., 1996). The most commonly used sensor chip (Rich and Myszka, 2001) 
is coated with a carboxymethyldextran (CMD) matrix (Löfås and Johnsson, 1990) which 
provides a flexible anchor for ligand immobilisation (Fig. 5.4) and is proposed to allow 
interactions to occur as they would in solution (Johnsson et al., 1991).  
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Perhaps the most significant and documented problem in producing high quality 
binding data is caused by mass transfer (also termed mass transport) (Fig. 5.5) 
(Myszka, 1997; Schuck and Minton, 1996). Many approaches have been taken to 
describe and so eliminate it from binding data (Myszka et al., 1997, 1998a). Mass 
transfer is principally due to the intrinsic design of the sensor chip and continuous flow 
system whereby the mobile analyte in the flowing portion of the channel diffuses 
through an unstirred solvent layer to bind with the immobilised ligand (Fig. 5.5) 
(Myszka, 1997). The rate of diffusion to the binding surface (i.e. mass transfer) may be 
sufficiently slow to affect the rate of binding, especially for high-affinity or rapidly 
associating macromolecules (Glaser, 1993; Myszka et al., 1998b).  
 
To minimise these effects, it has been recommended that kinetic studies are performed 
at high flow rates (i.e. >20µl/min) with a low amount of ligand immobilised (i.e. <100RU) 
(Edwards et al., 1997). The high flow rate reduces the height of the unstirred solvent 
layer, which increases the transfer rate of the analyte to and from the sensor chip 
surface (Fisher et al., 1994; Karlsson et al., 1994). Lowering the amount of surface 
ligand present also decreases the rate at which the analyte is depleted from the 
unstirred solvent layer such that diffusion does not control the association process. 
Similarly, if unbound analyte is not removed from the surface rapidly it may rebind 
producing a slower apparent dissociation rate. Rebinding is also minimised by having a 
low amount of ligand present (Myszka, 1997).  
QuickTime™ and a
GIF decompressor
are needed to see this picture.
Fig. 5.4.  Types of 
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Fig. 5.5.  Diagram of the interaction occurring at the surface of a biosensor 
chip. The ligand (B) is immobilised to the sensor chip via a flexible linker 
and the analyte (AO) flows over the surface. The initial association phase 
involves the diffusion of AO through the unstirred solvent layer at the rate of 
mass transfer (km). The association (ka) and dissociation (kd) rates are 
produced when the complex AB is formed (Myszka, 1997).  
 
The determination of binding and equilibrium kinetics from SPR data were significantly 
improved with the introduction of global data fitting into the BIAevaluation software 
(version 3.0) in 2000. Prior to this it was not possible to analyse binding curves using 
several different interaction models in order to identify which one best described the 
data. Kinetic information was previously extracted from binding curves using what has 
been proven, in some instances, to be an overly simplistic bimolecular model [Eqn 5.1].  
 
     
A  +  B  
koff
←       
kon   →     
  AB       [Eqn  5.1]   
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This equation is based on A being the mobile analyte, B the immobilised ligand, and 
AB the complex they form with particular association (kon) and dissociation (koff) rates. 
With this model, data fitting initially involved utilising linear regression (Karlsson et al., 
1991), non-linear curve fitting (O’Shannessy et al., 1993; Roden and Myszka, 1996), 
and later numerical integration of the equations describing the interaction kinetics 
(Karlsson and Fält, 1997; Morton et al., 1995; Myszka et al., 1997). Some of the 
problems encountered with this model were due to the fact that interactions occurring 
on the biosensor surface did not obey the pseudo-first-order rate equation that these 
data fitting models were based on (Bowles et al., 1997; O’Shannessy and Winzor, 
1996). This equation assumes that, under ideal conditions, the concentration of mobile 
analyte is constant and that mass transfer is not affecting the rate of diffusion to or 
binding with the ligand (Glaser, 1993; Karlsson et al., 1994).  
 
Significantly, it has been demonstrated previously that for these conditions to be met a 
relatively high concentration of ligand must be immobilised particularly to produce a 
significant change in refractive index upon binding (Lipschultz et al., 2000; Schuck, 
1996; Strandh et al., 1998). This has also been found to affect the accuracy of the 
binding data through increased mass transfer, steric hindrance, crowding, and 
aggregation on the surface of the sensor chip (Edwards et al., 1997; Schuck, 1996; 
Morton and Myszka, 1998).  
 
Many investigators have analysed approaches which could be taken to successfully 
describe equilibrium binding constants and in particular these have focussed on 
describing binding as a two-step process (Edwards et al., 1997). The first step is the 
transfer of the analyte (AO) to the sensor chip surface and the second step is binding of 
the analyte (A) to the ligand (B) to form the complex AB (Fig. 5.5) (Fisher et al., 1994; 
Morton et al., 1995; Myszka et al., 1997). The equation describing this binding model 
includes diffusion or transfer of the analyte to and from the binding surface [Eqn 5.2].  Chapter 5.  Benzimidazole binding kinetics 
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Ao  
km
←       
km   →     
  A + B  
koff
←       
kon   →     
  AB     [Eqn  5.2]   
 
The mass transfer coefficient (km) is dependent on the diffusion coefficient of the 
protein, dimensions of the flow cell, and the flow rate (Karlsson et al., 1994). This 
model has been used to describe several different experimental systems (Markgren    
et al., 2001; Morton and Myszka, 1998; Myszka et al., 1998a; Oddie et al., 1997). The 
progression of this approach was made when it was identified that by fitting association 
and dissociation curve data for a series of ligand and analyte concentrations and flow 
rates simultaneously, referred to as global data fitting or analysis, discrimination could 
then be made between different reaction mechanisms (Morton et al., 1995) while also 
removing the effects of mass transfer (Myszka, 1997). With global data fitting it was 
possible to describe kinetic parameters from several sensorgrams simultaneously, 
which significantly improved the quality of the parameters (Karlsson and Fält, 1997; 
Roden and Myszka, 1996). This also allowed more complex interaction models, such 
as heterogenous ligands, mass transfer limited, and multivalent ligands, to be 
described (Ben Khalifa et al., 2001; Markgren et al., 2001).  
 
SPR biosensor technology offers several advantages for characterising 
macromolecular interactions over traditional analysis techniques (reviewed by Rich and 
Myszka, 2000; Schuck, 1997). The principal advantages of SPR biosensors are that 
neither the ligand nor the analyte requires labelling, whilst also being highly sensitive, 
specific, and versatile (Myszka, 1997; O’Shannessy, 1994). For these reasons it has 
been applied to the description of several types of interaction including antigen-
antibody (Myszka et al., 1997; Oddie et al., 1997), protein-drug or receptor-ligand 
(Karlsson et al., 2000; Markgren et al., 2001), protein-DNA (Bondeson et al., 1993; 
Fisher et al., 1994), and DNA-DNA (Bates et al., 2002; Persson et al., 1997).  
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While the most widely described interactions are high-affinity (Markgren et al., 2001; 
Myszka  et al., 1998b) methods for evaluating low-affinity (Ka <10
4M
-1)  and                
low-molecular-weight (<1,000Da) interactions have been described (Karlsson et al., 
2000; Ohlson et al., 1997; Strandh et al., 1998). More recently some analysis has been 
presented whereby the interaction between high-molecular-weight ligands with very 
low-molecular-weight analytes, <100Da, especially drug-receptor interactions, has 
been described (Davis and Wilson, 2000; Karlsson et al., 2000; Rich et al., 2001). The 
application of SPR as a drug-screening tool is therefore a relatively recent development 
in the field of optical biosensors (Markgren et al., 1998; Rich et al., 2001) and one for 
which experimental liposome-based sensor chips have recently been developed (Baird 
et al., 2002; Erb et al., 2000).  
 
As optical biosensors have now been developed for the detection of binding between 
high-molecular-weight targets and low-molecular-weight ligands the present study was 
undertaken. The aim of this study was to specifically develop a method for determining 
the binding kinetics (Ka,  Kd) occurring between the low-molecular-weight 
benzimidazoles with their postulated target protein, the high-molecular-weight 
protozoan α- or β-tubulin, using an SPR-based technique.  
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The activity of the benzimidazoles, which were initially developed as anthelmintics, has 
been most widely studied in the parasitic nematode H. contortus, although more 
recently their in vitro activity against several intestinal parasites has been 
demonstrated.  This  includes  differential  activity  of  various  benzimidazoles  against      
G. duodenalis (Katiyar et al., 1994; Meloni et al., 1990; Morgan et al.,  1993)  and         
E. intestinalis (Franssen et al., 1995; Katiyar and Edlind, 1997; Ridoux and Drancourt, 
1998). Previous kinetic studies with tritiated-benzimidazoles have established that they 
bind with a high affinity (>10
7M
-1) to the cytoskeletal protein β-tubulin in the 
benzimidazole-sensitive  H. contortus (Gill and Lacey, 1992; Lubega and Prichard, 
1991b; Prichard, 2001) although the kinetics of this binding have not been investigated. 
In addition to this it has also been previously shown that refolded recombinant tubulin 
from several organisms is capable of binding tubulin antagonists, including 
benzimidazole compounds (Hollomon et al., 1998; Lubega et al., 1993; Oxberry et al., 
2001b).  
 
 
The aims of this study were:  
 
1.  To immobilise G. duodenalis  α- and β-tubulin monomers onto biosensor 
chips using amine coupling and affinity capturing techniques  
 
2.  To allow binding to occur between several benzimidazole compounds with 
the immobilised tubulin monomers to determine their binding affinities  
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5.2.2.  Materials and Methods  
 
5.2.2.i.  Immobilisation of recombinant protozoan 
tubulin  
 
The BIAcore 2000 system, research grade carboxymethylated dextran CM5 sensor 
chips, and standard BIA-certified HBS running buffer (0.01M  HEPES,  pH  7.4,         
0.2M sodium chloride, 3.4mM  EDTA),  and  the  Amine  Coupling  Kit  containing              
N-hydroxysuccinimide (NHS), N-ethyl-N'-(3-diethyl-aminopropyl)-carbodiimide (EDC), 
and ethanolamine-hydrochloride were obtained from BIAcore AB (Uppsala, Sweden). 
Recombinant G. duodenalis α- (rGDα) and β-tubulin (rGDβ) were produced in E. coli as 
MBP fusion proteins as previously described (Chapter 2; MacDonald et al., 2003a). 
The sensor chips (SC-1, SC-2) were immobilised with four binding surfaces each 
(Table 5.2); FC-1: unbound, blocked CMD matrix; FC-2: anti-MBP monoclonal 
antibody; FC-3: anti-α-tubulin (SC-1) or anti-β-tubulin (SC-2) monoclonal antibody;     
FC-4: rGDα (SC-1) or rGDβ (SC-2). Standard amine coupling chemistry was used to 
attach the anti-MBP monoclonal antibody, anti-α- or anti-β-tubulin monoclonal 
antibodies, or rGDα or rGDβ onto the CM5 sensor chip.  
 
The immobilisation steps were carried out using HBS buffer at 25°C with a 20µl/min 
flow rate. All four channels were simultaneously activated for 7 min with 0.05M NHS 
and 0.2M EDC. The respective monoclonal antibodies, rGDα, or rGDβ were injected at 
a concentration of approximately 20µg/ml in 10mM sodium acetate, pH 4.4, for 7 min. 
Unreacted  N-hydroxysuccinimide esters were then blocked with 1M ethanolamine-
hydrochloride, pH 8.5, for 7 min. The MBP-rGDα (SC-1, FC-2) or MBP-rGDβ (SC-2, 
FC-2) fusion proteins and rGDα (SC-1, FC-3) or rGDβ (SC-2, FC-3) were immobilised 
onto their respective antibodies using a standard affinity capturing method. Subsequent 
analysis was performed in MBS running buffer containing 0.1M  MES  (pH  6.5),        
0.2M sodium chloride, and 10% DMSO.  Chapter 5.  Benzimidazole binding kinetics 
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Sensor chip  
 
Flow 
channel  
 
SC-1  
 
SC-2  
 
Approximate 
MW proteins 
(kDa)  
 
FC-1 
 
Reference surface  
 
Reference surface  
 
0  
 
FC-2 
 
Anti-MBP antibody  
+ MBP-rGDα-tub  
 
Anti-MBP antibody  
+ MBP-rGDβ-tub  
 
20  
100  
 
FC-3  
 
Anti-α-tubulin antibody
+ rGDαtub  
 
Anti-β-tubulin antibody
+ rGDβ-tub  
 
20  
50  
 
FC-4  
 
rGDα-tub  
 
rGDβ-tub  
 
50  
 
Table 5.2.  Binding surfaces created on each flow channel (FC) of sensor 
chip-1 (SC-1) and sensor chip-2 (SC-2).  
 
5.2.2.ii.  Benzimidazole binding experiments  
 
Stock solutions of albendazole and mebendazole (SmithKline Beecham 
Pharmaceuticals) were prepared in 100% DMSO and diluted immediately prior to use 
in MBS running buffer to minimise refractive index changes following sample injections 
onto the sensor chip. The solubility of albendazole and mebendazole in MBS running 
buffer over a 1 to 1,000nM range was assessed by light scattering at OD 320nm using 
a Shimadzu UV-1201 spectrophotometer at 25°C. The interaction between 
albendazole and the immobilised tubulin monomers was optimised by monitoring 
binding at flow rates of 10, 20, or 30µl/min over a 0 to 1,000nM range (200nM 
increments) injected for 30, 60, 90, 120, or 150 sec, randomly and in quadruplicate.     
A blank sample of 25µl of MBS running buffer was injected between each drug sample. 
Suitable regeneration conditions were determined using either 0.01M glycine (pH 2.7), 
0.01M sodium hydroxide injected for 30 sec, or MBS running buffer (5 min) at 30µl/min.  Chapter 5.  Benzimidazole binding kinetics 
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5.2.2.iii.  Analysis of binding reaction sensorgrams 
and global data fitting  
 
The response from the four binding surfaces were initially corrected for baseline drift, 
instrument noise, refractive index changes, and non-specific binding using graphical 
tools in the BIAevaluation software (version 3.0, 2000). This was done by subtracting 
the reference surface (FC-1) sensorgram from each test surface (FC-2, -3, -4) for each 
sensor chip individually. The association (kon) and dissociation (koff) rates and 
equilibrium constants (Ka, Kd), respectively, were calculated using the global data fitting 
component of the BIAevaluation software. The response value at equilibrium (RUeq) 
was determined for each albendazole concentration ([ABZ]) under stabilised conditions 
with respect to flow-rate, pH, temperature, and surface integrity. RUeq represents the 
amount of albendazole complexed with the surface, either CMD matrix alone or with 
the tubulin monomers. Comparison was made between the tubulin monomers 
immobilised directly to the CMD matrix with those anchored via a direct antibody or 
antibody to the MBP fusion partner.  
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5.2.3.  Results and Discussion  
 
The SPR-based technique was designed such that the changes in resonance occurring 
during benzimidazole-binding exclusively reflected the kinetic parameters of the 
interaction. This was achieved by attempting to minimise the occurrence of a 
heterogenous binding surface, non-specific binding, and the effects of mass transfer in 
order to produce accurate and high quality binding data suitable for kinetic analysis 
(Ben Khalifa et al., 2001; Roden and Myszka, 1996).  
 
 
5.2.3.i.  Immobilisation of recombinant G. duodenalis 
tubulin monomers  
 
To minimise or eliminate the potential occurrence of non-specific and non-uniform 
binding of the target protein several different immobilisation methods were investigated 
including direct amine coupling and affinity capturing with specific antibodies. The 
antibodies used were either to the tubulin protein or the fusion partner of an MBP-
tubulin fusion protein. There are several advantages to this approach, most of which 
stem from the creation of a uniform and flexible binding surface. The uniformity is 
brought about by immobilising the target protein by virtue of its fusion partner (MBP) 
which produces a highly consistent and reproducible means of exposing the target 
protein to compounds in the flow channel.  
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In addition to this, by distancing the site of immobilisation of the tubulin from potential 
benzimidazole binding sites there is no loss of these sites or steric hindrance resulting 
from non-specific binding to other sites. This is particularly relevant if the synergistic 
activity of several compounds is to be studied simultaneously. The flexibility of this 
system arises from using an antibody specific to a commonly used fusion partner and 
also, in this case, to the α- or β-tubulin monomers. This reduces the amount of time 
required to optimise the immobilisation and binding conditions and greatly increases 
the number of target proteins which can be studied using the same method of 
immobilisation.  
 
These different binding surfaces were created to allow comparison of their suitability for 
the determination of benzimidazole binding kinetics. In attempting to create a uniform 
binding surface there are several potential problems with each approach that could 
result in heterogeneity in the binding surface. When tubulin was immobilised via amine 
coupling it involved esterification of amino groups that are found randomly over the 
surface of the tubulin monomers. It is therefore difficult to create a uniform orientation 
of the tubulin to the analytes (i.e. albendazole, mebendazole) in the flow channel using 
amine coupling. This may result in a variable reduction in the number of potential drug 
binding sites. The main advantage of direct amine coupling is that the final amount of 
tubulin immobilised was much higher when compared with the affinity capture based 
approach (Table 5.3).  
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The affinity capture immobilisation approach was utilised to specifically address the 
problem of heterogeneity of tubulin immobilised directly to the sensor chip surface. This 
approach involved immobilising monoclonal antibodies to α- or β-tubulin, or to the MBP 
fusion proteins (MBP-rGDα or MBP-rGDβ) using amine coupling. For the same reasons 
discussed above, some heterogeneity would therefore exist due to the random 
orientation of the antibodies onto the sensor chip. One way of addressing this problem, 
therefore, was to saturate the chip surface so that a large number of correctly 
orientated antibodies would be produced as a proportion of the total number of 
antibody molecules immobilised. The main disadvantage of this approach is that the 
greater the amount of antibody which is immobilised, the greater the amount of mass 
attached to the chip surface and so the higher the baseline resonance from the 
surface. Given that the maximum resonance value that can be reliably detected with 
the BIAcore 2000 is 70kRU, if 15kRU is occupied by the antibody, without the tubulin 
attached, then it will significantly reduce the working range for detection of 
benzimidazole binding. In addition to this, binding will occur close to the detection limit 
of the system and some of the conditions to minimise the effects of mass transfer will 
no longer be addressed.  
 
Following immobilisation the anti-α- and anti-β-tubulin antibodies produced a baseline 
resonance of 9,835 and 9,725RU, respectively, while the anti-MBP monoclonal 
antibody produced a baseline of 10,100RU (Table 5.3). The rGDα, rGDβ, or MBP-rGDα, 
MBP-rGDβ were then introduced to the appropriate channels on the sensor chip and 
immobilised by affinity capture. As predicted, the final amount of resonance from these 
surfaces was significantly higher than from the directly immobilised recombinant tubulin 
monomers (Table 5.3). However, the final amount of tubulin molecules orientated 
correctly for drug binding by anchoring them via an antibody is predicted to be higher 
than via direct amine coupling.  
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Immobilisation 
method 
 
Ligand  
 
Corrected 
RU  
 
Amount 
protein 
(ng/mm
2)  
 
Amount 
tubulin 
(ng/mm
2)  
 
rGDα-tub
 
5,060  
 
5.1  
 
5.1  
 
rGDβ-tub
 
5,171  
 
5.2  
 
5.2  
 
anti-α-tub mAb
 
9,835  
 
9.8  
 
--  
 
anti-β-tub mAb
 
9,725  
 
9.7  
 
--  
 
Amine coupling:  
 
anti-MBP mAb
 
10,100  
 
10.1  
 
--  
 
anti-α-tub mAb
+ rGDα-tub
 
14,315  
 
14.3  
 
4.5  
 
anti-β-tub mAb
+ rGDβ-tub
 
13,510  
 
13.5  
 
3.8  
 
anti-MBP mAb
+ MBP-GDα-tub
 
13,290  
 
13.3 
 
3.2  
 
Affinity capturing: 
 
anti-MBP mAb
+ MBP-GDβ-tub
 
13,505  
 
13.5  
 
3.4  
 
Table 5.3.  Comparative amounts of recombinant G. duodenalis tubulin 
(rGDα-tub or rGDβ-tub) immobilised to the CMD matrix using amine 
coupling or affinity capturing.  
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Another potential problem that was identified with this method of immobilising tubulin 
as a fusion protein with MBP is the additional mass that the MBP produces on the 
sensor chip. The α- and β-tubulin proteins and MBP all have approximate molecular 
weights of 50kDa with fusions between them being approximately 100kDa. While this 
mass difference did not affect the amount of tubulin immobilised (Table 5.3) it did result 
in a much greater amount of protein being attached to the sensor chip as indicated by 
the higher baseline resonance on the affinity capturing surfaces. The potential problem 
this creates is that it may increase the effects of mass transfer by limiting the rate of 
diffusion of the analyte (i.e. albendazole or mebendazole) to its target ligand (tubulin). 
To identify whether this was occurring a binding surface of recombinant G. duodenalis 
α- and β-tubulin alone was created (i.e. FC-4 on SC-1 and SC-2, respectively). Binding 
data from this surface was subtracted from the channels containing the MBP-tubulin 
fusion proteins to identify any MBP-related binding events.  
 
5.2.3.ii.  Determination of benzimidazoles affinity for 
protozoan tubulin  
 
To minimise the effects of mass transfer on the binding results the compounds were 
diluted in MBS running buffer (0.1M MES (pH 6.5), 0.15M  sodium  chloride,              
10% DMSO) and blank injections of running buffer were made between each injection 
of drug. The immobilised tubulin was found to be stable in this buffer, with and without 
the inclusion of benzimidazoles, as no decrease in resonance was observed during the 
course of the drug-binding assays. The injection of MBS running buffer did not produce 
any change in resonance which indicated that the effects of mass transfer due to 
refractive index differences between the solution the analyte and ligand were in had 
been completely eliminated. Additionally, the effects of mass transfer due to changes in 
volume within the flow channel accompanying sample injection had also been 
removed.  Chapter 5.  Benzimidazole binding kinetics 
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The benzimidazoles, albendazole and mebendazole, were tested over a 0 to 1,000nM 
range, with 200nM increments, and the different drug concentrations were injected 
randomly and in quadruplicate during each binding trial; the results of four separate 
trials were utilised to construct the final equilibrium binding plots (Fig. 5.6). The 
reference surface was treated identically to the test surfaces with respect to running 
buffer, addition of ligands, regeneration conditions, and blocking of unbound amine 
coupling sites. The amount of resonance from this surface also indicated that it did not 
have any antibodies or recombinant tubulin attached to its surface.  
 
QuickTime™ and a TIFF (Uncompressed) decompressor are needed to see this picture.
 
 
Fig. 5.6.  Overlay plots of uncorrected binding curves showing the 
interaction between albendazole and G. duodenalis  β-tubulin. The 
uncorrected sensorgrams from averaged quadruplicate injections of 
albendazole (0 - 1,000nM) over immobilised G. duodenalis  β-tubulin are 
shown.  
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The uncorrected sensorgrams (Fig. 5.6), (i.e. reference surface not subtracted) 
illustrate the concentration-dependent change in resonance resulting from albendazole 
binding with the surface of the sensor chip. Unfortunately, when the sensorgram from 
the unbound, blocked CMD matrix reference surface, (i.e. FC-1 on both sensor chips) 
was subtracted from the test surfaces (i.e. FC-2, -3, -4, both sensor chips) a straight 
line at 0RU ± <0.1% was obtained (results not shown). These results indicate that the 
majority of the binding that is being measured involves non-specific interaction with the 
CMD matrix. When the binding conditions were tested at flow rates of 10, 20, or 
30µl/min there was no significant change or reduction in the amount of non-specific 
binding (Fig. 5.7). Similarly, when binding was monitored with drug injections for 30 to 
150 seconds (30 sec increments) there was no reduction in non-specific binding (data 
not shown). There was also no significant difference in the amount of non-specific 
binding between albendazole and mebendazole over the same concentration range 
and under identical flow rate and binding conditions.  
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Fig. 5.7.  Effect of flow rate on albendazole binding with CMD matrix. 
Corrected sensorgrams for albendazole binding with the reference surface 
at flow rates of 10, 20, and 30µl/min. Samples were injected for 30 sec and 
data was collected for quadruplicate binding experiments.  
 
5.2.3.iii.  Global fitting of benzimidazole equilibrium 
binding data  
 
In this study the careful design of experimental controls was utilised to minimise 
possible binding artefacts which may result from using a 1:1 binding model with data 
which deviates from the pseudo-first-order kinetic model (O’Shannessy and Winzor, 
1996) to determine the binding kinetics [Eqn 5.2]. The binding data obtained with the 
range of albendazole and mebendazole concentrations tested was analysed using the 
global data fitting component of the BIAevaluatiion software (v. 3.0). This allowed the 
association (kon) and dissociation (koff) components of the binding curves to be 
analysed simultaneously at several ligand and analyte concentrations, flow rates, pH 
values, and injection times (Ben Khalifa et al., 2001; Roden and Myszka, 1996). From Chapter 5.  Benzimidazole binding kinetics 
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this data the equilibrium constants (Ka,  Kd) were determined with immobilised 
recombinant G. duodenalis β-tubulin (Table 5.4).  
 
Using global data fitting several different binding models were interrogated to identify 
which one best described the binding data. The various models which could be 
demonstrated include 1:1 interactions with and without mass transfer limited, ligand 
multivalency, and 2:1 interactions. With the albendazole and mebendazole binding 
results the 1:1 interaction with mass transfer limited was found to best describe the 
binding curves with rapid-on and rapid-off (i.e. high affinity, rapid dissociation, 
reversible) binding profiles (Fig. 5.6). This model was confirmed by the rapid 
dissociation of the albendazole and mebendazole binding complexes in running buffer, 
without the requirement for specific additives, such as glycine, for regeneration of the 
binding surface or to dissociate the benzimidazoles. This rapid dissociation is also 
typical of non-specific interactions, as was occurring on the sensor chip with the 
carboxy-methylated dextran.  
 
 
 
Albendazole  
 
Mebendazole  
 
Parameter  
rGDβ-tubulin  CMD matrix   rGDβ-tubulin   CMD matrix  
 
Ka (M
-1)  
 
 5.46 x 10
6  
 
 1.37 x 10
7  
 
 5.21 x 10
6  
 
 1.51 x 10
7  
Kd (M)    1.83 x 10
-7    7.31 x 10
-8    1.91 x 10
-7    6.62 x 10
-8  
kon (Ms
-1)    6.54 x 10
5    7.99 x 10
5    7.81 x 10
5    8.47 x 10
5  
koff (s
-1)    0.12    0.0584    0.15    0.0561  
Rmax (RU)   217    65.2    202    73.1  
 
Table 5.4.  Affinity rates and constants determined for albendazole and 
mebendazole with recombinant G. duodenalis β-tubulin (rGDβ-tubulin) or a 
CMD matrix.  Chapter 5.  Benzimidazole binding kinetics 
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5.2.3.iv.  Non-specific binding with the CMD matrix  
 
A possible reason for the non-specific binding is that the immobilised tubulin has been 
lost from the sensor chip. However, this is not believed to be the reason as the amount 
of resonance from the surfaces containing tubulin remained relatively constant 
throughout the drug binding assays. This also includes changes in baseline resonance 
following storage of the sensor chip at 4°C. This indicates, therefore that the amount of 
mass, or tubulin, attached to the surface remained constant.  
 
More recently, several investigators have proposed that immobilised proteins can 
undergo 3-D conformational changes (Mannen et al., 2001; Paynter and Russell, 2002) 
which can result in a loss of specific activities, such as protein-protein interactions 
(Ober and Ward, 2002) or drug-binding capacity. It is possible that the conformation of 
the immobilised tubulin was altered as a result of the continuous flow system, 
conditions used for immobilisation, or storage of the sensor chip at 4°C. If this has 
occurred it could result in the loss of the benzimidazole binding site or a significant 
reduction in the benzimidazoles affinity for it.  
 
The methods which could be employed to eliminate the non-specific binding with the 
CMD matrix depend on the cause of the binding. If it is due to the amine coupling 
immobilisation technique (Kortt et al., 1997) then it may be removed by using an 
alternative technique (e.g. thiol coupling) although this would still involve a CMD matrix. 
It may be more appropriate to use a different type of sensor chip and the BIAcore 
lipophilic membrane chips (L1 Pioneer chips) have recently been utilised by several 
investigators studying drug binding kinetics (Baird et al., 2002). Some researchers 
have also created specialised experimental surfaces, such as polylysine-heparin-
polylysine (Benítez and Jiménez, 2002), which may also be applicable to this binding 
assay.  
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Alternatively, if the non-specific binding is considered from the point of view of the 
benzimidazole then it may be possible to attach it to a carrier peptide which could 
prevent it from binding with the CMD matrix. This approach may be difficult to perform 
successfully as it would require a peptide which does not interfere with tubulin-binding 
while also preventing non-specific binding. If this approach could however, be 
developed it would also result in a larger change in resonance following binding with 
immobilised tubulin. A carrier peptide could also be used to attach the benzimidazoles 
to the CMD matrix irreversibly, although this would be difficult to do without also 
interfering with the tubulin-binding properties of the drug.  
 
It is also possible that the benzimidazoles were not able to bind with tubulin in a 
continuous-flow system, such as the one used in the BIAcore instruments, but instead 
require a static environment to interact with their binding site. This could be tested by 
analysing binding using a spectrophotometric method, such as fluorescence quenching 
(Werbovetz et al., 1999).  
 
5.2.4.  Conclusions  
 
The development of optical biosensors has greatly facilitated measurements of the rate 
of formation and dissociation of complexes in real-time and without the requirement for 
drug or target labelling, which may interfere with drug-binding assays (Schuck, 1997). 
The technique developed by BIAcore is ideally suited to the quantitative 
characterisation of macromolecular interactions as it can be used to determine the 
functional activity of a complex described by its kinetic rate constants and equilibrium 
constants.  
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It has been demonstrated that different benzimidazole compounds exhibit various 
efficacies for G. duodenalis and E. intestinalis in vitro. In order to investigate whether or 
not this efficacy is related to binding affinity for their proposed target protein, β-tubulin, 
an SPR-based system was designed to characterise this interaction. This technique 
was based upon the initial immobilisation of recombinant G. duodenalis α- or β-tubulin 
onto a biosensor chip followed by the measurement  of  refractive  index  changes       
(i.e. resonance) resulting from benzimidazole binding. The application of this method to 
the determination of benzimidazole binding kinetics would be a significant improvement 
on existing methods involving tritiated or photo-affinity labelled benzimidazoles and 
heterogenous tubulin extracts (Gill and Lacey, 1992; Lacey and Prichard, 1986; 
Lubega and Prichard, 1991a).  
 
In this preliminary study a CMD-matrix was utilised as an immobilisation support which 
utilises a hydrophilic binding environment. Despite the development of a mass transfer 
limited binding environment and the testing of different protein immobilisation 
techniques, flow rates, immobilised protein concentrations, drug concentrations, pH of 
interaction, and addition of buffering agents during binding trials this technique was not 
successful. Under the conditions utilised in this study the benzimidazole compounds, 
albendazole and mebendazole, were shown to bind rapidly, reversibly, and with a high-
affinity (10
7M
-1) with the CMD matrix to an extent which masked the detection of any 
binding which was occurring with the protozoan tubulin. The approach described in this 
study has however, clearly demonstrated the absolute importance of using a reference 
binding surface in SPR-based techniques.  
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5.3.  Characterisation of benzimidazole binding  
using fluorescence quenching  
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5.3.1.  Introduction  
 
The anti-protozoal activity of the benzimidazoles, which were initially developed as 
anthelmintics, has been demonstrated in vitro against a number of protozoa including 
G. duodenalis (Cedillo-Rivera and Munoz, 1992; Katiyar et al., 1994; Meloni et al., 
1990; Morgan et al., 1993) and E. intestinalis (Didier et al., 1998; Katiyar and Edlind, 
1997; Ridoux and Drancourt, 1998). This activity has also been demonstrated in vivo 
for the treatment of giardiasis (Lemée et al., 2000; Reynoldson et al., 1998) and 
microsporidiosis (Dore et al., 1995; Molina et al., 1995, 1998). G. duodenalis  and        
E. intestinalis are both significant opportunistic parasites which are also recognised as 
significant waterborne pathogens (Dowd et al., 1998; Furness et al., 2000). They cause 
different severities of gastrointestinal symptoms (Furness et al., 2000; Leder et al., 
1998) which are generally self-limiting but can become life-threatening in 
immunocompromised individuals (e.g. transplantation, HIV-positive) (Gumbo et al., 
1999; Raynaud et al., 1998). At present, the most effective therapy for both these 
parasites is the benzimidazole group of compounds, particularly albendazole (Hall and 
Nahar, 1993; Meloni et al., 1990; Molina et al., 1998; Reynoldson et al., 1998).  
 
The mechanism underlying the mode of action of the benzimidazoles has been most 
extensively studied with the parasitic nematode H. contortus (Lacey and Prichard, 
1986; Lubega and Prichard, 1990; Nare et al., 1996). These studies have resulted in 
the proposal that the benzimidazoles bind to the β-tubulin monomer prior to 
dimerisation with α-tubulin  which  prevents  subsequent  microtubule  formation  (Kwa      
et al., 1995). More specifically, it has been proposed that the benzimidazoles bind to a 
high-affinity binding site on the β-tubulin monomer (Lubega et al., 1993). One of the 
most important limiting factors in further characterising the binding kinetics of the 
benzimidazoles has been the lack of techniques to either extract homogenous tubulin 
from protozoan parasites or produce correctly folded and biologically active 
recombinant tubulin.  Chapter 5.  Benzimidazole binding kinetics 
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In order to address these problems and to further investigate the molecular basis of the 
mode of action of benzimidazoles in protozoa an E. coli-based protein expression 
system was utilised to produce biochemically active and assembly-competent α- and   
β-tubulin from G. duodenalis, E. intestinalis, and C. parvum (Chapter 2; MacDonald     
et al., 2003a). The recombinant tubulin produced by this method had a purity of greater 
than 95% and was free of post-translational modifications. When assembled into 
microtubules in vitro they were free of accessory proteins (MAPs) which made them 
ideal for benzimidazole-binding assays.  
 
In this study the binding affinities of several benzimidazoles has been determined for 
recombinant tubulin in both a monomeric and dimeric state. This analysis was 
performed using a fluorescence quenching method based on measuring the amount of 
intrinsic fluorescence from tryptophan residues. This fluorescence is blocked when 
drugs bind directly with or close to these amino acids. This technique has been 
successfully used by several investigators to determine the binding kinetics of the anti-
mitotic compounds colchicine (Banerjee and Ludueña, 1992; Banerjee et al., 1997; 
Chakrabarti et al., 1996) and taxol (Díaz et al., 2000; Han et al., 1996) although more 
recently it has been applied to Leishmania tubulin to assay dinitroaniline binding 
(Werbovetz et al., 1999).  
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5.3.2.  Materials and Methods  
 
5.3.2.i.  Expression of protozoan tubulin in E. coli  
 
The expression of α- and β-tubulin genes from G. duodenalis, E. intestinalis, and        C. 
parvum has been previously described (Chapter 2; MacDonald et al., 2003a).      The 
recombinant tubulin was maintained in MBS buffer containing 0.1M MES (pH 6.5), 0.2M 
sodium chloride, 0.05% sodium azide, with protease inhibitors 1mM PMSF, 0.7mg/ml 
leupeptin, and 0.5mg/ml pepstatin A. The protein samples were quantified using a Bio-
Rad Protein assay (Bradford, 1976) and analysed by SDS-PAGE and immunoblotting 
as previously described (Chapter 2; MacDonald et al., 2003a).  
 
5.3.2.ii.  Dimerisation and polymerisation of 
recombinant tubulin monomers  
 
The recombinant tubulin monomers (5mg/ml) were dimerised and polymerised in buffer 
containing 0.1M MES (pH 6.5), 1mM magnesium chloride, 1mM EGTA, and 0.5mM 
GTP. Dimerisation was performed at 4°C for 30 min and the progress and incorporation 
of both α- and β-tubulin into the heterodimers was monitored by native AGE and 
denaturing SDS-PAGE and Western blotting as described previously (Chapter 2; 
MacDonald et al., 2003a). GDP- or GTP-bound dimeric tubulin was polymerised into 
microtubules using a previously described method (Díaz et al., 2000; Lubega et al., 
1993) by incubation at 37°C for 30 min and included a control sample with 5% DMSO 
and test samples with the benzimidazoles (0-200mM) tested in quadruplicate. The 
addition of the compounds to the polymerisation samples produced a final DMSO 
concentration of ≤5%. Following the addition of 3.4M glycerol the samples were 
clarified by centrifugation at 2,500 x g at 4°C for 15 min using a Beckman Avanti J-30I 
centrifuge. The pelleted microtubules were rinsed in MBS buffer and analysed by SDS-
PAGE and Western blotting as described (Chapter 2; MacDonald et al., 2003a).  Chapter 5.  Benzimidazole binding kinetics 
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To monitor the effect of the benzimidazoles on polymerisation, microtubule assembly 
was performed with increasing drug concentrations (0-200mM, 10mM increments) and 
aliquots were removed at 5 min intervals. The inhibition of assembly was monitored by 
change in turbidity measured spectrophotometrically at 351nm (Shimadzu UV-1201 
spectrophotometer) and compared to control samples of recombinant αβ-tubulin ± 5% 
DMSO. All measurements were made in triplicate and each drug concentration was 
tested in quadruplicate. To determine if the benzimidazoles de-polymerise assembled 
microtubules they were also added at high molar concentrations (1M) to microtubules 
assembled as described above. Any change in turbidity accompanying microtubule 
disassembly was monitored spectrophotometrically at 351nm.  
 
5.3.2.iii.  Determination of benzimidazole binding 
kinetics  
 
Stock solutions of the benzimidazoles, albendazole, albendazole-sulphoxide, 
fenbendazole, mebendazole, oxibendazole, parbendazole, and thiabendazole 
(SmithKline Beecham Pharmaceuticals) were prepared in 100% DMSO. The amount of 
binding by the benzimidazoles to α-,  β-, and αβ-tubulin (2µM) from G. duodenalis,         
E. intestinalis, and C. parvum was measured following incubation at 37°C for 30 min at 
5 min intervals. To determine the association rates tubulin monomers (2µM) in MBS 
buffer were incubated with different benzimidazoles (0-1,000nM) or 10% DMSO 
(negative control) at 37°C for 30 min in quadruplicate. Aliquots were removed at 5 min 
intervals for fluorescence analysis. The dissociation constants were determined by 
monitoring the time-dependent change in fluorescence from the tubulin-benzimidazole 
complexes as the different benzimidazoles were released from their binding sites 
following a 200-fold dilution of the complex. Dissociation curves were plotted and 
analysed using non-linear regression to determine the dissociation constant (koff). This 
analysis also accounted for the proportion of tubulin-benzimidazole complexes which 
did not dissociate after 15 min.  Chapter 5.  Benzimidazole binding kinetics 
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All the fluorescence measurements were performed using a Perkin Elmer 
luminescence spectrometer LS50 with an excitation wavelength of 280nm and 
emission wavelength of 340nm (initially tested over 300-400nm range). The 
fluorescence measurements were corrected for inner-filter effects according to Mertens 
and Kagi (1979) [Eqn 5.3].  
 
Fcorr = Fobs . antilog(A280 + A320)/2      [Eqn 5.3]  
 
where Fobs and Fcorr are the observed and corrected fluorescence values and A280, A320 
are the absorbances at the excitation and emission wavelength, respectively. The 
association and dissociation data was analysed using a non-linear curve fitting program 
(Prism, GraphPad Software) and a one-site binding equation. The association rate (kon) 
was calculated from equations 5.4 and 5.5 to determine the rate of change in 
fluorescence following addition of the benzimidazoles and these results were graphed 
semi-logarithmically against time.  
 
 ( Fmax – Ft ) = A . e 
-kon t      [Eqn  5.4]   
 
where Fmax is the maximum protein fluorescence, Ft is the protein fluorescence at time 
t, A is the amplitude of the binding phase, kon is the apparent association constant at 
time  t. The apparent association constant (kon) for each benzimidazole tested was 
calculated (Eqn 5.5) as:  
 
  kon = α/[BZ]       [Eqn  5.5]   
 
where α is the slope of the semi-logarithmic binding plot and [BZ] is the benzimidazole 
concentration. The affinity constant (Ka) was obtained from the ratio of the association 
(kon) and dissociation (koff) rates.  
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5.3.3. Results  
 
5.3.3.i.  Effect of benzimidazole compounds on   
tubulin fluorescence  
 
All the benzimidazole compounds tested (Fig. 5.1; Table 5.1) quenched the tryptophan 
fluorescence intensity of G. duodenalis β-tubulin in a concentration-dependent manner 
(Fig. 5.8). These initial fluorescence results also indicate that the amount of quenching 
by each of the benzimidazoles ranged from maximal quenching (albendazole) to 
minimal quenching (thiabendazole) compared with unbound tubulin. Similar results 
were obtained with E. intestinalis β-tubulin (results not shown). The relative difference 
in fluorescence quenching between Giardia and Cryptosporidium β-tubulin reflects the 
low affinity or amount of binding by the benzimidazoles tested with tubulin from the 
benzimidazole-insensitive C. parvum (Table 5.5).  
 
QuickTime™ and a TIFF (Uncompressed) decompressor are needed to see this picture.
 
 
Fig. 5.8.  Relative amount of change in fluorescence by seven 
benzimidazoles (10µM) with G. duodenalis β-tubulin (2 µM) over a 30 
min period.  
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The semi-log arithmetic plot (Fig. 5.9) demonstrates that each benzimidazole binds with 
recombinant G. duodenalis β-tubulin in a monophasic manner although with different 
apparent association rates (kon) which were calculated from the slope of these plots. 
The high-affinity benzimidazoles, albendazole, fenbendazole, and mebendazole, had 
the highest average kon of 1.95 ± 0.45 x 10
7M
-1min
-1. The medium-affinity 
benzimidazoles, albendazole-sulphoxide, oxibendazole, and parbendazole, produced 
an average kon of 7.14 ± 0.69 x 10
5M
-1min
-1. The lowest-affinity benzimidazole tested, 
thiabendazole, had an average association rate of 7.05 ± 0.55 x 10
2M
-1min
-1. These 
results indicate there was a significant difference in the association rates between the 
high- and low-affinity benzimidazoles (α=0.05, tvalue 7.5 > t0.05,3 2.353). Similar results 
were obtained with recombinant E. intestinalis β-tubulin (Table 5.5).  
 
QuickTime™ and a TIFF (Uncompressed) decompressor are needed to see this picture.
 
 
Fig. 5.9.  Semi-log arithmetic plot of benzimidazole differential binding with 
G. duodenalis  β-tubulin. The average association kinetics of high- (■ ), 
medium- (▲ ), and low- (▼ ) affinity benzimidazoles for G. duodenalis          β-
tubulin are indicated.  Chapter 5.  Benzimidazole binding kinetics 
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The average association constants (kon) for albendazole with α-, β-, and αβ-tubulin from           
G. duodenalis, E. intestinalis, and C. parvum were also determined (Table 5.5). These 
results clearly illustrate the high affinity of albendazole for monomeric β-tubulin and 
heterodimeric αβ-tubulin from the two benzimidazole-sensitive parasites, G. duodenalis 
and  E. intestinalis. The association constants for G. duodenalis and E. intestinalis       
β-tubulin or αβ-tubulin were approximately 10
7M
-1min
-1 compared with approximately 
10
3M
-1min
-1 for the benzimidazole-insensitive C. parvum. These results also indicate 
that albendazole has a very low binding affinity (i.e. 10
2M
-1min
-1) for α-tubulin from all 
three parasites.  
 
 
Association constants (kon) (M
-1min
-1)  
 
Organism  
 
α-tubulin  
 
β-tubulin  
 
αβ-tubulin  
 
G. duodenalis   1.10 x 10
2   1.95 x 10
7   1.84 x 10
7  
E. intestinalis   1.50 x 10
2   1.86 x 10
7   1.70 x 10
7  
C. parvum   1.24 x 10
2   7.20 x 10
2   3.01 x 10
2  
 
Table 5.5.  Association constants for albendazole with α-, β-, or αβ-tubulin 
from G. duodenalis, E. intestinalis, and C. parvum.  
 
The dissociation rate of the benzimidazole-tubulin complexes was determined by 
incubating them in a 200-times molar excess of β-tubulin in MBS buffer which resulted 
in a benzimidazole specific dissociation. This was measured as an increase in relative 
fluorescence values as a result of a decrease in the quenching effect from the 
dissociating benzimidazole compounds. The resulting dissociation curves (Fig. 5.10) 
were used to determine the dissociation rates (koff) with β-tubulin from G. duodenalis 
(Table 5.6), E. intestinalis (Table 5.7), and C. parvum (Table 5.8). The rate of 
dissociation (koff) was 0.269min
-1 (G. duodenalis) and 0.261min
-1 (E. intestinalis) for the 
high-affinity benzimidazoles (i.e.  albendazole,  fenbendazole,  mebendazole).  The    Chapter 5.  Benzimidazole binding kinetics 
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mid-range benzimidazoles (i.e. albendazole-sulphoxide, oxibendazole, parbendazole) 
had dissociation rates of 0.345min
-1 (G. duodenalis) and 0.355min
-1 (E. intestinalis). 
The lowest affinity benzimidazole, thiabendazole, had dissociation rates of 0.542min
-1 
(G. duodenalis) and 0.497min
-1 (E. intestinalis) (Fig. 5.10, Table 5.6). These results 
indicate that the rate of dissociation (koff) for all the benzimidazole compounds was 
inversely proportional to the binding affinity (kon) with the highest dissociation rate being 
observed with the lowest affinity benzimidazole, thiabendazole. Conversely, the 
slowest dissociating benzimidazoles were the high-affinity albendazole, fenbendazole, 
mebendazole. These results indicate that the differential efficacy of the benzimidazoles 
tested is due to a higher affinity and slower dissociation of the benzimidazole from the 
benzimidazole / β-tubulin complex.  
 
QuickTime™ and a TIFF (Uncompressed) decompressor are needed to see this picture.
 
 
Fig. 5.10.  Average dissociation curves of benzimidazole derivatives from 
G. duodenalis β-tubulin. The high- (■ ), medium- (▲ ), and low- (◆ ) affinity 
benzimidazole compounds were dissociated from G. duodenalis β-tubulin. 
This resulted in a decrease in the amount of quenching of the fluorescence 
from β-tubulin which is indicated in these dissociation curves.  Chapter 5.  Benzimidazole binding kinetics 
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5.3.3.ii.  Comparative binding affinities of 
benzimidazoles with protozoan tubulin  
 
To investigate the relationship between the strength of binding to tubulin and the 
chemical nature of the benzimidazole compound the affinity constant (Ka) was 
calculated by the ratio of the association (kon) and dissociation (koff) rates. The 
association constant for each benzimidazole compound tested with β-tubulin  from       
G. duodenalis (Table 5.6), E. intestinalis (Table 5.7), and C. parvum (Table 5.8) were 
determined. Using this method, there was a clearly identifiable differential affinity of the 
high- and medium-affinity benzimidazole compounds with β-tubulin from G. duodenalis 
and E. intestinalis which was not observed with C. parvum. In considering the affinity 
constant of the benzimidazoles tested with β-tubulin  from  the  sensitive  organisms,       
G. duodenalis and E. intestinalis, there was no significant difference between the 
affinity rates for any of the benzimidazoles (α=0.05, tvalue 1.914 < t0.05,3 2.353). However, 
when the affinity constants of the benzimidazole-insensitive C. parvum was compared 
with those of G. duodenalis or E. intestinalis, all the benzimidazoles tested had a 
significantly lower affinity for C. parvum β-tubulin (α=0.05, tvalue 42.9 > t0.05,3 2.353).  
 
The differential affinity of the benzimidazole derivatives which distinguished them as 
having either a high-, medium, or low-affinity for β-tubulin was also observed between 
the two benzimidazole-sensitive organisms (Table 5.6 and 5.7). However, the 
difference in affinity between the high-, medium, or low-affinity benzimidazoles was not 
observed with the affinity constants derived from C. parvum β-tubulin (Table 5.8). The 
highest affinity constants of the benzimidazoles tested were observed with 
albendazole, fenbendazole, and mebendazole with an average Ka of 7.25 ± 0.40 x 
10
7M
-1 (G. duodenalis) and 7.13 ± 0.18 x 10
7M
-1 (E. intestinalis). Lower affinities were 
demonstrated  with  albendazole-sulphoxide,  oxibendazole,  and  parbendazole            
(G. duodenalis Ka 2.07 ± 0.58 x 10
6M
-1 and E. intestinalis Ka 1.84 ± 0.48 x 10
6M
-1). Chapter 5.  Benzimidazole binding kinetics 
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Thiabendazole had the lowest and most variable affinity constant (G. duodenalis Ka 
1.30 ± 1.1 x 10
3M
-1 and E. intestinalis Ka 1.26 ± 0.97 x 10
4M
-1). The trend in binding 
affinities was observed for monomeric β-tubulin from G. duodenalis and E. intestinalis 
but not C. parvum for which very low binding affinities were determined (average Ka 2.1 
x 10
2M
-1) for all the benzimidazoles tested.  
 
 
 
Binding parameter  
 
Benzimidazole  
derivative    
kon (M
-1min
-1)  
 
koff (min
-1) 
 
Ka (M
-1)  
 
Albendazole  
Fenbendazole  
Mebendazole  
 
1.95 ± 0.45 x 10
7 
 
2.69 x 10
-1 
 
7.25 ± 0.40 x 10
7 
 
Albendazole-sulphoxide 
Oxibendazole  
Parbendazole  
 
7.14 ± 0.69 x 10
5 
 
3.45 x 10
-1 
 
2.07 ± 0.58 x 10
6 
 
Thiabendazole  
 
7.05 ± 0.55 x 10
2 
 
5.42 x 10
-1 
 
1.30 ± 1.1 x 10
3 
 
Table 5.6.  Summary of binding kinetics and affinity constants for seven 
benzimidazoles with recombinant G. duodenalis β-tubulin.  
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Binding parameter  
 
Benzimidazole  
derivative    
kon (M
-1min
-1)  
 
koff (min
-1) 
 
Ka (M
-1)  
 
Albendazole  
Fenbendazole  
Mebendazole  
 
1.86 ± 0.22 x 10
7 
 
2.61 x 10
-1 
 
7.13 ± 0.18 x 10
7 
 
Albendazole-sulphoxide 
Oxibendazole  
Parbendazole  
 
6.53 ± 0.51 x 10
5 
 
3.55 x 10
-1 
 
1.84 ± 0.48 x 10
6 
 
Thiabendazole  
 
6.39 ± 0.63 x 10
3 
 
4.97 x 10
-1 
 
1.29 ± 0.97 x 10
4 
 
Table 5.7.  Summary of binding kinetics and affinity constants for seven 
benzimidazoles with recombinant E. intestinalis β-tubulin.  
 
 
 
Binding parameter  
 
Benzimidazole  
derivative    
kon (M
-1min
-1)  
 
koff (min
-1) 
 
Ka (M
-1)  
 
Albendazole  
Fenbendazole  
Mebendazole  
 
7.20 ± 0.44 x 10
2 
 
2.88  
 
2.50 ± 0.20 x 10
2 
 
Albendazole-sulphoxide 
Oxibendazole  
Parbendazole  
 
4.80 ± 0.35 x 10
2 
 
2.41  
 
1.99 ± 0.35 x 10
2 
 
Thiabendazole  
 
4.75 ± 0.52 x 10
2 
 
2.61  
 
1.82 ± 0.45 x 10
2 
 
Table 5.8.  Summary of binding kinetics and affinity constants for seven 
benzimidazoles with recombinant C. parvum β-tubulin.  
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5.3.3.iii.  Inhibition of microtubule assembly by 
benzimidazole compounds  
 
The recombinant α- and β-tubulin monomers from all three parasites were dimerised 
and the αβ-tubulin heterodimers polymerised to form microtubules. The effect of the 
benzimidazoles on the amount of polymerisation or microtubule assembly was 
monitored spectrophotometrically (i.e. turbidimetry). With G. duodenalis  and                
E. intestinalis  αβ-tubulin, the highest affinity benzimidazoles (i.e. albendazole, 
fenbendazole, mebendazole), had the greatest inhibitory effect on polymerisation 
compared with the lower affinity benzimidazoles (i.e. albendazole-sulphoxide, 
oxibendazole, and parbendazole). The lowest affinity benzimidazole, thiabendazole, 
had the least effect on polymerisation, particularly during the initial ten minute 
assembly phase (Fig. 5.11).  
 
The results for G. duodenalis and E. intestinalis microtubule assembly were not 
significantly different to each other while none of the benzimidazoles tested significantly 
reduced the rate of assembly of C. parvum  microtubules  (results  not  shown).  With      
C. parvum  αβ-tubulin all seven benzimidazoles tested reduced the final amount of 
microtubules assembled by 5 to 10% without affecting the rate at which (maximum) 
assembly occurred (i.e. slope of assembly phase, 3 to 10 min).  
 
In addition to these findings, when excess molar concentrations of albendazole, 
fenbendazole, mebendazole were added to microtubules assembled in the absence of 
any benzimidazoles there was no decrease in turbidity or absorbance indicating they 
did not de-polymerise the microtubules under these conditions.  
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Fig. 5.11.  Effect of several benzimidazoles on the in vitro  assembly  of     
G. duodenalis microtubules. The average absorbance of heterodimeric       
αβ-tubulin (■ ) mixed with a 10 times molar excess of low- (▲ ), medium- (◆ ), 
and high- ( ) affinity benzimidazoles are indicated over a 30 min period.  
 
5.3.4.  Discussion  
 
The mechanism underlying the activity of the benzimidazoles against parasitic protozoa 
has not been determined. This study was undertaken to identify whether the 
benzimidazoles bind to their proposed target protein, β-tubulin, with different affinities 
when this protein is derived from either benzimidazole-sensitive or -insensitive 
organisms.  For  this  study,  the  binding  affinities  of  a  number  of  benzimidazole            
R5-derivatives were determined with monomeric and heterodimeric β-tubulin from two 
parasites with a clearly demonstrated high in vitro efficacy, G. duodenalis  and             
E. intestinalis, and one with a low in vitro efficacy, C. parvum, to the benzimidazoles 
tested.  
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This study has clearly demonstrated two important aspects of the benzimidazoles 
mechanism of action in these parasites. Firstly, regardless of the chemical composition 
of the benzimidazole compound tested they have an indistinguishable affinity for 
monomeric β-tubulin and dimeric αβ-tubulin. Secondly, they have a demonstrably higher 
affinity for β-tubulin from benzimidazole-sensitive organisms when compared with a 
benzimidazole-insensitive organism.  
 
Interestingly, the R5-derivatives tested in this study produced distinctive binding 
affinities with G. duodenalis and E. intestinalis recombinant β-tubulin. These affinities, 
described by the constants Ka and Kd,  divided  the  benzimidazoles  tested  into          
high-affinity (i.e. albendazole, fenbendazole, mebendazole), medium-affinity (i.e. 
albendazole-sulphoxide, oxibendazole, parbendazole), or low-affinity (thiabendazole) 
derivatives. A similar range of affinities is reflected in their observed in vitro efficacies 
against these two parasites (Katiyar and Edlind, 1997; Morgan et al., 1993). These 
binding constant results therefore suggest that at least some part of their efficacy is 
due to their differential binding affinity for β-tubulin which is related to the chemical 
group present in the R5 side-chain of the benzimidazole.  
 
The relationship between the association (kon) and dissociation (koff) rates of these 
benzimidazole derivatives was demonstrated to be inversely proportional. This 
suggests that the lower in vitro efficacy of the rapidly dissociating benzimidazoles         
(i.e. albendazole-sulphoxide, oxibendazole, parbendazole, and thiabendazole) may be 
partly due to their inability to form stable benzimidazole-β-tubulin complexes with the 
converse being true of the higher efficacy benzimidazoles (i.e. albendazole, 
fenbendazole, mebendazole).  
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This relationship is also reflected in the effect each benzimidazole was found to have 
on the polymerisation of αβ-heterodimers into microtubules. One of the proposed 
mechanisms of action of the benzimidazoles is through binding to the microtubule 
which destabilises the lattice structure of the tubule, subsequently resulting in its 
disintegration via depolymerisation (reviewed by Lacey, 1988). The findings of this 
study partially support this model although via a different mechanism. The addition of 
the different benzimidazoles to assembling αβ-tubulin heterodimers had a 
benzimidazole-dependent effect on both the rate and amount of microtubules 
assembled for the benzimidazole-sensitive parasites. That is, the highest affinty 
benzimidazoles (i.e. albendazole, fenbendazole, mebendazole) decreased both the 
rate and amount of microtubule assembly which was observed to decrease with the 
medium- and low-affinity derivatives. The benzimidazoles were also demonstrated to 
inhibit the assembly of G. duodenalis and E. intestinalis microtubules (i.e. albendazole, 
fenbendazole, mebendazole) while having no demonstrable effect on the 
polymerisation of C. parvum heterodimers.  
 
The microtubule assembly assay also demonstrated that none of the benzimidazole 
compounds tested were able to depolymerise assembled microtubules although these 
tubules were naturally depolymerised by increasing the assembly temperature above 
37°C. This indicates that whilst the microtubules were capable of depolymerisation this 
was not promoted or favoured by the presence of the benzimidazole derivatives tested. 
These results may indicate that the benzimidazole-binding site on β-tubulin from 
sensitive protozoa is located at or near the inter-heterodimer interface as the presence 
of the benzimidazoles is sufficient to arrest or inhibit microtubule assembly.  
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Taken together, these results may indicate that a benzimidazole-β-tubulin cap is formed 
at the growing or assembling ends of the microtubules and this cap prevents the further 
elongation or polymerisation of the microtubule. Whether the inhibition of assembly is 
due to steric hindrance, blockage of GTP hydrolysis, or another mechanism is unclear 
from this study. These results also indicate that it is likely all the benzimidazoles tested 
interact with the same binding site on β-tubulin but the strength of this binding is 
partially dependent on the chemical composition of the R5 group of the benzimidazole 
derivatives.  
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In order to determine the binding affinity of several benzimidazoles with β-tubulin from 
benzimidazole-sensitive and -insensitive organisms it was initially necessary to 
produce protozoan α- and β-tubulin in a recombinant form using an E. coli expression 
system (Chapter 2). This method of expressing α- and β-tubulin produced high yields of 
the protein when it was fused to a high-solubility fusion partner, MBP or GST. The MBP 
and GST fusion partners, as well as providing a means of producing α- and β-tubulin as 
a soluble cytoplasmic protein in E. coli, also provided a convenient means of purifying 
the tubulin fusion proteins.  
 
This resulted in the recombinant tubulin monomers being purified to a high enough 
level for attempts to crystallise it to be undertaken (Chapter 3). The αβ-tubulin protein 
has been crystallised previously but only in the form of a 2-D crystal which has meant 
electron, and not X-ray, crystallography was utilised to construct a 3.5Å 3-D model of 
the mammalian αβ-tubulin heterodimer. The differences between previously applied 
methods to produce 3-D αβ-tubulin crystals and those used in this project will be 
discussed particularly in regard to understanding why the protozoan recombinant           
αβ-tubulin also failed to yield X-ray quality 3-D crystals.  
 
As a result of this, and in order to produce a 3-D model of αβ-tubulin from 
benzimidazole-sensitive and -insensitive organisms, a homology or comparative 
modelling approach was utilised (Chapter 4). The homology models produced using 
this method allowed a structurally significant hydrophobic benzimidazole-binding 
domain to be identified. The role of the individual amino acid residues which comprise 
this domain may perform in binding with several different benzimidazoles is discussed 
using this model. This discussion also takes into account previous studies of the 
molecular basis of benzimidazole-resistance in the nematode H. contortus and the 
fungi A. nidulans.  Chapter 6.  General Discussion 
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To substantiate the role that protozoan β-tubulin is proposed to perform in binding with 
the benzimidazole compounds a series of biochemical experiments were conducted 
(Chapter 5). In this way the association and dissociation rates, and subsequently the 
affinity constant, for several benzimidazoles with α-, β-, or, αβ-tubulin from sensitive and 
insensitive protozoa were determined. From these experiments it was identified that 
the benzimidazoles tested could be separated into three categories of having high-, 
medium-, or low-affinity for protozoan β-tubulin. Of the benzimidazoles used in this 
study, six were R5-carbamate derivatives while the seventh benzimidazole lacked an 
R5 side group (i.e. thiabendazole). The influence that the structure of each 
benzimidazole derivative tested had on the observed association rate, dissociation 
rate, and affinity constant is discussed in terms of the proposed hydrophobic binding 
domain. In particular, the influence of binding between the amino acid residues of the 
hydrophobic binding domain with the different R5 side-groups of the benzimidazoles on 
the final observed affinity constants is also discussed. A discussion is also provided of 
the structure-activity relationships that can be identified by combining the amino acids 
proposed to create the hydrophobic binding domain with the observed in vitro binding 
affinities for each benzimidazole compound used in this study.  
 
In order to identify the benzimidazole binding region on the β-tubulin protein it was 
initially necessary to produce natively folded α- and β-tubulin free of post-translational 
modifications and accessory proteins such as MAPs. This was necessary as post-
translational modifications and MAPs may interfere with benzimidazole-binding. 
Additionally, the post-translational modifications may also produce a modified form of 
the tubulin protein which does not assemble to form microtubules. It was therefore 
necessary to develop a recombinant protein expression system capable of producing 
soluble α- and β-tubulin. It was essential that the tubulin monomers were soluble as 
there is considerable speculation that recombinant proteins which are encapsulated Chapter 6.  General Discussion 
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into inclusion bodies are not correctly folded and are a sub-population of folding 
intermediates which the host cell either could not continue to fold into a stable 3-D 
structure or the cell detects as foreign and so inactivates by sequestering them in 
inclusion bodies.  
 
In addition to this, and particularly when considering the tubulin folding pathway, 
several co-factors and chaperones are required for tubulin to obtain its correct 3-D, 
biologically-active structure. It is therefore reasonable to predict that tubulin which has 
been solubilised from inclusion bodies and completely denatured will not refold into its 
correct 3-D structure. This protein folding problem is commonly recognised as one of 
the limiting steps in producing biochemically active proteins from denatured ones.  
 
Several studies have examined the drug-binding characteristics of re-folded 
recombinant tubulin monomers without considering whether a heterologous or 
homogenous pool of tubulin folding intermediates has been created. These studies 
also fail to establish the existence of other intrinsic biological functions of native tubulin 
in the refolded form of the protein. These essential activities include the ability of 
heterodimers to assemble into microtubules and also to act as a GTPase. It is 
reasoned that unless these essential tubulin functions are demonstrated it will not be 
possible to confidently examine the drug-binding characteristics of tubulin, or to relate 
these in vitro drug-binding characteristics to in vivo drug efficacy.  
 
To avoid potential problems associated with refolding the tubulin monomers, an E. coli 
host strain was utilised as it will produce recombinant tubulin without any post-
translational modifications. In addition to this, E. coli does not express endogenous 
tubulin such that the tubulin extracted from these host cells consisted only of the 
cloned protozoan tubulin.  
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A comparison was made between several fusion proteins which could be attached to 
tubulin to ensure it was expressed as a soluble protein. These fusion partners were 
MBP and GST which are commercially available as expression vectors and are 
recommended for heterologous over-expression of soluble proteins in E. coli. The third 
fusion partner, consisting of a poly-His fusion sequence, was also utilised to establish 
the intrinsic solubility of tubulin in the presence of this low-solubility fusion partner. The 
three fusion partners, MBP, GST, and poly-His, were all transcriptionally controlled by 
the T7 RNA promoter so that any differences in protein expression levels could be 
attributed to the nature of the fusion partner. In this way the low intrinsic solubility of 
tubulin was demonstrated and the significant improvement in solubility brought about 
by the MBP and GST fusion partners was clearly identifiable.  
 
Other conditions affecting tubulin’s expression level were also assessed, including the 
choice of E. coli host strain which were all based on the BL21(DE3) genotype. The 
BL21(DE3)pLysS strain contains an additional plasmid to minimise the basal 
expression of α- and β-tubulin. The third strain tested, BL21(DE3)RIL, was modified to 
contain high levels of codons which are normally present in prokaryotic proteins but are 
in limited supply in E. coli. The amount of soluble α- and β-tubulin expressed in each   
E. coli strain was similar for G. duodenalis, C. parvum, and E. intestinalis (Table 2.3). 
However, there was a substantial difference in soluble tubulin expression levels 
between the three E. coli strains tested. The BL21(DE3) strain yielded the lowest 
amount of soluble tubulin with average expression levels 25 to 35% of those observed 
with the BL21(DE3)pLysS and BL21(DE3)RIL strains. The highest tubulin expression 
levels were observed with the BL21(DE3)pLysS strain. Taken together, these results 
indicate that the amount of expression of soluble α- and β-tubulin in E. coli is influenced 
by the choice of host strain and strains which suppress basal expression of tubulin are 
preferable to ones lacking this feature.  
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The amount of expression of recombinant tubulin in E. coli was also found to be 
affected by the rate of protein synthesis as determined by the temperature at which the 
E. coli expressing the tubulin was cultured. Determining the effect of temperature on 
tubulin expression levels involved expressing the tubulin-MBP fusion proteins at 15°C, 
25°C, 30°C, or 37°C in the E. coli strain BL21(DE3)pLysS. This parameter was found 
to significantly affect the amount of soluble tubulin fusion proteins produced in a 
temperature-dependent manner. Optimal tubulin expression levels were observed at 
37°C for α- and β-tubulin from all three parasites tested (i.e. 30-40 mg/l). These total 
amounts of soluble protein decreased by up to 60% at 30°C (i.e. 25-35 mg/l) and a 
further 50% at 25°C (i.e. 15-25 mg/l). Expression of recombinant tubulin at 15°C was 
less than a quarter of the level observed at 37°C (i.e. <10 mg/l). These results 
indicated that the rate of protein synthesis at 37°C was optimal for the maximal 
expression of tubulin-MBP fusion proteins in the E. coli BL21(DE3)pLysS strain.  
 
A further aim of producing soluble tubulin as a fusion protein was that it would provide 
a convenient means of purifying the tubulin monomers. This was necessary for trials to 
crystallise the protozoan tubulin especially to obtain a 3-D crystal suitable for X-ray 
crystallography. The required level of purity of protein for successful crystallisation is 
generally believed to be higher than 98% although this can vary depending on the 
nature of the protein being crystallised (Rhodes, 2000). Prior to this study, several 
groups have tried unsuccessfully to produce 3-D crystals of tubulin extracted from 
bovine or porcine brain microtubules. It should be noted that brain tissue has 
subsequently been found to contain α- and β-tubulin biotypes with a high degree and 
wide range of post-translational modifications. This would result in a highly 
heterogenous tubulin sample and it is believed that this has significantly hindered the 
formation of 3-D crystals. This has primarily been due to the high level of heterogeneity 
as several α- and β-tubulin biotypes were present in microtubules extracted from brain 
tissue.  Chapter 6.  General Discussion 
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The approach used in this study with recombinant, highly purified, and homogeneous 
αβ-tubulin was designed to address some of the problems that have previously been 
identified as potential reasons why tubulin had failed to crystallise. The tubulin biotype 
heterogeneity problem was addressed by producing recombinant tubulin which was 
double purified; initially by affinity chromatography and secondly by anion-exchange 
chromatography. This ensured that both the α- and β-tubulin monomers had a purity of 
greater than 98% as assessed by SDS-PAGE and Western blotting with specific         
anti-α- or anti-β-tubulin monoclonal antibodies.  
 
A second reason suggested for why tubulin had failed to form 3-D crystals is structural 
instability caused by the highly acidic and unstructured carboxy-terminus of α-  and      
β-tubulin. This is particularly significant for β-tubulin  as  when  tubulin  is  in  an                
αβ-heterodimeric form the carboxy terminus of α-tubulin is buried within the inter-
monomeric region while the carboxy-terminus of β-tubulin is exposed to inter-dimeric 
interactions (Löwe et al., 2001; Nogales et al., 1999). To address this problem the α-,  
β-, and αβ-tubulin proteins were treated with subtilisin, a protease enzyme which 
selectively cleaves each tubulin monomer so as to remove the carboxy-terminus           
(i.e. residue Asp-438 on α-tubulin and residue Gln-433 on β-tubulin; Redeker et al., 
1992). The effect of removing the carboxy-termini on the overall charge of the tubulin 
monomers was clearly illustrated using a non-denaturing agarose gel which separated 
the tubulin monomers on the basis of their overall charge.  
 
The final reason which has previously been cited for why tubulin has failed to form 3-D 
crystals was termed thermal instability which related to tubulin’s structural instability 
and rapid denaturation at temperatures above 4°C. As the tubulin used in 
crystallisation plates could therefore denature before forming crystal nuclei a solution to 
this problem was sought in two ways. Firstly, the tubulin was maintained at or below 
4°C at all times during the protein extraction and purification process to minimise the Chapter 6.  General Discussion 
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amount of denatured tubulin present in samples used for crystallisation trials. 
Crystallisation plated were also incubated at 4°C, in addition to room temperature, to 
minimise the denaturation of monomeric or dimeric tubulin during crystal formation. 
The second approach to addressing the thermal instability of tubulin was that this 
problem had been observed with αβ-tubulin heterodimers. It was therefore possible that 
monomeric α- and β-tubulin, in addition to αs- and βs-tubulin, may be significantly more 
stable than heterodimeric αβ-tubulin derived from extracted microtubules.  
 
A final alternative approach which was utilised in this project was taken from the 
observation that all previous material used for electron crystallography was crystallised 
sheets of αβ-tubulin heterodimers assembled into microtubules which then aligned in 
an anti-parallel manner (Wolf et al., 1996). This meant that the αβ-tubulin heterodimers 
had been assembled into microtubules in vitro in the presence of GTP and a divalent 
cation such as zinc or magnesium. While this approach had successfully produced 2-D 
crystals it is also possible that it had prevented the formation of 3-D crystals. Therefore, 
in this study, the α-,  β-,  αs-,  βs-,  αβ-, and αβs-tubulin were not assembled into 
microtubules prior to application to crystallisation screening but were instead treated as 
monomers or heterodimers.  
 
Despite testing over one-hundred separate crystallisation conditions and incubating the 
crystallisation plates for two-years, none of the approaches taken in this project were 
suitable for the formation of 3-D crystals of recombinant protozoan tubulin. Although   
3-D birefringent crystals of <1.0mm were produced these were too small and fragile for 
X-ray analysis and without further analysis it was not possible to identify that these 
were αβ-tubulin crystals. Although this was a disappointing result, especially as it would 
have provided a conclusive model of the benzimidazole-binding site, there are 
alternative approaches which were utilised to obtain a lower resolution model to 
provide this information.  Chapter 6.  General Discussion 
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An alternative to producing a model of protozoan β-tubulin from a crystal structure was 
to create a homology model of protozoan β-tubulin with the mammalian 3-D structure. 
This homology model compared benzimidazole-sensitive organisms (G. duodenalis 
and E. intestinalis) and -insensitive organisms (C. parvum and B. taurus) and identified 
several potentially significant amino acid differences. From the homology models of    
β-tubulin it was possible to identify a hydrophobic binding region from amino acid 
residue Ala-186 to Phe-213. This hydrophobic benzimidazole-binding region is not 
seen on the β-tubulin from insensitive organisms (C. parvum and B. taurus).  
 
In order to determine the binding kinetics of several benzimidazoles with recombinant 
α-,  β-,and  αβ-tubulin from benzimidazole-sensitive and -insensitive protozoa two 
methods were investigated. The first method involved analysing the ability of each 
benzimidazole compound to bind with it’s target protein which had been immobilised on 
a biosensor chip. The basis of this method is the measurement of resonance from the 
sensor chip surface which is altered by the amount of mass attached to the chip 
surface. An initial investigation was made into whether or not this method was suitable 
for assessing the binding kinetics between immobilised β-tubulin from the sensitive 
organism  G. duodenalis and the benzimidazole compounds albendazole and 
mebendazole. These two compounds have been previously shown to exhibit a high 
efficacy for G. duodenalis (Katiyar et al., 1994; Morgan et al., 1993). Following analysis 
of direct binding data of albendazole and mebendazole, over a 0-1000nM range, it was 
demonstrated that the interaction between albendazole and mebendazole with the 
CMD  matrix  was  equal  to  or  greater  than  the  binding  with  the  immobilised                   
G. duodenalis α- or β-tubulin.  
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These results indicated that under the range of conditions tested to determine the 
amount of binding between albendazole and mebendazole with immobilised β-tubulin, 
the two compounds were instead binding with the matrix. Whilst this non-specific 
binding was rapid and reversible it occurred to an extent where it blocked the detection 
of the interaction with G. duodenalis tubulin. This non-specific binding was not reduced 
despite testing a wide range of conditions including variation in the pH of buffers, ligand 
surface concentration, ligand immobilisation technique, analyte (albendazole or 
mebendazole) concentration, and flow rate.  
 
The second method which was investigated to analyse the binding reaction between 
recombinant  α- and β-tubulin monomers and dimers with the benzimidazoles was a 
fluorescence quenching method based on measuring the amount of intrinsic 
fluorescence from tubulin’s tryptophan residues. The intrinsic fluorescence of αβ-tubulin 
monomer is primarily due to the indolic group of tryptophan residues of which α-tubulin 
and β-tubulin each have four residues; the fluorescence from some of these residues is 
blocked as a result of dimerisation which, based on the 3.5Å dimer model (Löwe et al., 
2001) will result in a loss of two residues into the α-/β-tubulin inter-monomer interface. 
The amount of fluorescence emitted from monomeric or heterodimeric β-tubulin was 
found to be quenched when benzimidazole compounds were bound to this protein. 
This  method  has  been  extensively  utilised  to  study  the  binding  kinetics  of  the           
anti-tumour drug colchicine with tubulin (Banerjee  and  Ludueña,  1992;  Chakrabarti     
et al., 1996; Guha and Bhattacharyya, 1997). In addition to this, the benzimidazole 
derivatives tested were also shown to affect the rate and amount of polymerisation by 
benzimidazole-bound  αβ-tubulin heterodimer as assessed by a spectrophotometric 
analysis of microtubule formation in vitro.  
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The high-affinity benzimidazoles identified in this study were albendazole, 
fenbendazole, and mebendazole. By utilising the benzimidazole-sensitive/-insensitive 
homology models, these three compounds were all proposed to form significant 
interactions within the proposed hydrophobic binding domain. More importantly, these 
interactions were proposed to involve the key substituted amino acids in this binding 
domain, Ile-189, Val-199, and Phe-200. More specifically these interactions are 
proposed to be based on binding with the aliphatic side-group of Ile-189 as this has a 
strong electron-withdrawing potential. The hydrophobic aliphatic side-group of Val-199 
is also crucial in increasing the hydrophobicity at the base of this benzimidazole-
binding loop, especially when it is compared with benzimidazole-insensitive β-tubulin 
models. It is unlikely that Val-199 is directly involved in binding these three 
benzimidazoles as spatially it is predicted to be too far from the propyl side chain of 
albendazole or the phenyl ring of fenbendazole or mebendazole.  
 
The most significant interaction in this binding domain was proposed to involve the 
highly aromatic phenyl group of Phe-200 which is located in a position where it forms 
an electrophilic interaction with the R5 propyl group of albendazole and the phenyl 
group of fenbendazole and mebendazole. The additional  carbonyl  group  on  the          
R5 group of mebendazole is also proposed to participate in this electron-sharing 
interaction with amino acid Phe-200. The amino acid-R5-side group interactions 
proposed in this model would therefore result in the high affinity, slow dissociation 
binding kinetics observed for these three benzimidazole derivatives.  
 
The medium-affinity benzimidazoles that were identified in this study were 
albendazole-sulphoxide, oxibendazole, and parbendazole. As with the high-affinity 
benzimidazoles, the homology models identified several significant side-chain 
interactions between the amino acid residues of benzimidazole-sensitive protozoa and 
these R5 carbamates. Therefore, these interactions also involve the benzimidazole-Chapter 6.  General Discussion 
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sensitivity defining amino acids Ile-189, Val-199, and Phe-200. Taken together, and 
compared with the chemical side groups of the high affinity R5 derivatives, it would 
appear that the loss of the R5-sulphyl group has had a quantifiable effect on the affinity 
constants of these drugs. Although this group is proposed to interact with the 
conserved amino acid Cys-201, this interaction is likely to be based on an electrophilic 
S-O bond which would appear to contribute to the overall rates of association and 
dissociation of the high-affinity benzimidazoles compared with the medium-affinity 
benzimidazoles.  
 
Based on the proposed benzimidazole binding model the medium-affinity 
benzimidazoles would form an electrophilic O-O bond which would not form as stable 
an interaction of the S-O interaction of albendazole, fenbendazole, and mebendazole. 
The principal interactions identified for the medium-affinity benzimidazoles involve 
either a propyl- (albendazole-sulphoxide and oxibendazole) or butyl- (parbendazole) 
carbon chain which interacts with the aliphatic groups of Ile-189 and Val-199 and the 
aromatic group of Phe-200. The increased hydrophobicity of the proposed 
benzimidazole-binding domain as a result of the amino acid residues Ala-185, Leu-192, 
and Ile-202 is also proposed to have a significant effect on the formation of a relatively 
stable benzimidazole-β-tubulin complex as a result of the stable R5 carbamates.  
 
The final benzimidazole tested in this study was thiabendazole which lacks an R5-side 
group, instead having an R2-thiazole group. Of the seven benzimidazoles tested, 
thiabendazole had the lowest association rate, highest dissociation rate, and 
consequently the lowest affinity constant. The affinity constant was 1.4 ± 1.1 x 10
3M
-1 
which is approximately 10
4  times  lower  than  the  high-affinity  benzimidazoles  and      
10
3 times lower than the medium-affinity benzimidazoles. This represents a significant 
reduction in the affinity of this benzimidazole for β-tubulin which agrees with the 
proposed homology model. The three key amino acids within the proposed binding Chapter 6.  General Discussion 
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site, Ile-189, Val-199, and Phe-200, are unlikely to interact with the central benzimidine 
ring structure as it would not be close enough to these residues for binding to occur.  
 
With this benzimidazole-binding model the R2-thiazole group would be situated near 
the amino acid residues located at the top of this binding region. Whilst some binding 
may occur with these residues they are conserved between benzimidazole-sensitive 
and -insensitive organisms. Additionally, they are also conserved between 
benzimidazole-sensitive and -resistant, organisms, such as H. contortus. This means 
these amino acids are unlikely to form the basis of the selective activity of the 
benzimidazoles, including thiabendazole, for β-tubulin from particular protozoa.  
 
Taken together, the homology model-based benzimidazole-binding domain and the       
in vitro binding kinetics provide a model of benzimidazole / β-tubulin binding which has 
not been clearly identified previously. This is particularly true when the molecular basis 
of benzimidazole-sensitivity and -insensitivity is considered. This model of 
benzimidazole binding proposes that the benzimidazoles bind with a hydrophobic 
region of β-tubulin such that the R5 side-group of the benzimidazoles is brought into 
contact with three key non-conserved amino acids. These amino acid residues are     
Ile-189, Val-199, and Phe-200 which are located in a hydrophobic binding region which 
was demonstrated to only be present on the β-tubulin model of the benzimidazole-
sensitive protozoa, G. duodenalis and E. intestinalis. The interaction between the 
benzimidazole R5 side-group and residues Ile-189, Val-199, and Phe-200 of β-tubulin 
are therefore proposed to be central to the mechanism of action of these compounds.  
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There are several aspects of this project which could be addressed in future studies. 
To establish conclusively the molecular basis of this proposed benzimidazole-binding 
domain site-directed mutagenesis should be performed. This could initially be of each 
amino acid within this domain to determine which amino acid substitutions affect the 
benzimidazole association and dissociation rates and affinity constants. It is also 
technically conceivable to propose that all the key amino acids could be mutated to 
produce a recombinant protein with the amino acid sequence of a benzimidazole-
insensitive organism but only in this benzimidazole-binding region. If there was a 
complete loss of benzimidazole binding then it would provide strong evidence of the 
location of the key amino acid(s) involved in the formation of the benzimidazole binding 
site.  
 
It would also be informative to compare the benzimidazole-binding  properties  of          
β-tubulin extracted from benzimidazole-sensitive and -insensitive organisms. If the 
native protein was found to display a similar benzimidazole binding profile as the 
recombinant protein used in this study it would strengthen the argument that a valid 
benzimidazole-binding site has been identified. This is believed to be necessary to 
address the possibility that the benzimidazole-binding site which has been identified in 
this study using recombinant tubulin is the result of the protein being folded in E. coli 
which may have created an incorrectly folded region with benzimidazole-binding 
properties.  
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Another aspect of this study which could be addressed in future work relates to the 
dynamic behaviour of microtubules in organisms and the fact that the tubulin used in 
this study was a homogenous and purified protein interacting under controlled in vitro 
conditions with a chemically pure ligand. It would therefore be valuable to investigate 
the  in vivo binding properties of the benzimidazoles with actively assembling 
microtubules. There are several microscope-based techniques available for studying 
the growth of microtubules and some have also been developed to investigate the 
influence of specific drugs on this process (Grego et al., 2001; Viani et al., 2000). 
Similar approaches could be applied to the study of benzimidazole binding with 
protozoan microtubules. A further advantage of this approach is that microtubules from 
different regions of the protozoa could be studied in this way, such as either 
cytoskeletal or flagellar microtubules. It should be noted that producing sufficient 
amounts of flagellar or ventral disc microtubules for this type of analysis would be a 
significant technical challenge which could potentially preclude its successful 
execution.  
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Appendix I  
 
Alignment of α-tubulin deduced amino acid sequences  
            1         10         20         30         40         50        
Porcine  > MRECISIHV  GQAGVQIGNA CWELYCLEHG IQPDGQMPSD KTIGGGDDSF NTFFSETGAG 
H.sapien > MRECISIHV  GQAGVQIGNA CWELYCLEHG IQPDGQMPSD KTIGGGDDSF NTFFSETGAG 
C.parvum > MRECISIHV  GQAGIQIGNA CWELFCLEHG INPDGQMPMS EQNGISDDAF NTFFSETGAG 
G.duoden > MRECISVHI  GQAGVQIGNA CWELYCLEHG IQHDGQMPSD KTIGGGDDAF NTFFSETGAG 
E.intest > MRECISVHI  GQAGVQIGNA CWELYCLEHG IQHDGQMPSD KTIGGGDDAF NTFFSETGAG 
           ---------  ---------- ---------- ---------- --------*- ---------- 
 
           60         70         80         90         100        110        
Porcine  > KHVPRAVFVD LEPTVIDEVR TGTYRQLFHP EQLITGKEDA ANNYARGHYT IGKEIIDLVL 
H.sapien > KHVPRAVFVD LEPTVIDEVR TGTYRQLFHP EQLITGKEDA ANNYARGHYT IGKEIIDLVL 
C.parvum > KHVPRAVFVD LEPTVVDEIR SGTYRQLFHP EQLINGKEDA ANNFARGHYT VGKEILEVCL 
G.duoden > KHVPRAVFVD LEPTVVDEVR AGSYRQLYHP EQLISGKEDA ANNYARGHYT IGKEIVDLVL 
E.intest > KHVPRAVFVD LEPTVIDEVR TGTYRQLFHP EQLISGKEDA ANNFARGHYT IGKEIVDLCL 
           ---------- ---------- ---------- ----*----- ---------- -----*---- 
 
           120        130        140        150        160        170        
Porcine  > DRIRKLADQC TGLQGFSVFH SFGGGTGSGF TSLLMERLSV DYGKKSKLEF SIYPAPQVST 
H.sapien > DRIRKLADQC TGLQGFSVFH SFGGGTGSGF TSLLMERLSV DYGKKSKLEF SIYPAPQVST 
C.parvum > DRIRKLADNC TGLQGFLMFN AVGGGTGAGL GTLLLERLSV DYGKKSKLNF CTWPSPQLST 
G.duoden > DRVRKLADNC SGLQGFLIFH SFGGGTGAGF GSLFLERLSV DYGRKSKLEF VVYPSPQIAT 
E.intest > DRVRKLADNC SGLQGFLIFH SFGGGTGAGF GSLFLERLSV DYGRKSKLEF VVYPSPQIAT 
           --------*- ------**-- -------*-- *---*----- ---------- **--*--*-- 
 
           180        190        200        210        220        230        
Porcine  > AVVEPYNSIL TTHTTLEHSD CAFMVDNEAI YDICRRNLDI ERPTYTNLNR LIGQIVSSIT 
H.sapien > AVVEPYNSIL TTHTTLEHSD CAFMVDNEAI YDICRRNLDI ERPTYTNLNR LIGQIVSSIT 
C.parvum > AVVEPYNAVL STHSLLEHAD VAVMLDNEAI YDICRrNLNI EQPAYTNLNR LIAQVISSLT 
G.duoden > AVVEPYNTIL AAHSMLEHSD CAFMVDNEAM YDICRRNLDI ERPTYTNLNR LIAQCISSIT 
E.intest > AVVEPYNTIL AAHSMLEHSD CAFMVDNEAM YDICRRNLDI ERPTYTNLNR LIAQCISSIT 
           -------*-- *--**----- ---------- ---------- ---------- --*-**---- 
 
           240        250        260        270        280        290        
Porcine  > ASLRFDGALN VDLTEFQTNL VPYPRGHFPL ATYAPVISAE KAYHEQLSVA EITNACFEPA 
H.sapien > ASLRFDGALN VDLTEFQTNL VPYPRGHFPL ATYAPVISAE KAYHEQLSVA EITNACFEPA 
C.parvum > ASLRFDGALN VDITEFQTNL VPYPRIHFML SSYAPIISAE KAFHEQLSVA EITNAVFEPQ 
G.duoden > ASLRFDGALN VDLTEFQTNL VPYPRIHFPL CSYAPIISSE KAYHEKLSVA ELTNSVFEPA 
E.intest > ASLRFDGALN VDLTEFQTNL VPYPRIHFPL CSYAPIISSE KAYHEKLSVA ELTNSVFEPA 
           ---------- ---------- -----*---- **---*---- ---------- -----*---- 
 
           300        310        320        330        340        350       
Porcine  > NQMVKCDPRH GKYMACCLLY RGDVVPKDVN AAIATIKTKR TIQFVDWCPT GFKVGINYEP 
H.sapien > NQMVKCDPRH GKYMACCLLY RGDVVPKDVN AAIATIKTKR TIQFVDWCPT GFKVGINYEP 
C.parvum > NQMAKCDPRH GKYMACCLMY RGDVVPKDTN AAVATIKTKR TIQFVDWCPT GFKCGINYQP 
G.duoden > NMMVKCDPRH GKYMACCMMY RGDVVPKDVN AAIAVIKTKR TIQFVDWCPT GFKVGINYQP 
E.intest > NMMVKCDPRH GKYMACCMMY RGDVVPKDVN AAIAVIKTKR TIQFVDWCPT GFKVGINYQP 
           ---------- --------*- ---------- ---------- ---------- --------*- 
 
           360        370        380        390        400        410       
Porcine  > PTVVPGGDLA KVQRAVCMLS NTTAIAEAWA RLDHKFDLMY AKRAFVHWYV GEGMEEGEFS 
H.sapien > PTVVPGGDLA KVQRAVCMLS NTTAIAEAWA RLDHKFDLMY AKRAFVHWYV GEGMEEGEFS 
C.parvum > PTVVPGGDLA KVMRACCMIS NSTAIAEVFN RMDHKFDLMY SKRAFVHWYV GEGMEEGEFS 
G.duoden > PTVIPGGDLA KVQRSCLMIS NTTAIAEVWS RMDHKFDLMY AKRAFVHWYV GEGMEEGEFS 
E.intest > PTVIPGGDLA KVQRSCLMIS NTTAIAEVWS RMDHKFDLMY AKRAFVHWYV GEGMEEGEFS 
           ---------- -----*--*- -------*-* -*-------- ---------- ---------- 
 
           420        430          
Porcine  > EAREDMAALE KDYEEVGVDSV  
H.sapien > EAREDMAALE KDYEEVGVDSV  
C.parvum > EAREDLAALE KDYEEVGAEFD  
G.duoden > EAREDLAALE KDYEEIGAETL  
E.intest > EAREDLAALE KDYEEIGAETL  
           -----*---- -------****  
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Alignment of β-tubulin deduced amino acid sequences  
          1         10         20         30           40         50         
B.taurus> MREIVHIQA GQCGNQIGAK FWEVISDEHG IDPTG~~SYHGD SDLQLERINV YYNEAAGNKY 
H.sapien> MREIVHIQA GQCGNQIGAK FWEVISDEHG IDPTG~~SYHGD SDLQLERINV YYNEAAGNKY 
C.parvum> MREIVHVQG GQCGNQIGAK FWEVISDEHG IDPTGtgTYHGE SDLQMERINV FYNEASGGRY 
G.duoden> MREIVHIQA GQCGNQIGAK FWEVISDEHG VDPSG~~EYRGD SELQIERINV YFNEAAGGRY 
E.intest> MREIIHIQT GQCGNQIGAK FWETISGEHG VDPSG~~KYVGT SDLQIERINV YYNEASGKKY 
          --------- ---------- ---------- *--*-..*-*-- ----*----- -------+-- 
 
          60         70         80         90         100        110         
B.taurus> VPRAILVDLE PGTMDSVRSG PFGQIFRPDN FVFGQSGAGN NWAKGHYTEG AELVDSVLDV  
H.sapien> VPRAILVDLE PGTMDSVRSG PFGQIFRPDN FVFGQSGAGN NWAKGHYTEG AELVDSVLDV  
C.parvum> VPRAILVDLE PGTMDSVRAG PFGSLFRPDN FIFGQSGAGN IWAKGHYTEG AELLDAVMDV  
G.duoden> VPRAILVDLE PGTMDSVRAG PFGQIFRPDN FVFGQSGAGN NWAKGHYTEG AELVDAVLDV  
E.intest> VPRAVLIDLE PGTMDSVRAG PFGELFRPDN FVFGQSGAGN NWAKGHYTEG AELIDAVMDV  
          ---------- --------+- ---------- ---------- ---------- -----+----  
 
          120        130        140        150        160        170         
B.taurus> VRKESESCDC LQGFQLTHSL GGGTGSGMGT LLISKIREEY PDRIMNTFSV VPSPKVSDTV  
H.sapien> VRKESESCDC LQGFQLTHSL GGGTGSGMGT LLISKIREEY PDRIMNTFSV MPSPKVSDTV  
C.parvum> VRHEAESCDC LQGFQITHSL GGGTGSGMGT LLVGKIHEEF PDRILQTFSV FPSPKVSDTV  
G.duoden> VRKRSEACDC LQGFQICHSL GGGTGAGMGT LLIAKIREEY PDRMMCTFSV VPSPKVSDTV  
E.intest> VRKEAESCDC LQGFQITHSL GGGTGAGMGT LLIAKIREDF PDRMICTFSV VPSPKVSDTV  
          ---------- -----+---- -----*---- ---*------ ---*------ ----------  
 
          180        190        200        210        220        230         
B.taurus> VEPYNATLSV HQLVENTDET YCIDNEALYD ICFRTLKLTT PTYGDLNHLV SATMSGVTTC  
H.sapien> VEPYNATLSV HQLVENTDET YSIDNEALYD ICFRTLKLTT PTYGDLNHLV SATMSGVTTC  
C.parvum> VEPYNATLSI HQLVENSDAV QVIDNEALYD ICFRTLKLTN PSYGDLNHLV SVAMSGVTCC  
G.duoden> VEPYNATLSV HQLVEHADEV FCIDNEALYD ICFRTLKLTN PTYGDLNHLV SLVMSGCTSC  
E.intest> VEPYNATLSI HQLVENADEV FCIDNEALYD ICFRTLKLSN PGYGDLNHLV SLVMSGVTSC  
          ---------- ------*--+ *--------- ---------+ ---------- -**-----*-  
 
          240        250        260        270        280        290         
B.taurus> LRFPGQLNAD LRKLAVNMVP FPRLHFFMPG FAPLTSRGSQ QYRALTVPEL TQQMFDAKNM  
H.sapien> LRFPGQLNAD LRKLAVNMVP FPRLHFFMPG FAPLTSRGSQ QYRALTVPEL TQQMFDSKNM  
C.parvum> LRFPGQLNSD LRKMSVNLVP FPRLHFFMIG FAPLTSRGSQ QYRSLSVAEL TQQMFDAKNM  
G.duoden> LRFPGQLNAD LRKLAVNLIP FPRLHFFLVG FAPLTSRGSQ IYRALTVPEL VSQMFDNKNM  
E.intest> LRFPGQLNAD LRKLAVNMIP FPRLHFFLVG FAPLTARGSQ KFKTYSVSEL TQQMFDSKNM  
          ---------- --------+- -------**- ---------- *--------- ----------  
 
          300        310        320        330        340        350         
B.taurus> MAACDPRHGR YLTVAAVFRG RMSMKEVDEQ MLNVQNKNSS YFVEWIPNNV KTAVCDIPPR  
H.sapien> MAACDPRHGR YLTVAAVFRG RMSMKEVDEQ MLNVQNKNSS YFVEWIPNNV KTAVCDIPPR  
C.parvum> MCASDPRHGR YLTASVMFRG RMSTKEVDEQ MLLVQNRNSS YFVEWIPNNI KSSVCDIPPK  
G.duoden> MAASDPRHGR YLTAAAMFRG RMSTKEVDEQ MLNIQNKNSS YFVEWIPNNM KVSVCDIPPR  
E.intest> MTASDPRKGR YLTAAAMFRG RISTKDVDEQ MSMVQSKNSS YFVEWIPSNM KVAVCDIAPT  
          ---+------ ---+--+--- ---+------ ---------- ---------* -*--------  
 
          360        370        380        390        400        410        
B.taurus> GLKMSATFIG NSTAIQELFK RISEQFTAMF RRKAFLHWYT GEGMDEMEFT EAESNMNDLV  
H.sapien> GLKMSATFIG NSTAIQELFK RISEQFTAMF RRKAFLHWYT GEGMDEMEFT EAESNMNDLV  
C.parvum> GLKMASTFVG NSTAIQEMFR RVAEQFTSMF RRKAFLHWIS GEGMDEMEFT EAETNMNDLV  
G.duoden> GLKMAATFIG NSTCIQELFK RVGEQFSAMF RRKAFLHWYT GEGMDEMEFT EAESNMNDLV  
E.intest> GLEMSATFVG NSTSIQELFK RVSDQFTVMF RRKAFLHWYT GEGMDEMEFT EAESNMNDLV  
          ---------- ---*------ -+-------- ---------- ---------- ----------  
 
          420        430         
B.taurus> SEYQQYQDVP VEEDEYPDDE  
H.sapien> SEYQQYQDVP VEEDEYPDDE  
C.parvum> SEYQQYQDVP VEEDEYPDDE  
G.duoden> SEYQQYQDAG VDEGEEFLVN  
E.intest> SEYQQYQDAT VEADEEFLVN  
          --------** -----*****  
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